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The importance of miRNAs in regulating gene expression has been addressed in several 
haematological cancers including myelodysplastic syndrome (MDS). In MDS, miR-145 
and miR-146a have been associated with some of phenotypic features of 5q- syndrome. 
Monosomy 7/7q deletion is the second most common chromosomal abnormality in MDS 
and identifies a subgroup of patients with poor prognosis. Thus far, no studies have 
examined the role of miRNA dysregulation in MDS patients with monosomy 7. In this 
study we examined the functional consequences of deletion of miRNAs localized to 7q 
with particular focus on miR-595, which is localized to 7q36.3, which is commonly deleted 
region in 7q- and -7. 
Most of the available methodologies for miRNA target identification are based on 
computational algorithms. Therefore, there is a relatively high incidence of false positive 
target identification. To enable the identification of biologically relevant microRNA targets, 
a novel functional assay was developed in our lab, which is based on positive/negative 
selection (Gaken et al, 2012). Using this assay, I identified functional targets of miR-595 
and correlated this with the MDS phenotype. 
Applying the functional assay to identify targets for miR-595 resulted in the identification 
of several targets including RPL27A, a large ribosomal subunit protein that was validated as 
a target for miR-595 by qRT-PCR and western blot analysis.  
Given the recognised association of ribosomal protein (RPS14) with 5q- syndrome, subtype 
of MDS, I assessed the biological function of RPL27A in order to identify its contribution 
to the disease pathogenesis. Using Polysomes fractionation,. RPL27A knockdown showed a 
reduction in the large ribosomal subunit (60S). On day 6 of the knockdown, the depletion 
of RPL27A led to p53 activation and induced variable levels of apoptosis in all cell lines 
Interestingly, like RPS14 knockdown, the effect of RPL27A knockdown in 48 h was p53 
dependent. The p53 independent effect, which was observed on day 6, was attributed to a 
defect in ribosome biogenesis based on the disruption of nucleolar staining in HCT-116 and 
HCT-116 p53-/- with depleted RPL27A using fibrillarin antibody and similar effects were 
seen with RPS14. 
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To investigate whether the effect of RPL27A knockdown on erythroid differentiation is 
similar to the other ribosomal proteins, RPL27A knockdown was performed in normal 
CD34+ and resulted in reduce viability and apoptosis within 10 days. Post-transcriptional 
p53 overexpression was also observed; which led to a marked increase in the mRNA 
expression of p53 targets, p21 and Bax. Following 10 days in liquid culture, RPL27A 
knockdown blocked the proliferation and differentiation of erythroid cells relative to 
myeloid and megakaryocyte lineages. Similar observations have been made in 5q- 
syndrome due to RPS14 haploinsufficiency and in Diamond Blackfan anemia patients with 
mutations in large or small ribosomal subunit proteins.  
Lastly this study showed that miR-595 is significantly downregulated in MDS patient 
samples possessing -7/-7q anomalies compared to those with a normal karyotype. In 
conclusion, haploinsufficency of miR-595 in patients with -7/7q del might contributes to 
disease pathogenesis and these effects are mediated via RPL27A modulation.  
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SFA Sooty foot ataxia  
shRNA Short Hairprain RNA(shRNA)  
SiLAC Stable isotope labelling with amino acids in cell culture  
SMZL Splenic marginal zone lymphoma   
snoRNA Small nuclear RNAs  
SNP array Single nucleotide polymorphism microarray  
SRSF2 Splicing factor arginine/serine-rich 2  
StemSpanSFEM  Serum-Free Medium  
TAE Tris Acetate-EDTA buffer 
TF Transcription factor  
THP1 Human acute monocytic leukaemia cell line  
TLRs Toll-like receptors  
TP53(P53) Tumour protein 53  
TPO Human Thrombopoietin  
TRAF6 TNFR-associated factor 6  
TRC The RNAi Consortium  
T-regs Regulatory T cells 
U2Af1 U2 small nuclear RNA auxiliary factor 1  
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UPD Uniparental Disomy  
UPL Universal Probe Library  
UTR Un translated region 
WHO World Health Organization  
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1.1 MDS Background 
Myelodysplastic Syndrome (MDS) is a group of heterogeneous clonal haematological 
disorders characterized by ineffective haematopoiesis, which results in hypercellular bone 
marrow, defective maturation of hamatopoietic stem cells, and cytopenia (Toyama et al. 
1993b, Steensma et al. 2003, Van Etten et al. 2004). 
Variability within disease severity corresponds to the diversity of the disease's pathological 
features. MDS patients that have progressed to a more aggressive state, are at a high risk of 
transforming into patients with acute myeloid leukaemia (AML) in 30% of all cases. 
According to clinical severity and disease progression, the survival rate of this disease 
ranges from a few months to ten years (Bennett et al. 2004). The broad heterogeneity of the 
clinical course, which is reflected by the diversity of its morphological features, provides 
the basis of classification systems and prognostic scoring systems. Classification systems, 
i.e the World Health Organization (WHO), is based on the percentage of blasts, ring 
sideroblasts, peripheral blood monocyte counts and cytogenetic results (Bennett et al. 
2002). The WHO classification—which was developed from a previous classification 
system, the French-American British (FAB)—can be seen in Table 1.1. Prognostic scoring 
systems, i.e. International Prognostic Scoring System (IPSS), is used in the assessment of 
disease diagnosis and prognosis. IPSS dependent upon cytogenetic results, blast ratio and 
cytopenia (Greenberg et al. 1997, Mufti 2004, Mufti et al. 2008). The prognostic scoring 




Table 1.1:MDS classification based on WHO dependent FAB classification (Bennett et al. 2002). 
French-American British (FAB) World Health Organization (WHO) 
Refractory Anaemia (RA) 
Refractory Anaemia (RA)  
Refractory Cytopenia with Multilineage Dysplasia 
(RCMD)  
Myelodysplastic Syndrome (MDS) Unclassified 
(MDS-U) 
MDS with isolated del (5q) 
Refractory Anaemia with Ringed Sideroblasts 
(RARS) 
Refractory Anaemia with Ringed Sideroblasts 
(RARS) 
RCMD and Ringed Sideroblasts (RCMD-RS)  
Refractory Anaemia with Excess Blasts (RAEB) 
RAEB-1 
RAEB-2  
RAEB in Transformation (RAEB-T) Acute Myeloid Leukaemia (AML)  




0 0.5 1.0 1.5 2.0 
Bone Marrow Blast <5 5-10 ----- 11-20 21-30 
Karyotype Good Intermediate Poor   
Cytopenia 0/1 2/3    
Prognosis Score IPSS Subgroup Median AML transformation (in 
years) 
Median Survival (in 
years) 
0 Low 9.4 5.7 
0.5-1.0 Intermediate-1 3.3 3.5 
1.5-2.0 Intermediate-2 1.1 1.2 
>2.5 High 0.2 0.4 
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1.2 MDS Genetic Changes 
Disease phenotypical heterogeneity such as severity of cytopenia, blast count, response to 
treatment and progression to AML, can all be attributed to genetic changes. These changes 
can be cytogenetic alterations, genetic mutations as well as, or instead of, epigenetic 
abnormalities. Among the different aberrations, cytogenetic abnormalities account for 
roughly 50% of cases and are, therefore, important for disease diagnosis and prognosis 
(Haase et al. 2007). Studies over the last 25 years on the cytogenetic examination in MDS 
patients, has shown an increase in the incidence rate of chromosomal abnormalities related 
to the disease. These rate rose from 40-50% according to the recent estimated data (Toyama 
et al. 1993b, Sole et al. 2005, Haase et al. 2007). MDS with normal karyotype considered a 
favourable prognostic sign (Sole et al. 2005). Similarly, a single chromosomal abnormality, 
such as t(1q), 5q-, t(7)q, 9p-, 12q, t(17q), 20q-, +21, -21, -X, -Y, is also favourable in the 
prognosis with a median survival rate from 32 months to more than nine years (Haase et al. 
2007). Despite this, complex karyotypes with three or more abnormalities and chromosome 
7 abnormality are poor prognostic markers with lower survival rates (Haase et al. 2006). 
The most common chromosomal abnormalities in MDS, along with their contribution to 
disease prognosis are shown in Table 1.3 . 
Reliance purely, upon conventional cytogenetic analysis to study the changes within 
chromosomal aberration has become less favourable and insufficient, due to conventional 
technologies can only detect 50% of the genetic changes in MDS. The main limitations of 
this assay lie in the difficulty of obtaining metaphases with good resolution, as well as the 
difficulty in acquiring adequate and proper samples for analysis (Earle et al. 2007). 
Consequently, the application of other techniques—such as fluorescence in situ 
hybridization (FISH)—have overcome metaphase cytogenetic limitations and enhanced 
disease diagnosis (Rigolin et al. 2001). Rigolin et al. (2011) used the FISH technique to 
detect the common chromosomal abnormalities associated with MDS, such as -5/5q-, -7/7q, 
trisomy 8 and 17p- in MDS patients with normal karyotype: as identified by metaphase 
cytogenetic analysis (Rigolin et al. 2001). The FISH analysis identified chromosomal 
abnormalities in 17% of patients with normal karyotype. Furthermore, FISH-positive cases 
were not merely associated with a higher percentage of bone marrow blasts, but also with a 
higher tendency toward AML progression. This observation implies that utilisation of FISH 
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can confer changes within the IPSS categorisation, specifically in patients with normal 
karyotype.  
Despite for the fact that cytogenetic analysis has been improved after the development of 
FISH, the technique has some disadvantages, for instance the fluorescent probe hybridizing 
to known regions only (Najfeld 2003). Despite this, other advanced techniques such as 
array comparative genomic hybridization (aCGH) as well as single nucleotide 
polymorphism microarray (SNP a) allow for the identification of novel genetic aberrations 
that are not predicted with the use of conventional cytogenetic analysis.  
 Starczynowski et al. applied aCGH screening on CD34+ cells that were isolated from a 
low–risk subtype MDS with a normal cytogenetic karyotype. This study reported cryptic 
changes on different chromosomes that were not previously observed by cytogenetic 
analysis (Starczynowski et al. 2008). Additionally, the prognosis of lower-risk MDS 
patients with minimal alteration as detected by aCGH was significantly correlated with a 
higher overall survival and a lower frequency of progression to AML. The differences 
between conventional cytogenetic analysis and aCGH in the detection of chromosomal 
changes can be seen in Figure 1.1.  
SNPa is used to ascertain the copy number (CN) changes and detection of loss of 
heterozygosity (LOH) within a particular region. LOH occurs as aresult of the deletion of 
chromosomal material or through uniparental disomy (UPD) changes. The high-resolution 
of this technique allows for the prediction of UPD, which arises when a cell acquires two 
copies of one parental chromosome (Raghavan et al. 2005). Detection of UPD provides an 
advantage to SNPa over alternative techniques, due to the fact that UPD is a prominent 
defect, associated with different haematological malignancies (Fitzgibbon et al. 2005, 





Table 1.3: Common cytogenetic abnormalities in MDS subtypes (Bejar et al 2011). 
Chromosomal 
Abnormalities 
Frequency (%) Pathogenic Mechanism Clinical Consequence 
 5q- 15 Haploinsufficiency for 
RPS14, miR-145/146a, 
CTNNA1, EGR1, APC, 
NPM 
Good prognosis, high 
rate of response to 
lenalidomide 




Trisomy 8 5-8 Unknown Can help predict 
response to 
immunosuppression, 
some evidence as a 
marker of progression 
to AML 
    20q- 2-5 Unknown Good prognosis 
    -Y 2-4 Age-related phenomenon 
that may not be disease 
related 
Good prognosis. May 
be useful as a marker of 
clonal haematopoiesis 
 Complex (three or 
more abnormalities) 
10-15 Various; often abnormal 
chromosome 17 (P53 
locus) 
Poor prognosis 
-13/13q-, 11q-, 12p-, 
9q-, idic(X)(q13), 
i(17q), t(11;16), t(3;21), 
t(1;3), t(2;11), inv(3), 
t(6;9) 
Rare Various, mostly 
unknown; chromosome 
3q26 lesions alter 
expression of EVI1 
Presumptive evidence 
of MDS in patients with 
otherwise unexplained 
refractory cytopenia and 
no morphologic 




One of the more significant studies on the application of SNPa upon MDS was undertaken 
by Mohamedali et al. Within this study, researchers applied SNPa analysis on low-risk 
MDS patients with normal karyotype, and on MDS patients with 5q deletion to detect CN 
and UPD. This study showed that UPD was present in 46% of low-risk MDS patients, and 
that most of the UPD defects were observed on the long arm of chromosome 4 within those 
RARS, RCMD and RAEB patients with normal cytogenetic karyotype with mean 
prevalence of 25%, 12% and 17%, respectively. Additionally, UPD on 4q was detected in 
6% of patients with 5q-, while CN changes were detected, but with lower frequency levels, 
when compared to UPD. Furthermore, patients with higher IPSS score—who possessed 
normal cytogenetic karyotype—were identified with CN changes, specifically deletion, by 
SNPa. This correlation between IPSS scoring and SNP array reflects the importance of this 
method in disease diagnosis and prognosis (Mohamedali et al. 2007). 
Application of SNPa and other advanced molecular techniques such as high throughput 
sequencing, have led to the identification of novel genetic aberrations associated with 
MDS. For instance, SNPa identified the TET oncogene family member 2 (TET2) mutation, 
a common mutation within myeloid malignancies, which was discovered in a micro-
deletion in 4q24 (Jankowska et al. 2009). Other genetic mutations that are associated with 
myeloid malignancies have been identified by SNPa as a result of either UPD or micro-
deletion such as the enhancer of zeste homolog 2 (EZH2), the myeloproliferative leukaemia 
virus oncogene (MPL), and Casitas B-lineage lymphoma proto-oncogene (CBL) (Dunbar et 
al. 2008, Szpurka et al. 2009, Makishima et al. 2010).  
Some of the identified mutations, including tumour protein 53 (P53), EZH2, ETS variant 6 
(ETV6/TEL), AXL1 and Runt-related transcription factor 1 (RUNX1) have all been found in 
association with an overall decrease in survival rate of patients, thereby stressing the 
importance of detecting such mutations within disease prognosis (Bejar et al. 2011, Bejar 
2014). Understanding the mechanism that causes these mutations as well as the effect of 
these mutations upon the biological function, will increase knowledge about MDS 
pathogenesis. A summary of the most commonly-identified mutations associated with 







Figure 1.1: chromosomal abnormalities predicted by array CGH in MDS patients 
with normal cytogenetic karyotype (reproduced from Starczynowski et al. 2008).  
A) Proportion of patients with chromosomal abnormalities predicted by conventional cytogenetic 
analysis (on the right) and by array CGH (on the left). B) Alterations detected by array CGH 
aligned to chromosomes. Lines to the right of chromosomes indicate chromosomal amplification 
with lines on the left indicating deletion in chromosomal material (Starczynowski et al. 2008). 
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Table 1.4:  Common genetic changes associated with MDS ( Bejar et al 2011) 
Genetic 
mutations 
Frequency (%) Pathogenic Mechanism Clinical Consequence 
 TET2 Approximately 
20 
Unknown Unknown 
    RUNX1 15-20 Mutations typically alter DNA-
binding domain or disrupt protein-
binding domain 
Increased risk of progression 
to AML; more common in 
therapy-related MDS 
    TP53 5-10 Loss of function of p53 tumour 
suppressor activity; associated with 
chromosomal instability 
Often complex cytogenetic, 
relative resistance to therapy, 
poor prognosis 
    ASXL1 10-15 Unknown; most mutations are 
distal heterozygous frame shifts, 
suggesting a dominant negative 
function 
Unknown 




Loss of GTPase activity leads to 
constitutive activation of 
serine/threonine kinase 
Increased risk of progression 
to AML 
    EZH2 6 Loss of histone 3 lysine 27 
methyltransferase activity 
Poor prognosis 
    CBL/CBLB Rare Loss of ubiquitin ligase activity; 
mutants can inhibit wild-type 
enzymatic function 
Unknown; increased risk of 
progression to leukaemia in 
MPN and in CMML where 
this mutation is more common 
    JAK2 5% of RA, 50% 
of RARS-T 
Constitutive activation of tyrosine 
kinase 
Unknown; does not appear to 
alter prognosis 
    MPL 5% of RARS-T Constitutive activation of tyrosine 
kinase 
Unknown 
    ATRX Rare Loss of function leads to decreased 
alpha-globin expression, likely 
through epigenetic dysregulation 
Acquired alpha-thalassemia, 
often with very severe 
anaemia 
    NPM1 Rare Terminal frame shift disrupts 
nucleolar localization signal 
leading to cytoplasmic 
redistribution of protein 
Unknown; this mutation is 
very common in AML with 
normal cytogenetics 
    IDH1, IDH2 Rare Missense mutations alter catalytic 
function to convert α-ketoglutarate 
into 2-hydroxyglutarate while 
consuming NADPH 
Associated with more 
advanced disease and 
progression to AML 
    CEBPA Rare Loss of function known to impair 
granulopoiesis 
Unknown; germline mutations 
associated with risk of AML, 
not MDS 
    WT1 Very rare Impairment of transcription factor 
activity 
Unknown; mutations are more 
common in AML and 
associated with poor outcomes 
    PTPN11 Very rare Alters function of gene product 
SHP2, an adaptor protein with 
tyrosine phosphatase activity 
More common in JMML, rare 
in CMML 
    FLT3, 
CSF1R, CKIT 
Very rare Constitutive activation of tyrosine 
kinase 
Associated with more 
advanced disease and 
progression to AML 
Note on Table 1.4: Rare mutations are present in 2% to 5% of patients; very rare refers to individual 
reports or < 2% of patients. Abbreviations: CTNNA1, alpha-catenin 1; EGR1, early growth response 
1; APC, adenomatous polyposis coli; NPM1, nucleophosmin 1; GTPase, guanosine triphosphatase; 
MPN, myeloproliferative neoplasms; NADPH, nicotinamide adenine dinucleotide phosphate; 
JMML, juvenile myelomonocytic leukemia. Genes: NRAS, neuroblastoma RAS viral (V-ras) 
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oncogene homolog; CBL, Casitas B-lineage Lymphoma; JAK2, Janus kinase2;IDH, Isocitrate 
dehydrogenase  (NADP+); mitochondrial PTPN11, Protein tyrosine phosphatase, non-receptor type 
11;FLT3, fms-related tyrosine kinase 3; CEBPA, CCAAT/enhancer binding protein (C/EBP), 
alpha; wt1, Wilms tumour 1;NPM, Nucleophosmin (nucleolar phosphoprotein B23, numatrin). 
Recently, high throughput sequencing discovered a new set of gene mutations affecting the 
RNA-splicing machinery. RNA splicing occurs after transcription in which introns are 
removed and exons are joined to form mRNA, a mechanism catalysed by the spliceosome 
(a complex of small nuclear ribonucleoproteins -snRNPs). Distinct splicesomal mutations 
were discovered in MDS patients; including Splicing factor 3B subunit 1 (SF3B1) in  
RARS MDS, U2 small nuclear RNA auxiliary factor 1 (U2AF1); and Splicing factor 
arginine/serine-rich 2 (SRSF2) in CMML MDS and other advanced forms of MDS 
(Papaemmanuil et al. 2011). In contrast to other MDS mutations predicted within other 
haematological malignancies, these mutations were found in 45%-85% of MDS patients, 
and furthermore are rarely seen in other myeloid malignancies. This phenomenon, 
therefore, provides an insight into the exclusive role of these mutations as part of MDS 
pathogenesis (Yoshida et al. 2011). For prognostic implications, SF3B1 is associated with a 
good prognosis, while U2AF1 and SRSF2 mutations are associated with poor prognosis, 
making these mutations a potential marker for both diagnosis and treatment (Makishima et 
al. 2012). 
Besides all the genetic alterations that have been discovered in association with MDS 
subtypes, other new genetic changes have been discovered and identified as having a 
contributory factor to MDS. Several more studies too have demonstrated the importance of 
microRNAs (miRNAs) within haematological disorders as well as how these miRNAs are 
integrated in different myelopoiesis pathways. Expression profiling for miRNAs in MDS 
patients has identified dysregualtion in some miRNAs, which were subsequently associated 
with the pathological effects on disease development (O'Connell et al. 2008, O'Connell et 
al. 2011). Further details regarding miRNAs and their association with MDS subtypes, 
particularly MDS with monosomy 7/7q-, will be discussed in the following sections. 
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1.3 miRNA Background 
miRNAs are single-stranded endogenous small non-coding RNAs, 18-25 nucleotides long, 
miRNA function as regulators of gene expression either by translation inhibition or mRNA 
degradation (Bartel 2004a). The first miRNAs were discovered in 1993 and 1997, were 
named Lin-4 and Let-7, respectively. They were identified in Caenorhabditis elegans 
(C.elgans) and function as regulators of development (Lee et al. 1993, Moss et al. 1997). 
Since their discovery, knowledge about miRNAs has expanded and thousands of mature 
miRNAs have been identified in almost every metazoan organism, including worms, flies, 
plants, animals (including human), with the use of deep sequencing studies, the number of 
which is still increasing (Lim et al. 2003, Bentwich et al. 2005). It has now been 
established that many miRNAs regulate key biological processes including cell 
proliferation, differentiation and  apoptosis of hematopoietic progenitors (Chen et al. 2004, 
Cheng et al. 2005, Karp et al. 2005, Almeida et al. 2011).  
Several miRNAs genes are located at fragile sites and within chromosomal regions 
implicated in cancer (Calin et al. 2004). Recent studies have found that 50% of miRNA 
genes are identifiable within cancer-associated regions of the genome, with more than 30 
miRNAs being associated with apoptosis (Calin et al. 2004, Yang et al. 2009). For 
instance, miR-15 and miR-16 contributed to apoptosis by targeting the antiapoptotic gene B 
cell lymphoma 2 (BCL2) (Cimmino et al. 2005). Several studies have demonstrated the 
involvement of miRNAs within different types of cancer through its effect on the 
expression of oncogene or tumour suppressor genes. For example, miR-145 and miR-155 
are differentially expressed in cancer of breast, colon, as well as lymphoma (Michael et al. 
2003, Metzler et al. 2004, Iorio et al. 2005).  
1.4 microRNA Biogenesis  
miRNA genes are transcribed into long, immature primary miRNAs (pri-miRNAs). Little is 
known about the transcription of miRNAs, and recent analysis of the miRNAs gene 
location shows that the miRNAs are either transcribed either as a single transcription unit or 
else as a polycistronic transcription unit (a unit including regions for different, non-
overlapping genes). These transcription units are located within different genetic regions; 
some being located within the introns of  protein- coding genes or in non-coding genes, and 
some being present in the exon of non-coding genes (Rodriguez et al. 2004, Du et al. 2005). 
 32 
The structure of six pri-miRNAs are shown in Figure 1.2. The pri-miRNAs which are 
generated in the nucleus through the action of RNA- polymerase II, are processed by 
Drosha, a type III RNAse. Consequently, a hairpin-shaped precursor miRNA (pre-miRNA) 
of 70-100 nucleotides is formed. This pre-miRNA is then transported to the cytoplasm and 
further processed by another member of the RNAse III family Dicer. This process creates 
in a 18-25 bp-long double strand RNA molecule: the mature miRNA/miRNA* duplex (Lee 
et al. 2002, Yi et al. 2003). This duplex is then separated by a helicase and one strand, the 
miRNA, binds to the RNA induced silencing complex (RISC) thereby becoming the active 
mature microRNA. The intricacies of this binding mechanism are expounded upon within 
the following section. The other strand, miRNA*, is degraded. Strand separation relies on 
thermodynamic stability; the less stable strand tends to start with uracil: the miRNA strand 
(Schwarz et al. 2003). When mature miRNA in the complex binds to a perfectly 
complementary binding region in the 3’UTR (untranslated region) of an mRNA, this results 
in specific degradation of the mRNA while imperfect binding results in translation 
inhibition (Lee et al. 1993, Bartel et al. 2004b, Eulalio et al. 2008, Garzon et al. 2008, 
Bartel 2009, Jadersten et al. 2009, Yang et al. 2009). The mechanisms that are involved in 
miRNA biogenesis are depicted in Figure 1.3.               








































Figure 1.2: The structure of six primary miRNA transcripts that encode six different 
miRNAs (reproduced from Du et al. 2005). 
The primary miRNA transcripts differ based on the following. A) Examples of miRNA 
transcription units, miR-21 transcript is a single unit and polycistronic unit as seen in miR-17-92-1 
cluster. B) miRNAs that are transcribed alongside other genes (as indicated in the figure above) at 
different positions. miR-15a ∼16-1 in the intron of non-coding RNA. miR-106b in the intron of 
protein coding mRNA whereas miR-155 and miR-198 in the exon of non-coding RNA and in the 
exon of protein coding mRNA, respectively. DLEU2, deleted in lymphocytic leukaemia 2; MCM7, 
minichromosome maintenance deficient 7; BIC, B-cell integration cluster; FSTL1, follistatin-like 






Figure 1.3: Outline of the steps involved in microRNA biogenesis (reproduced from 
Garzon et al. 2009) 
MicroRNA genes are transcribed in the nucleus to produce a long nucleotide sequence (Primary 
microRNA). This molecule is tthen further processed by the Drosha enzyme into a precursor 
miRNA. The resulting molecule undergoes further processing in the cytoplasm by the Dicer enzyme 
and forms mature microRNA. The binding of mature miRNA with the RISC complex causes either 
mRNA cleavage or inhibition of translation (Garzon et al. 2009). 
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1.5 miRNA Regulation 
MiRNAs regulate the expression by mRNA degradation or inhibition of translation. 
Although, it remains unclear how miRNAs carry out these functions, there are several 
potential mechanisms that may explain their role in post-transcriptional regulation.  
It is a requirement that miRNAs bind to the RISC complex in order to become functional. 
The RISC complex is composed of the Argonaute (AGO) family of proteins, that are the 
effector molecules within the process of miRNA regulation. Each Argonaute protein is 
composed of PAZ and PIWI, domains. The PAZ domain binds to the 3’end of single 
stranded RNAs, whereas PIWI binds to the 5’ end (Song et al. 2003, Yan et al. 2003, 
Parker et al. 2004). Furthermore, PIWI has the ability to cleave RNA strands similarly to 
RNase H, with which it demonstrates its structural similarities (Rhoades et al. 2002, Song 
et al. 2004). 
The resulting miRNA/RISC complex functions as a post-transcriptional regulator based on 
how it binds to individual mRNA. In plants, a majority of miRNAs bind with perfect 
homology to their mRNA targets (Rhoades et al. 2002). Conversely, human and animal 
miRNAs usually do not bind with perfect homology. The miRNAs bind to the 3’-UTR of 
an mRNA via a ‘seed’ region, which it situated at positions 2-7 in the miRNA. Perfect 
matching of the seed region with mRNA results in cleavage of the mRNA, while 
mismatching and bulges in the seed region block translation (Brennecke et al. 2005, Lewis 
et al. 2005). 
1.6 Target Identification 
miRNAs influence the expression of neumerous target genes, through their interaction with 
mRNA and regulation of the mRNA or protein expression. Identification of miRNA targets 
have been achieved either through broad prediction by computational algorithms or by 
specific functional assays. Target identification by computational algorithms, such as 
Targetscan, miRanda, miRgen, and miRdb, are predominantly based on the homology of a 
miRNA seed region with the 3’UTR binding site in the target gene (Bartel 2009). However, 
the perfect matching between miRNA seeds and binding sites in their targets are neither 
necessary nor sufficient for all binding mechanisms. (Metzler et al. 2004, Didiano et al. 
2006, Beitzinger et al. 2007, Easow et al. 2007, Alexiou et al. 2009). Examples for non-
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seed matches were seen in the validated target for let-7 in C.elegans, such as lin-41, which 
contain a bulge within the seed region (Orom et al. 2008). In humans, miR-10a targets 
ribosomal protein transcripts via non-seed sites in the 5' UTR (Orom et al. 2008). 
Biological experimental assays play a significant role in identifying miRNAs targets with 
each of them possessing its own advantages and disadvantages. Some of the commonly 
used methodologies are specific for validating individual targets such as; western blot, 
qRT-PCR and Luciferase reporter assays (Kuhn et al. 2008). The western blot technique 
determines translational regulation by examining the effect of miRNA on protein 
expression in cells that express the protein and cells that do not express the protein, whereas 
qRT-PCR identifies miRNA targets on the mRNA level only, with any changes in the gene 
expression identifying that this target is regulated by mRNA degradation. Furthermore, 
these methods are unable to discriminate between direct and indirect targets, which are 
deregulated in response to the deregulation of a direct miRNA target (Zhang et al. 2007). 
Alternatively, luciferase assays are dependent upon cloning of the binding site of putative 
target downstream luciferase reporter genes in their respective vector; thereby, the binding 
of endogenous or introduced miRNAs to the cloned miRNA target sequence reduces 
luciferase expression. This assay method can predict the direct target genes of a miRNA; 
however it has several disadvantages such as the determination of a cloning region and 
transfection techniques, in addition to being a time-consuming assay method (Lytle et al. 
2007, Kong et al. 2008). 
Given that individual microRNAs have the ability to regulate a number of genes, several 
experimental assays have evolved with the intention of screening a set of genes, targeted by 
a specific miRNA. Most of the reported methodologies are based on identifying the 
differential expression within both mRNA and proteins on the basis of variations within 
miRNA expression (Lewis et al. 2003, Thomson et al. 2011). Differential expression of a 
miRNA is attained either by miRNA transfection, which promotes miRNA overexpression, 
or else by knocking down endogenous miRNAs with the use of miRNA inhibitors such as 
antagomiRS (Krutzfeldt et al. 2005), miRNA sponges (Ebert et al. 2007) or anti-miRs 
(Elmen et al. 2008, Elmen et al. 2008). Several techniques have been employed in the 
examination of the effect of miRNA overexpression or repression on target gene 
expression. For instance, target identification from mRNA degradation by gene expression 
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profiling using expression array, remains one of the most widely employed techniques. 
Nevertheless, this method is unable to distinguish between direct and indirect effects (Lim 
et al. 2005) and it is associated with a false positive rate, which may result from mis-
hybridization (Thomson et al. 2004, Chiang et al. 2010). Although expression array studies 
were informative in identifying transcriptome changes in response to miRNA regulation, 
they were incapable of identifying the effect of miRNAs on translational repression. Thus, 
other methods were employed to determine the effects on translation by identifying the 
miRNA changes at the protein level.  
Proteomic analysis has assessed in the identification of targets resulting from translation 
inhibition. Stable isotope labelling with amino acids in cell culture (SiLAC) is one of the 
proteomic methods, and is based on the quantification of the abundance of the protein. This 
method relies on incorporating isotope labelled amino acid into the protein in cultured cells 
in comparison with normal protein. Mass spectrometry measures the mass of different 
proteins; providing a sensitive readout and helping to confirm the fact that a single miRNA 
regulates the expression of several proteins (Baek et al. 2008). The drawback of SiLAC 
assay is not only that the assay is expensive; it is also very time-consuming. Similar to gene 
expression arrays, proteomics method are unable to distinguish between direct and indirect 
miRNA targets. 
To identify direct miRNA targets, immunoprecipitation of the RISC components  
(Argonaute), which is based on using epitope–tagged Argonaute, pull down miRNA: 
mRNA associated pairs (Hendrickson et al. 2008). The immunoprecipitated target can then 
be identified through microarray or else by deep sequencing (Hafner et al. 2010). The main 
drawback of this assay is that it may immunoprecipitated mRNA that are not true targets 
when the interactions between Ago protein and mRNA occur subsequent to cell lysis. Also, 
this assay depends on stable binding between miRNA- mRNA and Ago protein (Mili et al. 
2004).  
Despite advancements of in our knowledge within this field, many miRNAs targets have 
not been identified due to the lack of highly sensitive or specific techniques. Based on 
miRBASE relase16, Sept 2010, there are presently 1048 identified human miRNAs, with 
only 206 of these having validated targets either by western blot or expression array 
(http://mirecords.umn.edu/miRecords/). Accordingly, novel experimental assays are 
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urgently required for an efficient screening and validation of miRNAs targets (Thomas et 
al. 2010).  
1.7 Functional characterization of miRNA 
1.7.1 miRNA Regulation of the Immune System 
Inflammatory response is initiated by the activation of signalling instigated by Toll-like 
receptors (TLRs) that are responsive to pathogen-associated molecular patterns (PAMPs) 
found on different classes of pathogens (Medzhitov et al. 1997). In response to pathogen 
infection, cells of the innate immune system provide a first line of defence; these cells 
include granulocytes, monocytes and natural killer cells (NK). Emerging evidence has 
identified the contribution of miRNAs in the development and function of innate immunity 
cells and their regulation of the TLR responses (Kawai et al. 2010).  
Recent studies have shown a unique expression profile of miRNAs in cells of the immune 
system and an important role in targeting target proteins involved in the regulation of 
inflammation (O'Neill et al. 2011). Also, miRNAs have been implicated in the regulation of 
the immune response, inclusive of the development and differentiation of innate and 
adaptive immune responses (Baltimore et al. 2008, Lodish et al. 2008). 
Inflammatory responses can cause deregulation of miRNA-producing transcripts and 
protein regulators of the miRNA biogenesis pathways that will ultimately affect the 
immune responses (O'Connell et al. 2010). KH-type splicing regulatory protein (KSRP) is a 
loop-binding factor that regulates several miRNAs, including miR-155, and assists in the 
rapid increase in mature miR-155 levels seen during inflammation (Yang et al. 2006). 
Additionally, certain inflammatory cytokines, such as interferons (IFNs), can repress dicer 
expression and thereby adversely affecting pre-miRNA processing (Wiesen et al. 2009). 
Figure 4 shows the effect of inflammation on regulating miRNA expression. 
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Figure 1.4: Regulation of mirRNA expression by inflammation response ( reproduced 
from (O'Connell et al. 2010) 
miRNA transcription is regulated by a transcription factor (TF) which is activated or repressed by 
Toll-Like receptors (TLRs), cytokines and antigens during immune response. Following the 
transcription, Pri-miRNA is processed to pre-miRNA under the regulation of multiple factors – 
some of these factors are influenced by inflammation. These factors include Drosha, DiGeorge 
syndrome critical region gene 8 (DGCR8), LIN28, KH-type splicing regulatory protein (KSRP), 
arsenate resistance protein 2 (ARS2), SMADs, p53 and adenosine deaminase acting on RNA 
(ADAR). The Pre-miRNA is then transported from the nucleus to the cytoplasm by exportin 5 and 
processed by dicer enzyme to produce miRNA duplex. When the double strands are separated the 
guide strand binds with RISC, this protein is then transported by importein 8 to the complement site 
in mRNA leading to target repression. Finally, miRNAs can be localized to specific organelles, 
such as stress granules or processing (P-) bodies, some of which can be regulated by inflammation 
(O'Connell et al. 2010). 
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Different studies have identified the upregulation of some miRNAs such as miR-146, miR-
9, miR-147, miR-21 and miR-155 in response to pathogen infection, following TLR 
activation (Taganov et al. 2006, O'Connell et al. 2007, Bazzoni et al. 2009, Liu et al. 2009, 
Sheedy et al. 2010). 
Among the first miRNAs to be identified for their importance in the innate immune 
response to microbial infection was miR-146. TLR signalling leads to the upregulation of 
miR-146 resulting in suppression of their targets proteins, including IL-1R associated 
kinase 1 (IRAK1), IRAK2 and TNFR-associated factor 6 (TRAF6) (Taganov et al. 2006, 
Hou et al. 2009). These proteins are an important component of the myeloid differentiation 
primary-response protein 88 (MYD88), which leads to nuclear factor-κB (NF-κB) 
activation as a result of TLR signalling – particularly of TLR2, TLR4, TLR5, TLR7, TLR8 
and TLR9 that are all found to promote the expression of miR-146 in the human acute 
monocytic leukaemia cell line (THP1) (Taganov et al. 2006). Both TRAF6 and IRAK1 
molecules have been recognized for their involvement in TLR and interleukin-1 (IL-1) 
receptor signalling (Kawai et al. 2010). The association of miR-146 with the innate 
immunity will be discussed later in the section on miRNAs in MDS with 5q deletion. 
TLR pathways could be silenced by mRNA through the targeting of multiple TLR targets, 
such as signalling receptors, transcription factors, cytokines and signalling regulators, all of 
which are components of TLR signalling pathways (e.g. MYD88, MAL1, IRAK1, IRAK2 
and TRAF6), and which bypass the excessive pro-inflammatory response toward pathogen 
infection by shutting down several TLR pathways. This reflects the importance of miRNAs 
in controlling the inflammatory response, which may result from a collaborative actions 
between miRNA with other well-described mechanisms (O'Neill et al. 2011).  
Similarly, miRNAs have contributed to the regulation of the development and function of 
adaptive immune cells. Earlier studies on dicer deletion in T and B cells displayed the 
involvement of miRNAs in lymphocyte biology. In regulatory T cells (Tregs), the role of 
miRNAs in maintaining homeostasis is demonstrated by development of severe 
autoimmunity in mice with lineage specific deletion of dicer in Treg cells that express miR-
146a. Therefore, mice with deletion in miR-146a  can develop a chronic inflammatory 
disorder (Muljo et al. 2005). In addition, dicer deletion in B cells caused an arrest of cell 
development at the pro-B cell stage (Koralov et al. 2008). 
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The importance of miRNA in the regulation of the immune responses has a potent impact 
in MDS, especially in low-risk MDS. Higher frequencies of natural killer cells (NK) cells 
and low Treg number were observed in low-risk MDS as compared to high-risk MDS. Also, 
NK-cells mediate cytotoxicity of BM precursor cells in low-risk MDS disease (Chamuleau 
et al. 2009). 
Since these initial observations, specific miRNAs have been identified in the targeting 
signal transduction proteins involved in TLR pathways and in intercalating immune cells 
development and functions, that have had a significant impact on the magnitude of the 
inflammatory response. 
1.7.2 miRNAs in Haematological Malignancies 
Given the specific role of miRNAs in the regulation of normal and leukaemic haemopoiteic 
proliferation and differentiation, it is of no surprise that surprise that these are a major 
research focus in a number of laboratories worldwide. In some haematological 
malignancies the reduced expression levels were obtained in association with specific 
genetic alterations such as chromosomal deletions (Chen et al. 2005). Calin et al. in 2002 
reported the first major role of specific miRNAs in certain leukaemic subtypes. This study 
showed that miR-15a and miR-16-1 were downregulated as a result of deletion at 13q14 in 
patients with chronic lymphocytic leukaemia (CLL) (Calin et al. 2002). Another study by 
Calin et al. was carried out to investigate the association of miRNA expression with known 
specific prognostic factors in CLL patients via miRNA microarray. Thirteen miRNAs were 
correlated with disease prognostic factors such as mutations in the immunoglobulin heavy-
chain variable-region (IgVH) gene or the expression of the 70-kD zeta-associated protein 
(ZAP-70) and the time between diagnosis and initial therapy (Calin et al. 2005).  
Differential expression of miRNAs has also been recognized in other types of leukaemia. 
For instance, 27 miRNAs were differentially expressed between acute lymphoblastic 
leukaemia (ALL) and acute myeloblastic leukaemia (AML) (Mi et al. 2007). Moreover, 
differential miRNA expression in leukaemia was found in chronic myeloid leukaemia 
(CML), in which the miR-17-19 cluster is induced depending on the expression of BCR-
ABL and c-MYC (Venturini et al. 2007).  
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Similarly, the role of specific miRNA changes has been identified in MDS. These changes 
are of paramount importance in the pathogenesis of this disease and that will be discussed 
in more detail in the following section. 
1.8 MDS and miRNA 
There is growing evidence indicating that there is an association between miRNA 
deregulation and MDS development and progression. Some studies have provided further 
insight into the contribution of miRNA in MDS. For example, changes in the expression of 
miR-125 and miR-155 may induce hematopoietic stem cell (HSC) self-renewal. 
Furthermore, deregulation of miR-145, miR-146, miR-150 and miR-122 may result in 
anaemia, thrombocytopenia and/or neutropenia. Several studies have described apparent 
differential gene expression of miRNAs in MDS with the use of high throughput miRNA 
analysis. Other studies have also focused on studying the expression pattern of specific 
miRNAs in MDS. Also, further studies have provided insights into studying miRNAs 
residing in the commonly deleted region (CDR) in chromosome 5 in 5q- syndrome. Figure 
5 shows an overview of miRNAs contribution to MDS pathogenesis (Rhyasen et al. 2012). 
 
 
Figure 1.5: miRNAs contribution to cellular basis of MDS.  
Text highlighted in red represents clinical, cellular and morphological features of MDS. The top red 
box includes some of the reported upregulated miRNAs in MDS and the green box includes some 
of the reported downregulated miRNAs. miRNAs effect in the pathogenesis of the disease is 
indicated by the dashed lines (Rhyasen et al. 2012).  
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1.8.1 Profiling Studies of miRNA Expression in MDS 
Hussein et al. have published the first expression profile of miRNAs in MDS patients. 
(Hussein et al. 2010a). They examined the expression of 365 miRNAs in BM-mononuclear 
cells (BM-MNCs) from 24 MDS subjects with normal and abnormal karyotypes, including 
5q-, -7, and +8 karyotypes in addition to three control samples. Low-density real-time 
PCR-based array was applied for this study. Interestingly, the authors found an association 
between chromosomal alteration and miRNAs regulation. The expression array used in this 
work included eight microRNAs located at chromosome 8, though none of these 
demonstrated showed any significant alteration of expression except for miR-383 and miR-
153. In both RA/RCMB with trisomy 8 and RA/RCMB with normal karyotype, miR-383 
was upregulated. On the other hand, the overexpression of miR-153 in association with 
trisomy 8 was also observed, and this finding may have previously been observed in AML 
cases with trisomy 8 (Garzon et al. 2008).  
Another interesting study by Sokol et al. investigated miRNA expression profiles in MDS 
by using a high-throughput microarray platform, which analysed 290 individual miRNAs 
(Sokol et al. 2011). This study examined BM mononuclear cells from 44 MDS patients 
composed of 66% low/intermediate 1 and 33% high/intermediate 2 risk patient samples 
(based on IPSS prognostic scoring system); with 17 normal control samples were also 
analysed. Based on this analysis, there was an upregulation within 42 miRNAs and a 
downregulation in 34 miRNAs in all MDS patients and controls. Of these, 13 miRNAs (e.g. 
miR-155, miR-125b and miR-181) were differentially expressed between MDS and normal 
controls, with the majority of these have been reported previously as having a role in 
haematopoiesis disorders.  
Further, this report showed a distinct variability in miRNA expression between low and 
high-risk groups, which can be used to discriminate accurately between these subtypes. 
Nine miRNAs were specifically upregulated (miR-181 /b/c/d, miR-221, miR-376b, 
miR125b, miR-155 and miR-130a) and one (miR-486-5p) was downregulated in high risk 
MDS patients. Some of these miRNAs have been validated by RT-PCR and Locked nucleic 
acid in situ hybridization (LNA). LNAs are chemically-modified bases that confer a high 
melting temperature to oligonucleotides, resulting in increased affinity for its 
complementary sequence and thereby making it ideal for the detection of small RNA 
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targets). Also of interest is the fact that this study was the first investigation that showed an 
overexpression of miR-155 in MDS, in accordance with the O’Connell study in murine 
mouse models (O'Connell et al. 2008).  
Merkerova et al. also focused on using miRNA arrays (Illumina array) in studying the 
expression profile of miRNAs in MDS cohorts (Dostalova Merkerova et al. 2011). This 
study is one of the earliest to analyse the expression in CD34+ cells. It showed the 
expression of 1,145 miRNAs in CD34+ from 39 MDS and sAML in comparison with six 
normal control donors. Interestingly, nine out of the 22 differentially expressed miRNAs 
were encoded on 14q32 and these were upregulated in MDS and AML with Metachromatic 
leukodystrophy (MLD) patients. Moreover, this work has corroborated the suggestions and 
observations of other studies with regards to the discrimination between MDS subtypes 
based on the detected differences in the expression pattern between low and high MDS and 
sAML. 
Finally, Erdogan et al. profiled 10 MDS and 10 control BM-MNCs using Agilant miRNA 
microarray (Erdogan et al. 2011). Thirteen miRNAs were differentially expressed between 
MDS and normal in concordance with similar studies in which some of these miRNAs (e.g. 
miR-10b, miR-150 and miR-378) were differentially expressed between MDS and the 
control. These 13 miRNAs were validated by RT-PCR analysis on paraffin-embedded 
samples and the result has shown a high correlation of miRNA expression between the two 
different sample sources, i.e. BM-MNCs and paraffin-embedded sections.  
1.8.2 Expression Analysis of Specific miRNAs in Different MDS Subtypes 
One of the earliest studies was carried out in 2009 by Pons et al., who examined the 
expression of 25 haematopoiesis-related miRNAs in the peripheral blood (PB) and bone 
marrow (BM) samples from 25 MDS patients and 12 controls using PCR. Twelve miRNAs 
were found to be overexpressed in BM in comparison with the control bone marrow sample 
(miR-10a, miR-10b, miR-15a, miR-16-1, miR-17-3p, miR-17-5p, miR-18a, miR-21, miR-
126, miR-155, miR-181a and miR-222). Only six of the miRNAs were overexpressed in 
MDS-PB in comparison with the control PB, (miR-17-3p, miR-17-5p, miR-18a, miR-15a, 
miR-21, and miR-142-3p) (Pons et al. 2009). Furthermore, three of the upregulated 
miRNAs (miR-17-3p, miR-17-5p and miR-18a) belonged to the to the 17-19 miRNA cluster 
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which has been shown to be overexpressed in other cancers such as lymphomas (Mi et al. 
2010) and are implicated in the regulation of apoptotic genes (Isken et al. 2008). In this 
study, the significant overexpression of miR-181a and miR-222 was seen in 84% of patients 
displaying advanced stages of MDS (Pons et al. 2009). Differential expression of miR-181a 
has also been reported elsewhere in correlation with AML subtypes (Debernardi et al. 
2007). In the same study, miR-15a and miR-16 were differentially expressed between high 
and low risk patients.  
There are several different studies on expression patterns of particular miRNAs in myeloid 
disorders by Hussein et al. In one of these, Hussein and his group investigated the 
expression of the miR-221/miR-222 cluster, miR-150 and miR-155 and their targets in MDS 
patients (Hussein et al. 2010b). These miRNAs have previously reported in normal and 
aberrant hematopoiesis (Felli et al. 2005, Choong et al. 2007, Bruchova et al. 2008, 
O'Connell et al. 2008). Formalin-fixed and paraffin-embedded bone marrow samples were 
retrieved from 52 MDS patients at different stages, based on WHO classification, in 
addition to 11 secondary AML and 20 control patients. These were analysed using the Taq 
Man array human microRNA expression assay. Overall, miR-155 expression was not 
significantly changed in MDS subjects and that contradicting the O’Connell’s study 
(O'Connell et al. 2008), where upregulation of this miRNA had induced MDS development 
in a murine mouse model. 
Furthermore, cytogenetic abnormality did not correlate with differences in the expression 
pattern of the miR-221/miR-222 cluster, miR-150 and miR-155 in MDS, or in sAML cases 
with complex karyotypes. The miR-221/miR-222 cluster showed similar expression patterns 
in both control and MDS, while in sAML only miR-221 was downregulated. This 
observation contradicts Pons’ finding with regard to the upregulation of miR-222 in sAML 
(Pons et al. 2009). The Takada et al. study of AML cases also did not show a differential 
expression of miR-221, however in this study miR-142 was overexpressed in AML cases 
that evolved from MDS (Takada et al. 2008). 
In contrast to the Hussein study (Hussein et al. 2010b), there are other studies that indicate 
some correlation between cytogenetic abnormality and miRNA regulation. Bousquet et al 
examined the expression of miR-125b (located at chromosome 11q23) in AML and MDS 
patients with translocation between chromosome 2 and chromosome 11, t(2;11)(p21;q23), 
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when compared with MDS and AML patients without translocation and with healthy 
individuals (Bousquet et al. 2008). Only in the subjects with t(2;11)(p21;q23) miR-125 was 
overexpressed. Another significant correlation of chromosomal abnormality with miRNA 
expression was also detected in AML patients with trisomy 8, which is one of the 
commonest abnormal karyotypes in MDS. It has been found that miR-30d, miR-124a and 
miR-153, encoded on chromosome 8 are upregulated in MDS patients with trisomy 8 
(Garzon et al. 2008).  
1.8.3 Expression Analysis of miRNAs in MDS with 5q deletion 
The 5q− syndrome is a subtype of myelodysplastic syndrome (MDS), characterized by a 
macrocytic anaemia, a normal or elevated platelet count and hypoplastic erythropoiesis 
megakaryocytes. Deletion in 5q results in haploinsufficiency of genes mapping to the CDR 
at 5q31-5q32 (Giagounidis et al. 2006). Expression patterns of the miRNAs residing within 
the deleted region have been investigated in different studies. 
Depletion of miR-143, miR-145, miR-146a and miR-378 were seen in different studies of 
MDS patients with 5q-, thereby suggesting that the contribution of these particular miRNAs 
to 5q- syndrome phenotype (Oliva et al. 2010, Starczynowski et al. 2010a, Kumar et al. 
2011, Sokol et al. 2011, Votavova et al. 2011). However, no differences in the expression 
of these miRNAs were seen in the studies by Hussein et al. and Boultwood et al. in MDS 
cases with -5q (Boultwood et al. 2007, Hussein et al. 2010a).  
Additionaly, the Starczynowski et al. found a significant reduction in the expression of 
miR-145 and miR-146a in MDS with 5q deletion in comparison to other MDS subtypes 
(Starczynowski et al. 2010a). As consequence of this, there was an obvious increase in the 
TIRAP and TRAF6 protein expression, the targets of miR-145 and miR-146a, respectively. 
The elevated expression of these targets has been previously encountered in MDS 
(Hofmann et al. 2002, Gondek et al. 2008, Starczynowski et al. 2008). In addition, the 
effect of target amplification enhances innate immune signalling pathways and this leads to 
the development of 5q- MDS features such as a raised platelet count, megakaryocytic 
abnormalities and neutropenia. Thus, these observations will emphasise the significant 
involvement of TIRAP and TRAF6 in myelopoiesis (Starczynowski et al. 2010a).  
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Another study by Kumar et al. demonstrated low expression of miR-145 in MDS with 5q- 
(Kumar et al. 2011). This study also demonstrated that the deregulation of miR-145 alters 
megakaryocyte production. Furthermore, this study has shown that the overexpression of 
miR-145 is associated with the reduced expression of Friend leukaemia integration 1 
transcription factor (Fli-1) gene. Fli-1 is known for its role in megakaryopoiesis and its 
overexpression can lead to myeloid malignancies.  
Knockdown of miR-145 and miR-146a in mouse hematopoietic stem/progenitor cells 
(HSPCs) leads to overexpression of TRAF 6, mediating the increase in IL-6 expression. 
The overexpression of interleukin 6 (IL-6) was observed in MDS patients particularly in 
5q- subtype (Starczynowski et al. 2010d, Kumar et al. 2011). IL-6 is a pleotropic cytokine 
that induces megakaryocyte proliferation, differentiation and platelet formation (Kishimoto 
2005). Therefore, IL-6 is being postulated as a target of lenalidomide in 5q- syndrome; 
lenalidomide suppresses the expression of IL-6 either by overexspressing miR-145 or miR-
146a or else by inhibiting TRAF 6 expression (Corral et al. 1999). 
In one of Hussein studies, miR-150 was overexpressed in MDS with 5q deletion in 
comparison with normal controls (Hussein et al. 2010b). Downregulation of this miRNA 
has been observed in erythroid differentiation in various studies (Choong et al. 2007, 
Guglielmelli et al. 2007) and the upregulation shown here might contribute to disease 
progression via the suppression of erythropoiesis. Furthermore, a significant inverse 
correlation between miR-150 expression and its target MYB (myeloblastosis) was also 
observed. Moreover, the 5q- syndrome has also been correlated with the overexpression of 
miR-125. It was reported by Bousqute et al. that miR-125 is accumulated in RAEB and 
AML subjects with t(2;11)(p21;q23) in addition to 5q- (Bousquet et al. 2008). Table 5 and 




Table 1.5: Downregulated miRNAs in MDS (Rhyasen and Starczynowski 2012) 
miRNA Chromosome MDS subtype References 
miR-197 1p13.3 All MDS Sokol et al, 2011 
miR-128b 2q21.3, 3p22.3 Del(5q) Merkerova et al,2011 
miR-1284 3p14.1 All MDS Erdogan et al, 2011 
miR-95 4p16.1 Del(5q) Votavova et al, 2010 
miR-1305 4q35.1 All MDS Erdogan et al, 2011 
miR-583 5q15 All MDS Merkerova et al,2011 
miR-143 5q33.1 Del(5q), 
RA/RCMD(tri8) 
Hussein et al, 2010 
miR-145 5q33.1 Del(5q), 
RA/RCMD(tri8) 
Hussein et al, 2010,Starczynowski et al, 2010, Oliva 
et al, 2010, Kumar et al,2010 
miR-146a 5q33.3 Del(5q), all MDS Sokol et al, 2011,Votavova et al, 2010, 
Starczynowski et al, 2010, Oliva et al,2010 
miR-206 6p12.2 Del(5q), all MDS Hussein et al, 2010, Sokol et al, 2011 
miR-93 7q22.1 RA/RCMD(tri8) Hussein et al, 2010 
miR-182 7q32.2 Del(5q) Hussein et al, 2010 
miR-335 7q32.2 Del(5q), 
RA/RCMD(tri8) 
Votavova et al, 2010 
miR-124 8p23.1 All MDS Sokol et al, 2011 
miR-875-
5p 
8q22.2 All MDS Sokol et al, 2011 
miR-30d 8q24.22 RA/RCMD(tri8) Hussein et al, 2010 
miR-661 8q24.3 RA/RCMD(tri8), 
del(5q) 




All MDS Sokol et al, 2011 
miR-326 11q13.4 All MDS Sokol et al, 2011 
miR-940 16p13.3 All MDS Merkerova et al,2011 
miR-423-
5p 
17q11.2 All MDS Merkerova et al,2011 
miR-10a 17q21.32 Del(5q), low-risk 
MDS, CMML 
Sokol et al, 2011, Merkerova et al,2011, Votavova et 





All MDS Merkerova et al,2011 
miR-150 19q13.33 Del(5q), all MDS Sokol et al, 2011, Erdogan et al, 2011, Hussein et al, 
2010 
miR-520c 19q13.41 Del(5q) Votavova et al, 2010 
miR-525-
5p 
19q13.41 All MDS Merkerova et al,2011 




Table1.6: Upregulated miRNAs in MDS (Rhyasen and Starczynowski 2012) 
miRNA Chromosome MDS subtype References 
miR-34a 1p36.23 Del(5q) Votavova et al, 2010 
miR-9 1q22, 5q14.3, 15q26.1 Del(5q) Hussein,2010 
miR-214 1q24.3 Del(5q) Hussein,2010 
miR-181 1q31.3 High-risk MDS, low-risk MDS Sokol et al, 2011, Pons et al,2009 
miR-29c 1q32.2 Del(5q), RA/RCMD (tri8) Votavova et al, 2010 
miR-378 5q33.1 Del(5q) Hussein,2010 
miR-133b 6p12.2 Del(5q) Hussein,2010 
miR-206 6p12.2 Del(5q), all MDS Hussein,2010,Sokol et al, 2011 
miR-148a 7p15.2 Del(5q) Hussein,2010, Votavova et al, 2010 
miR-335 7q32.2 Del(5q), RA/RCMD (tri8) Votavova et al, 2010 
miR-29a 7q32.3 Del(5q) Hussein,2010 
miR-486 8p11.21 Del(5q) Votavova et al, 2010 
miR-320 8p21.3 All MDS Sokol et al, 2011 
miR-548d 8q24.13, 17q24.2 Del(5q) Hussein,2010 
miR-151 8q24.3 Del(5q) Votavova et al, 2010 
miR-24 9q22.32, 19p13.12 Del(5q) Votavova et al, 2010 
miR-199b 9q34.11 Del(5q) Votavova et al, 2010 
miR-126 9q34.3 Del(5q) Merkerova et al,2011 
miR-130a 11q12.1 High-risk MDS, del(5q) Sokol et al, 2011, Merkerova et al,2011 
miR-100 11q24.1 All MDS Sokol et al, 2011 
miR-125b 11q24.1, 21q21.1 Del(5q), t(2;11), high-risk Hussein,2010, Sokol et al, 2011,Merkerova et 
al,2011, Metcalf et al,2005 miR-15a 13q14.3 Low-risk MDS Pons et al,2009 
miR-16 13q14.3, 3q26.1 Low-risk MDS Pons et al,2009 
miR-342 14q32.2 Low-risk MDS, del(5q) Hussein et al,2010, Erdogan et al, 2011 
miR-299-
3p 
14q32.21 All MDS Merkerova et al,2011 
miR-299-
5p 
14q32.21 All MDS Merkerova et al,2011 
miR-329 14q32.31 All MDS Merkerova et al,2011 
miR-370 14q32.31 All MDS Merkerova et al,2011 
miR-376 14q32.31 High-risk MDS Sokol et al, 2011 
miR-409-
3p 
14q32.31 All MDS Merkerova et al,2011 
miR-431 14q32.31 All MDS Merkerova et al,2011 
miR-432 14q32.31 All MDS Merkerova et al,2011 
miR-494 14q32.31 All MDS Merkerova et al,2011 
miR-654-
5p 
14q32.31 All MDS Merkerova et al,2011 
miR-665 14q32.31 All MDS Merkerova et al,2011 
miR-497 17p13.1 Del(5q) Hussein,2010 
miR-451 17q11.2 Del(5q) Votavova et al, 2010 
miR-17-92 17q13.3 Low-risk MDS Pons,2009 
miR-196a 17q21.32 All MDS Sokol et al, 2011 
miR-10a 17q21.32 Del(5q), low-risk MDS, 
CMML 
Sokol et al, 2011, Merkerova et al,2011, Votavova 
et al, 2010, Hussein,2010 miR-1 18q11.2, 20q13.33 Del(5q) Hussein et al,2010 
miR-133a 18q11.2, 20q13.33 Del(5q) Hussein et al,2010 
miR-199a 19p13.2, 1q24.3 Del(5q) Hussein et al,2010, Votavova et al, 2010 
miR-125a 19q13.33 Del(5q) Hussein et al,2010,Merkerova et al,2011 
miR-99b 19q13.33 Del(5q) Votavova et al, 2010 
miR-150 19q13.33 Del(5q), all MDS Sokol et al, 2011, Erdogan et al, 2011 Metcalf et al, 
2005 miR-155 21q21.3 High-risk MDS, low-risk MDS Sokol et al, 2011,Pons et al,2009 
miR-221 Xp11.3 High-risk MDS Sokol et al, 2011 
miR-222 Xp11.3 Low-risk MDS Sokol et al, 2011, Pons et al,2009 
miR-452 Xq28 Del(5q) Hussein et al,2010 
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1.9 MDS with Monosomy 7/7q- 
Monosomy 7/7q- is a common feature of MDS and occurs in 10-15% of MDS patients 
(Toyama et al. 1993a). Moreover, monosomy 7 is commonly seen in children with MDS 
with a frequency of 50% and is clearly seen as a single chromosomal anomaly, while, it 
also appears regularly in adults in conjunction with other complex aberrations (Luna-
Fineman et al. 1995, Kardos et al. 2003). The presences of chromosome 7 alterations are 
associated with poor prognosis, disease progression as well as weak response to treatment 
(Borgstrom et al. 1980, Yunis et al. 1986, Horiike et al. 1988, Schiffer et al. 1989).  
The precise location of the deletions in the long arm of chromosome 7 with specific break 
points has not, as of yet, been determined and it is still unclear if the break point 
recognition has any prognostic significance. Earlier studies have shown that deletions are 
interstitial, with a maximum segment length from 7q22-7q36. Conventional cytogenetic 
analysis and FISH have been commonly employed to detect the precise location of the 
deleted segment. The commonly deleted segments (CDS) that have been predicted are: 
7q22 (Kere et al. 1987, Kere et al. 1989a, Kere et al. 1989b, Kere 1989c, Pedersen-
Bjergaard et al. 1990, Lewis et al. 1996), 7q32-34 (Horiike et al. 1988), 7q32-qter 
(Pedersen-Bjergaard et al. 1990), 7q22-7q36 (Johansson et al. 1993) and 7q35-q36 (Dohner 
et al. 1998). A number of solid tumours also show interstitial deletions in 7q at different 
breakpoints (7q11, 7q22 and 7q31) and this has strengthened the belief of the possible 
presence of tumour suppressor genes on 7q (Liang et al. 1998, Tosi et al. 1999) (Zenklusen 
et al. 1996). For instance, CAVEOLIN-1 is one of the genes that are localized on the 
predicted deleted region in 7q31.1, which has been identified as a tumour suppressor gene 
(Hurlstone et al. 1999).  
There was no specific genetic alteration associated with chromosome 7 abnormalities in 
MDS, until the discovery of acquired UPD in the q arm of chromosome 7 in MDS/MPN 
patients through the application of SNPa in different studies (Gondek et al. 2008, Heinrichs 
et al. 2009, Ernst et al. 2010). The Ernst et al. study focused on screening the region of 
UPD to look for other genetic alterations within the UPD region with the use of SNPa and 
aCGH. This study determined the minimal deleted region (MAR) in 12 patients with 7q 
deletion to be 7q22.3-7qter (qter: the end of the q arm). Based on SNPa and aCGH 
predictions, a microdeletion in 7q36.1 was detected and aCGH result showed that 
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microdeletion encompasses EZH2, chromosome 7 open reading frame 33 (C7orf33), 
Cullin-1 (CUL1). Figure 6 showes UPD in chromosome 7 based on SNPa and micro-
deletion detection in 7q36.1. Furthermore, this study focused on the screening of EZH2 that 
has been found in association with myeloid malignancies (Simon et al. 2008). EZH2 
mutation was identified in nine out of 12 individuals with acquired UPD in chromosome 7. 
In addition, another study by Nikoloski et al. has predicted EZH2 in MDS patients and this 
study showed that patients with abnormal chromosome 7, who have EZH2 mutation, have a 
poor prognosis and a decreased overall survival (Nikoloski et al. 2010). 
The role of gene(s) localized on the CDS in the pathogenesis of MDS is still unclear. 
However, Homobox gene clusters are located in chromosome 7 and encode DNA binding 
transcription factors, which are themselves involved in cell differentiation and stem cellular 
haematopoiesis. A member of this cluster, HOXA9 is highly expressed in CD34+ cells of 
MDS patients when compared with healthy controls. This gene is considered as one of the 
poor prognostic markers (Bei et al. 2005). Such genetic changes may alter the regulation of 
microRNAs. 
Figure 1.6: Detection of micro-deletion by SNP array and aCGH in chromosome 7 in 
MDS patients.  
On the left side, SNP array detects UPD in the 7q in 12 individuals with MDS/MPN. The centre 
shows the detection of micro-deletion at 7q36.1 in one individual by SNP array. The right of the 
figure depicts the detection of the microdeletion by aCGH which showed that the deletion 
encompassing EZH2, CLU1, C7orf33 (Ernst et al. 2010). 
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1.10 miRNA Expression in MDS with Monosomy 7/7q- 
Despite the contribution of miRNAs in MDS pathogenesis, especially in their reported role 
with regard to 5q- syndrome, the association between microRNAs and chromosome 7 
abnormalities remain ambiguous (Garzon et al. 2008, Takada et al. 2008, Pons et al. 2009, 
Hussein et al. 2010b). On the basis of the most contemporary release of the miRbase 
resource, as of November 2011, there are 67 validated miRNAs on human chromosome 7, 
44 being situated on the q arm, and 29 being located within the predicted deleted segment 
by SNP array (q22-qter). (These data were obtained from: 
http://miRecords.umn.edu/miRecords/).  
From all the studies of the expression patterns of miRNAs in MDS and AML, there was no 
clear evidence of a correlation between miRNA expression in MDS and the occurrence of 
monosomy 7/7q- in patients with MDS. However, there is only one study that examined the 
expression of some of chromosome 7 miRNAs in relation to other disorders. Chigrinova et 
al, 2010 profiled DNA, RNA and miRNA from patients with diffuse large-B-cell 
lymphoma (DLBCL) who also possessed 7q+ (19%) though without 7q+ abnormality 
(Chigrinova et al. 2011). As expected overexpression of chromosome 7 miRNAs, miR-96, 
miR-182, miR-589, miR-25, miR-339, miR-489, miR106B and miR-29a, were present in 
DLBCL. 
Other studies too have detected a deregulation in some of chromosome 7 miRNAs utilizing 
expression profiling of hundreds of miRNAs in different diseases. For instance, miR-25, 
localized to 7q22.1, was upregulated in mantle cell lymphomas in comparison with normal 
B-cells (Di Lisio et al. 2010). Furthermore, miR-96, localized to 7q32.2, is upregulated and 
has been associated with carcinogenesis (Myatt et al. 2010). Also, miR-489 and miR-653, 
localized to 7q21.3, were deregulated in diffuse large B-cell lymphoma (Li et al. 2009).  
Some miRNAs within chromosome 7, particularly miR-29, were found to be significantly 
deregulated in different disorders in several independent studies. A study by Ruiz-
Ballesteros et al. has shown a downregulation of miR-29a/, miR-29b-1, 7q32.3, in patients 
with splenic marginal zone lymphoma (SMZL) that was considered as a B-cell malignancy 
lymphoma with deletion 7q32 (Mateo et al. 1999, Ruiz-Ballesteros et al. 2007). This study 
also reported the potential role of losing miR-29a/ miR-29b on the upregulation of TCL1A, 
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T-cell leukemia/lymphoma protein 1A. Interestingly, miR-29a / miR-29b were both 
downregulated in SMZL subjects with 7q deletions. This result implies the contribution of 
this deletion in haematological neoplasm and emphasises the biological importance of this 
region, which including miR-29a/ miR-29b, and TCL1A in MDS with -7/7q-. 
In 2009, Garzon et al, presented another significant observation on the impact of miR-29b 
expression on AML via DNA methyl transferases (DNMTs). Expression of miR-29b 
induces DNA hypomethylation resulting in a decrease in the expression of DNMT3A and 
3B along with re-expression of cyclin-dependent kinase inhibitor 2B (CDKN2B) and 
estrogen receptor 1 (ESR1). Similarly, it was reported that miR-29b decreased the 
expression of DNMT1 indirectly through the reduction of Sp1 expression, a known 
transactivating factor of the DNMT1 gene that is involved in the cell cycle, proliferation, 
apoptosis, and malignant transformation (Garzon et al. 2009). 
Furthermore, the formally discussed Hussein et al. (2010a) study, found 13 miRNAs 
encoded by chromosome 7 detected by miRNAs array (Hussein et al. 2010a). These 
miRNAs are : miR-96, miR-339, miR-182, miR-93, miR-25, miR-106b, miR-196b, miR-550, 
miR-148a, miR-153, miR-29a, miR-183 and miR-335. They were downregulated in RAEB-
2 with monosomy 7 as well as with the normal karyotype. Table 7 shows some studies that 
have identified an association between some of chromosome 7 miRNA and haematological 
malignancies.  
Hence, the identification of the deregulated miRNAs and their target genes might help with 
regards to developing an understanding of the dysregulation of haematopoiesis in patients 
with monosomy 7/7q-. 
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Table 1.7: Studies on miRNAs localized to chromosome 7q. 
MIRNAs Function References 
miR-29a/miR-29b1 Down regulation in patients with splenic marginal zone 





miR-106b Overexpression in multiple myeloma Pichiorri et al, 
2008 
miR-29b Decrease the expression of DNMT1 indirectly by the 
reduction of Sp1 expression, a known transactivating factor 
of the DNMT1 gene that is involved in the cell cycle, 
proliferation, apoptosis, and malignant transformation 
Garzon, 2009 
miR-489 Deregulated in diffuse large B-cell lymphoma (DLBCL)  Cheng Li et al 
, 2009 
Changes in Zinc finger protein growth factor lead to loss of 
function and changes in myeloid development  
Chinavenmeni 
et al,2009  
miR-653 Deregulated in diffuse large B-cell lymphoma (DLBCL)  Cheng Li et al 
,2009 
miR-25 Upregulated in mantle cell lymphomas  Di Lisio, 
Gomez-Lopez 
et al. 2010  
miR-96 Upregulation was contributed in carcinogenesis  Myatt, Wang 
et al. 2010 
miR-595 Upregulation in relation to POX in renal cancer cell W Liu et al, 
2010 
Upregulated in CD4+ in comparison to CD8+ in single 
positive thymocyte. 
Ghisi et al, 
2011 
miR-93, miR-106b, miR-25, 
miR-96, miR-29b 
Downregualted in AML Garzon et al. 
2008 
miR-96, miR-182 miR589, 
miR-25, miR-339, miR-489, 
miR106B and miR-29a 
Overexpression in patients with diffuse large-B-cell 
lymphoma (DLBCL) with +7q  
Chigrinova et 
al, 2010  
miR-96, miR-339, miR-182, 
miR-93, miR-25, miR-106b, 
miR-196b, miR-550, miR-
148a, miR-153 miR-29a, 
miR-183 and miR-335 
Down regulated with different fold in RAEB-2 with 






1.11 Project Aim 
It has been established that miRNAs expression plays an important role in the pathogenesis 
of MDS. However, there remain several limitations within published studies of the role of 
miRNA’s in patients with monosomy 7/7q-, which itself is a poor prognostic subgroup of 
MDS. Accordingly, this project studied the expression of some of chromosome 7 encoded 
miRNAs and identified their functional targets. However, due to the low sensitivity of the 
available target identification assays, a novel functional assay was developed in house by 
Dr. Joop Gäken will be applied within this study (Gaken et al. 2012). This assay has the 
potential for the rapid and specific detection of targets for a given miRNA, that might be of 
pathogenic importance in monosomy 7 disease. Therefore the aims of my thesis are: 
• To use the novel function assay to identify targets for miR-595 that is localized to 
the terminal of chromosome 7. 
• To elucidate the biological function of the identified target by deregulating the 
expression level of the target gene and examine the consequent effects on cellular 
function. 
• To compare the expression level of the selected miRNA and its validated targets in 








2.1.1 PCR, Gel Electrophoresis and Sequencing Materials 
Reagents Brand 
Agarose, molecular biology grade/electrophoresis grade Melford/Sigma 
BigDye® Terminator v3.1 Cycle Sequencing Kit Applied biosystems 
BigDye® XTerminator purification Kit Applied biosystems 
deoxynucleotide triphosphate mix (dNTP) (10mM) Promega 
Ethanol Sigma 
Ethidium Bromide (EB) Sigma 
Gel cleaning kit QiAEX II, gel extraction kit  Qiagen 
GoTaq® Colorless Master Mix Promega 
GoTaq® Flexi DNA Polymerase (5u/µl) Promega 
Nuclease-free water Sigma 
O’Gene Ruler ladder mix (0.1µg/µl) Fermentas 
6x Orange DNA loading Dye  Fermentas 
Tris Acetate-EDTA buffer (TAE buffer) Sigma 
2.1.2 DNA and RNA Extraction Materials 
Reagent Brand 
Chloroform Sigma 
DNeasy blood and tissue kit Qiagen 
Dimethyl sulfoxide (DMSO) Sigma 
2-Propanol (Isopropanol) Sigma 
Ethanol Sigma 
RNeasy Micro Kit Qiagen 
Phase lock Gel Heavy 2 ml 5 PRIME 
RNase free water Qiagen 
TRIzol® Invitrogen 
2.1.3 Cloning Materials 
Reagent Brand 
Bacto™ agar BD 
5-bromo-4- chloro-3-indolyl-β-D-Galactoside (X-Gal) Melford 
Carbenicillin solution 
100mg/ml in 50% Ethanol (10ml) 
Bioline 
Ligation buffer 10x buffer for T4 DNA ligase with 10 
mMATP  (10mM) 
New England Biolab 
Ligation enzyme T4 DNA ligase  (400U/ml) New England Biolab 
Luria Borth (LB) Sigma 
Maxi prep kit Gen Elute plasmid maxi Prep kit  Sigma 
MegaX DH10B Electrocomp™ Cells Invitrogen 
One Shot® Mach1™-T1R  Chemically Competent E.coli Invitrogen 
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Pure Yield™ plasmid Mini prep system Promega 
Restriction endonuclease and buffer New England Biolabs 
Topo TA cloning kit dual PROMOTER pcri-
Topovector  
Invetrogen 
Wizard® Plus SV Minipreps DNA Purification System Promega 
2.1.4 Cell Culture Materials 
Reagent Brand 
Ciprofloxacin (Ciproxin) Sigma 
Coomassi brilliant stain Sigma 
Dulbecco’s Modified Eagle Medium (DMEM) High 
glucose with (4.5 g/l) l-Glutamin, sodium pyruvate  
PPA/ Life Technologies 
Ethylenediaminate tetra acetic acid disodium salt 0.02% 
(EDTA) 
Sigma 
Fetal Bovine Serum (FBS) PAA/Sigma 
L-Glutamine-Penicillin – Streptomycin solution Sigma 
Phosphate buffered saline (PBS) PPA 
Rosswell Park Memorial Institute medium (RPMI 
1640) 
Sigma 
Sodium Pyruvate solution  Sigma 
Trypan Blue 0.4% , 0.85% NaCl Lonza 
TrypLE™ Express Enzyme (1x), phenol red Gibco 
Trypsin Solution (10x) Sigma 
2.1.5 Transfection Materials 
Reagent Brand 
Amaxa cell line neuclofector kit V Lonza 
Amaxa cell line neuclofector Kit R Lonza 
Ganciclovir (GCV) (250 mg) Invivo gene 
Geneticin (G418) disulfite salt Sigma 
Lipofectamine® RNAiMAX Reagent Invitrogen 
Lipofectamine® LTX  with Plus ™ Reagent Invitrogen 
miRIDIAN Hairpin Inhibitor, Human hsa-miR-595 
(5nmol) 
Thermo Scientific 





Ribosomal protein L27a siRNA (h) 10µM Santa Cruz biotechnology 
Stealth RNAi™ siRNA Negative control Invitrogen 





TRC human RPL5 shRNA(5) Open Biosystem-Thermo 
scientific 
TRC human RPS14 shRNA (4) Open Biosystem-Thermo 
scientific 
Tube Ultraclear VWR 
Zeocin (100mg/ml) Invivo gene 
2.1.6 qRT-PCR Materials 
Reagent Brand 
FastStart Universal Probe Master 12.5 ml Roche Diagnostic Limite 
MicroAmp™ Fast Optical 96 well reactions Plate with 
Barcode (0.1ml) 
Life technologies 
SuperScript® VILO™ cDNA Synthesis Kit Life Technologies 
Primers Integrated DNA 
Technologies, Sigma 
TaqMan® MicroRNA Reverse Transcription kit Life technologies 
TaqMan® Universal PCR Master Mix Life technologies 
TaqMan® MicroRNA Assay (has-miR-595) Life technologies 
TaqMan® MicroRNA Assay (RNU6B: Homo sapiens 
RNA, U6 small nuclear 2 (RNU6-2), small nuclear 
RNA) 
Life technologies 
TaqMan® MicroRNA Assay (RNU48: Homo sapiens 
small nucleolar RNA, C/D box 48 (SNORD48), small 
nucleolar RNA) 
Life technologies 
Universal Probe library Probes Roche Diagnostic Limited 
  
2.1.7 Western Blot and IP Materials 
Reagent Brand 
Bovine serum albumin (BSA) Fisher Scientific 
4’,6-diamidino-2-phenyllindole (DAPI) Sigma 
ECL Prime Western Blotting Detection Reagent GE Healthcare 
Formaldehyde Sigma 
Hyper film ECL GE Healthcare 
2-Mercaptoethanol Sigma 
Methanol Sigma 
Mounting medium Merk 
Nitrocellulose Membrane Invitrogen, GE Healthcare 
Non fat dried milk (Marvel) Sainsbury’s 
Novex sharp protein standards Invitrogen 
NuPAGE® Bis-Tris Mini Gel Invitrogen 
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Nupage® LDS Sample buffer (4x) Invitrogen 
Nupage® Tris –Acetate SDS Running buffer (20x) Invitrogen 
Nupage® Transfer buffer (20x) Invitrogen 
cOmplete Protease Inhibitor Cocktail Tablets Roche Diagnostic Limited 
PBS tablet Severn Biotech 
Protein A/G Plus-Agarose Immunopreceipitation 
Reagent 
Santa Cruz 
RadioImmunoPrecipitation Assay (RIPA) Buffer Thermo Scientific 
Sample Buffer, Laemmli 2x Concentrate Sigma 
Sheep serum Sigma 
Sodium chloride (NaCl) Sigma 
Tris Base Fisher Scientific 
TWEEN®20 Sigma 
2.1.8 Polyribosome Profiling Materials 
Reagent Brand 
Cycloheximide (CHX) (20mg/ml) Sigma 
cOmplete Protease Inhibitor Cocktail Tablets Roche Diagnostic Limited 
 
Polymer centriguge tubes, 14x 95 mmm Beckmen Coulter 
RNAsin® Plus RNase Inhibitor (40U/ul) Promega 
Sucrose Fisher scientific 
2.1.9 Cell cycle, Apoptosis and Viability Assays Materials 
Reagent Brand 
7-Aminoactinomycin D (7-AAD) Viability Staining 
Solution 
BioLegand 
Cell- based Assay Annexin V Binding buffer Cayman 
75% Ethanol Sigma 
Fluorescein isothiocyanate (FITC) Sigma 
Pacific Blue™ Annexin V BioLegand 
Propodium Iodide (PI) Sigma 
RNase A Sigma 
Tetrazoliumsalt[3-(4,5-Dimethylthiazol-2-yl) 
2,5diphenyltetrazolium- bromide] (MTT) 
Sigma 
2.1.10 CD34+ Isolation, Culturing and Flow Cytometer Analysis Materials 
Reagent Brand 
Anti-Human CD235a (Glycophorin A) APC eBioscience 
Anti-Human CD71 (Transferrin Receptor) PE eBioscience 
CD34 MicroBead Kit, human Miltenyi Biotec 
Recombinant Human Erythropoietin-α (EPO-α) BioVision 
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Fixable Viability Dye eFluor® 780 eBioscience 
FITC anti-human CD41 BioLegend 
Histopaque 1077 Sigma 
Human Interleukin-3 (IL-3) premium grade (10 µg) Miltenyi Biotec 
Human Interleukin-6 (IL-6) premium grade (10 µg) Miltenyi Biotec 
Human Thrombopoietin (TPO) Research grade (10 µg) Miltenyi Biotec 
Leukocyte cones National Blood Transfusion 
Service 
MACS BSA Stock Solution Miltenyi Biotec 
MACS Rinsing Solution Miltenyi Biotec 
MethoCult® H4034 Optimum (Methylcellulose 
Medium with Recombinant Cytokines for Human 
Cells) 
StemCell 
PerCP/Cy5.5 ant-human CD11b BioLegend 
Recombinant Human Granulocyte Colony-Stimulating 
Factor (G-CSF) (10 µg) 
Millipore 
Recombinant Human Fms-related tyrosine kinase 3 
ligand (FLT3LG) (10 µg) 
PeproTech 
Stem cell factor (SCF), human recombinant, expressed 
in Escherichia coli cell culture tasted (10 µg) 
Sigma 
StemSpan™SFEM (Serum-Free Medium for expansion 




pBabePuro Dr.Joop Gaken 
p3’Tkzeo Dr.Joop Gaken 
P3xFLAG-myc-CMV-26 Dr.Joop Gaken 
pSUPER.retro.neo Dr.Joop Gaken 
PLKO.1 lentiviral vector Dr. Jie Jiang 
2.1.12 Cell lines 
Cell line Provider Cell Source 
MCF7 Dr. Joop Gaken Human breast adenocarcinoma 
HeLa Dr. Joop Gaken Cervical cancer adenocarcinoma 
HepG2 Dr. Joop Gaken Hepatocellular carcinoma 
HCT-116 Professor. Mahvash 
Tavassoli  
Colorectal carcinoma 
HCT-116 p53-/- Colorectal carcinoma with P53 knockout 
K562 Dr.David Darling Chronic myelogenous leukaemia 
HEL Dr.Nick Lee Erythroleukaemia 
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U937 Dr. Terry Gaymes Histiocytic lymphoma 
Jurkat Dr. Terry Gaymes T lymphocyte 
KG-1 Dr. Terry Gaymes Acute myelogenous leukaemia 
2.1.13 Antibodies 










Anti-HSPA14 antibody Rabbit monoclonal Abcam (ab108612) 1:1000 

















Anti-RPL5 antibody Rabbit polyoclonal Abcam 1:500 
Anti-Fibrillarin 
antibody 
Rabbit polyclonal Abcam (ab5821) 1:200 
Phosph-Rb 
(Ser807/811) 
Rabbit clonal Cell signalling 1:1000 
Rabbit Anti Rabbit IgG ECL 1:2000 
Goat Anti goat IgG Alpha Diagnostic 1:2000 
Mouse Anti mouse IgG ECL 1:2000 
2.1.14 shRNA Sequences 










RPL27 lenti shRNA 
(sh1) TRCN0000117396 
ATCGCACCACATCAATGATGG 


















RPL5 lenti shRNA (sh2) 
TRCN0000074997 
AATCGTTTGGTACTGTGAGGG 
RPL5 lenti shRNA (sh3) 
TRCN0000074994 
ATCTCTGTTTGTCACACGAAC 








2.1.15 qRT-PCR Primer Sequences 
  
Description  Sequence Probe Supplier 
RPL27A-F 5' - ACGGGTGAATGCTGCTAAAA - 3' 32 Sigma 
RPL27A-R 5' - GAAGAATTTGGCCTTCACGA - 3'  Sigma 
RPS14-F 5’-GGTCCAGGGGTCTTGGTC-3’ 17 Sigma 
RPS14-R 5’-GGTCCAGGGGTCTTGGTC-3’  Sigma 
RPL5-F 5’-CACTGGCAATAAAGTTTTTTGGTG-3’ 24 Sigma 
RPL5-R 5’-AACCAGGGAATCGTTTG-3’  Sigma 
P53-F 5’-AGGCCTTGGAACTCAAGGAT-3’ 12 Sigma 
P53-R 5’-CCCTTTTTGGACTTCAGGTG-3’  Sigma 
MDM2-F 5' - GACTCCAAGCGCGAAAAC - 3' 68 IDT 
MDM2-R 5' - CAGACATGTTGGTATTGCACATT - 3'  IDT 
CDKN1A (p21)-F 5' - TCACTGTCTTGTACCCTTGTGC - 3' 32 IDT 
CDKN1A(p21)-R 5' - GGCGTTTGGAGTGGTAGAAA - 3'  IDT 
Bax-F 5' - AGCAAACTGGTGCTCAAGG - 3' 69 IDT 
Bax-R 5' - TCTTGGATCCAGCCCAAC - 3'  IDT 
GAPDH-F 5' - AGCCACATCGCTCAGACAC - 3' 60 IDT 











































miR-595F2 AGCCATCAAGATGGTCTGC EcoR1 Sigma 
miR-595R2 CCGGGACATGATGTGATTAG BamH1 Sigma 
miR-671F2 ATTTGACCGGCAGGCTTCT EcoR1 Sigma 







2.2 Buffer, Solutions and Media 
Solution  Preparation 
Blocking buffer for 
western blot 
5%(w/v) Marvel milk powder was dissolved in 1xTBST 
buffer 
BSA wash buffer 5g BSA was dissolved in 1L PBS 
Cell cycle staining 
solution 
400 µl of propidium iodide, 50 µl FITC, 500 µl RNase A 
(10mg/ml) and completed to 10 ml with PBS. Stored in dark 
at 4°C for up to two weeks. 
Coomassie brilliant blue 
stain 
0.25% Coomassie brilliant blue, 45% methanol, 10% acetic 
acid. Made up in dH2O and stored at room temperature. 
Destain solution 40%(v/v) methanol and 10% (v/v) acetic acid. Made up in 
dH2O and stored at room temperature. 
DMEM, complete culture 
medium 
10% FBS, 1% sodium pyruvate and 1% L-Glutamine-
Penicillin- Streptomycin Solution and stored at 4°C 
EPO  500U was made up in 1 ml dH2O and stored at -20°C 
FLT3L (1000ng/ml) Stock solution was prepared in 1ml dH2O to a final 
concentration of 10µg/ml and further dilution was made for 
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small working aliquots in 0.1%BSA in PBS at 1µg/ml final 
concentration and stored at -20°C 
TPO Stock solution was prepared in 1ml dH2O to a final 
concentration of 10µg/ml and further dilution was made for 
small working aliquots in 0.1%BSA in PBS at 1µg/ml final 
concentration and stored at -20°C 
G-CSF Stock solution was prepared in 1ml dH2O to a final 
concentration of 10µg/ml and further dilution was made for 
small working aliquots in 0.1%BSA in PBS at 1µg/ml final 
concentration and stored at -20°C 
Freezing medium for cell 
culture 
10% (v/v) DMSO was added to 90%(v/v) FBS and stored in 
-20°C 
FITC  1µg/ml PBS. Stored at 4°C in the dark 
GCV 10 mM stock solution was made in dH2O and stored in the 
fridge 
RNase A 10mg/ml dH2O stored at -20°C 
lL-3 Stock solution was prepared in 1ml dH2O to a final 
concentration of 10µg/ml and further dilution was made for 
small working aliquots in 0.1%BSA in PBS at 1µg/ml final 
concentration and stored at -20°C 
SCF Stock solution was prepared in 1ml dH2O to a final 
concentration of 10µg/ml and further dilution was made for 
small working aliquots in 0.1%BSA in PBS at 1µg/ml final 
concentration and stored at -20°C 
lL-6 Stock solution was prepared in 1ml dH2O to a final 
concentration of 10µg/ml and further dilution was made for 
small working aliquots in 0.1%BSA in PBS at 1µg/ml final 
concentration and stored at -20°C 
LB medium  Prepared by suspending of 10 g of LB in 500 ml of dH2O. 
The solution was autoclaved and stored at room 
temperature. 
Ampicillin LB agar plates LB Agar plate was prepared by dissolving 10g of LB and 
7.5 g Agar in 500ml dH2O. After autoclaving, the solution 
was allowed to cool to 50°C; 500 µl of carbenicillin 
(1µg/ml) was added. Then poured into sterile 100mm dishes 
at room temperature and stored at 4°C.  
MTT 5 mg/ml was made by dissolving MTT powder in PBS. The 
solution was filtered under sterile and small aliquot was 
frozen and stored at -20°C in dark. 
4% paraformaldehyde 40 g of paraformaldehyde powder was mixed with 40 ml 
PBS, heated at 60°C. To dissolve completely, the pH was 
adjusted with 1 N NaOH until the solution clears. Then, the 
volume was completed to 50ml with PBS and the solution 
was stored at 4°C. 
PBS 10 PBS tablet (phosphate buffer, potassium 
chloride0.02%(w/v), sodium chloride 0.8%(w/v)) dissolved 
in 1L dH2O. Stored at room temperature. 
DNA Loading dye The solution was made up in dH2O and composed of 
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30%(v/v) glycerol and 0.25% (w/v) Orange R. Stored at 
room temperature.  
Puromycin 1mg/ml working solution was made in dH2O from10 mg/ml 
stock solution. 
Primary antibody (for 
western blot) 
Primary antibodies were diluted in the blocking buffer with 
milk or in PBS with1% BSA and stored at 4°C. Sodium 
Azid (10µl/ml) was added for longer storage. 
Secondary antibody (for 
western blot) 
Secondary antibody was diluted in the blocking buffer with 
milk or in PBS with1% BSA. Antibody freshly made prior 
to use.  
RPMI 1640, complete 
culture medium 
10% (v/v) FBS, 1% (v/v) sodium pyruvate and 1% L-
Glutamine-Penicillin- Streptomycin Solution. Stored at 4°C. 
1x MES SDS Running 
buffer  
Buffer made by 1: 20 dilution of 20x Running buffer in 
dH2O. The 1x Solution composed of 50mM MES, 50mM 
Tris Base, 0.1% SDS and 1mM EDTA with pH7.3. The 
solution was stored at room temperature and used several 
times within a period of 3 weeks to 1 Month. 
1 x Transfer buffer  For 1L of 1x transfer buffer 50 ml of 20x transfer buffer was 
mixed with 20%(v/v) methanol and completed to 1L with 
dH2O. The 1x solution composed of Bicine, 25mMBis-Tris 
and 1mM EDTA, pH7.2. Solution was prepared freshly. 
2 x Sample buffer for 
western blot 
20% (v/v) NuPAGE LDS Samples Buffer (4 x), 10% (v/v) 
β- mercaptoethanol were made up in dH2O and stored at -
20°C. 
10 xTBS (Trsi -buffered 
saline) buffer 
12.11 g of 100 mM Tris-base was mixed with 87.66g of 
1.5M NaCl and made up in 1L of dH2O. The solution stored 
at room temperature. 
1xTBST(1xTBS/0.1% 
Tween-20) western blot 
washing buffer 
The solution was prepared by mixing 100 ml of 10 x TBS 
with 1 ml of Tween-20 and completed the volume to 1L 
with dH2O. Solution was stored at 4°C to avoid bacterial 
contamination. 
Solubilisation buffer for 
MTT assay 
The solution was prepared by mixing 10% (v/v) Triton X-
100 with 90% (v/v) Isopropanol and 2 drops of HCl 37% 
(12M). Stored at room temperature. 
1xTAE (Tris Acetate-
EDTA) 
Concentrated buffer powder (10x) was dissolved in 1L of 
dH2O to produce 1x TAE with 40mM Tris-acetate and 1 
mM EDTA. The solution was stored at room temperature. 
X-Gal 20 mg of X-Gal was dissolved in 1 ml of 
dimethylformamide (DMF) to make a final concentration of 
20 mg/ml. The solution was stored at -20°C. 
RIPA buffer  50 mM Tris pH7.4, 150 mM NaCl, 1% (v/v) Triton X-100, 




50mM Tris-HCl pH8.0, 0.5% (v/v) NP-40, 1mMEDTA,150 
mM NaCl, 1mM phenylmethanesulfonyl fluoride (PMSF) 
and  made up in dH2O. Prior to use protease inhibitor tablet 
was dissolved in 50 ml of the buffer. 
10-50% (w/v) Sucrose 0.5 ml of 1M Tris-HCl pH7.4 was mixed with 2.5 ml of 1.5 
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Solution (50 ml) M KCl, 75µl of 1M MgCl2 and 5g (10%) or 25g (50%) of 
sucrose. The solution was made up to 40 ml with dH2O, 
mixed well and was boiled in the water bath for 10 minutes 
to dissolve the sucrose. After cooling to room temperature, 
the solution was completed to 50 ml with dH2O and filtered 
through 0.45micron filter cup.  
55% (w/v) sucrose 27.5 g was dissolved in 50 ml dH2O. 
2xRSB (150 ml) 3 ml of 1M Tris-HCl pH7.4 was mixed with 3 ml of 1M 
NaCl and 450 µl of 1M MgCl2, solution was made up to 
150ml with dH2O. 
Protease Inhibitors (100x) 1 tablet was dissolved in 500 µl.  
Polysome lysis buffer Solution was made by mixing 375 µl of 2 x RSB, 300 µl of 
10% (v/v)Triton X, 300 µl of 5% Deoxycholate, 37.5 µl of 
4mg/ml CHX,15 µl of Protease Inhibitors (100x), 18.75 µl  
of RNAsin and made up to 1.5ml with dH2O 
2.3 Method 
2.3.1 Polymerase chain reaction (PCR) 
2.3.1.1 Oligonucleotide primers 
The microRNA primers were designed based on the primary sequence of the miRNA (80-
100bp) which was obtained from miRbase web resource (http://www.miRbase.org/). This 
sequence was blast analysed via NCBI nucleotide Blast (http://www.ncbi.nlm.nih.gov/) to 
find the complementary genomic region to the miRNA sequence, and ~4Kb size was 
selected. Primer3 software (http://frodo.wi.mit.edu/) was used to design primers for the 
amplification of ~1Kb fragment containing the miRNA. Restriction sites were incorporated 
into the primers sequences to facilitate cloning; enzymes were selected based on NEB 
cutter from New England Bio Lab database (http://tools.neb.com/NEBcutter2/index.php).  
miRNA Primers are listed in (2.1.16).  
Other oligonucleotide primers were designed to anneal to template genomic DNA using 
Primer3 software. DNA sequences were obtained from NCBI-gene 
(http://www.ncbi.nlm.nih.gov/gene).  Also, for the cloning of the generated PCR products, 
the endonuclease restriction sites were incorporated in the primers sequences and they were 
selected based on the NEB cutter as explained previously for the miRNA. Oligonucleotide 
primers were dissolved in Nuclease free water at a final concentration of 100µM.  
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2.3.1.2 DNA amplification via PCR 
For PCR amplification, genomic DNA from human cell lines was used to obtain genomic 
fragments. The PCR reaction mixtures were setup as illustrated in Table 2.1. Primer 
concentrations were adjusted to 100µM based on the oligodeoxynucleotide quality 
assurance document provided with the freezdried oligo’s. 
PCR reactions were carried out using a Thermocycler (Applied biosystem), with 
appropriate cycling conditions for each primer, as shown in Table 2.2. Subsequently, PCR 
products were checked on an 0.8-1 %  (w/v) agarose gel which is described in the following 
section.  
Table 2.1: PCR reaction mixture 
Component Amount 
Template DNA (10-100 ng/µl) ≈2 µl 
5x PCR buffer 10 µl 
MgCl2  5 µl 
0.25 mM dNTP-mix  1 µl 
Forward primer (0.2µM) 0.2 µl 
Reverse primer (0.2µM) 0.2 µl 
Go Taq DNA polymerase  0.25 µl 
H2O (to 50 µl) 
Total 50 µl 
 
Table 2.2: PCR cycle conditions 
Stage Temperature Duration Cycles 
1 95°C 5 min 1 
2 
95°C 1 min 
X40 As appropriate for the primers used 45 sec 
72°C 2.30 min 
3 72°C 5 min 1 
4 4°C Infinity - 
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2.3.2 Gel Electrophoresis and DNA Purification 
2.3.2.1 Agarose gel electrophoresis 
PCR products were run on an 0.8-1% (w/v) agarose gel prepared in 100 ml of 1 x TAE. The 
agarose was dissolved by heating the mixture to boiling point until it dissolved completely. 
After the agarose solution had cooled down to hot at the touch, ethidium bromide 
(0.08mg/ml) was added to allow visualization of DNA fragments under UV light. The 
edges of the electrophoresis tray were sealed with tape and wells’ combs were placed in the 
tray. The agarose solution was poured into the tray and allowed to solidify at room 
temperature. Following that, combs and seals were removed and the gel was transferred to 
the electrophoresis tank, which was filled with 1 x TAE buffer. Subsequently, the DNA 
samples were mixed with (1/6-1/10(v/v) 10 x gel loading dye and loaded into the wells. 5µl 
of the DNA ladder (10kb) was run in parallel with DNA samples as a marker for DNA 
fragment sizes. The gel was run at 120-145V for 20 to 45 minutes and visualised on a UV 
transilluminator. Pictures were taken by GeneFlash photo imager.  
2.3.2.2 Purification of DNA fragments from agarose gel 
The desired DNA fragments from the agarose gel were carefully excised under UV light 
using a clean scalpel. DNA was extracted from the gel and purified using QIAEX II 
Agarose Gel Extraction Kit (Qiagen), following manufacture’s protocol. The agarose gel 
was solubilized in 2 volumes of Buffer QX 1 and 10 µl of QIAEX II beads. The suspension 
was incubated for 10 minutes at 50°C and mixed every 2 minutes to enhance gel melting 
and mixing of the DNA binding beads. Once the gel had completely dissolved, the 
suspension was centrifuged for 30 seconds at 13,000 x g. Supernatant was discarded and 
the pellet was washed again with 500 µl QX1 buffer followed by another two washes with 
500 µl PE buffer to eliminate any agarose residue. Pellet was air-dried for approximately 
15-30 minutes. Subsequently, the bead pellet was resuspended in 20 µl dH2O and incubated 
for 5 minutes at 50 °C. Finally, the suspension was centrifuged for 30 seconds at 13,000 x g 
and the supernatant transferred into a new sterile tube and stored at -20°C. 
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2.3.3 Plasmid DNA Construction and Enzymatic Manipulation 
2.3.3.1 Cloning of PCR product into pCRII-TOPO 
The isolated DNA was cloned into the pCR2.1-TOPO vector using pCRII-TOPO TA 
cloning kit. Topo cloning was performed by mixing 1-2 µl of DNA with 0.5 µl PCR II-
TOPO vector (10ng/ µl), 0.5 µl salt (200 mM NaCl, 10 mM MgCl2), and the volume was 
adjusted to 3 µl with dH2O and the mixture was incubated for 10 minutes at room 
temperature. Subsequently, the plasmid was introduced into bacterial cells by 
transformation of plasmid DNA into chemically competent cells. 
2.3.3.2 Transformation of plasmid DNA into bacterial cells 
MACH1 chemically competent E.coli Top 10 cells were used. A tube containing 50µl 
MACHI cells was thawed on ice and mixed with 1µl of plasmid construct and the mixture 
was then flicked and incubated on ice for a further 30 minutes. Then, the tube was heated 
for 30 seconds at 42°C and immediately transferred to an ice bucket for an extra two 
minutes. The heating enables the permeabilisation of the bacterial membrane, this allow the 
penetration of DNA molecules, then membrane integrity is restored by incubation on ice 
(Panja et al. 2008). The plasmid mixture was then mixed with 350 µl LB medium and 
incubated for 30-45 minutes at 37°C and 100-150 µl of the bacterial suspension was plated 
on LB-agar plates with Carbenicillin (50µg/ml). Prior to plating the transformed bacteria, 
50µl of X-Gal (20mg/ml) substrate was spread on the agar plate to distinguish between 
colonies with an insert (which have a creamy white colour) and colonies without an insert 
(which are blue).  X-gal is used to indicate the activity of β-galactosidase, an enzyme 
encoded by the LacZ gene that hydrolyses X-gal and produces blue colonies. The 
successful ligation of the interested gene into the plasmid with the LacZ gene, which has a 
multiple cloning sites, results in the disruption of LacZ gene and no activation of β-
galactosidase, which results in the formation of white colonies.   
After overnight incubation at 37°C, three to six white colonies were picked and each of 
them was grown in 2ml LB medium with (50µg/ml) Carbenicillin for a minimum of 4 
hours and to a maximum of overnight in a shaking incubator  (lab companion shaker-IS-
971) at 37°C at 250 rpm. Plasmid DNA was purified according to the miniprep purification 
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method described in (2.3.4.1). 
2.3.3.3 Restriction digestion of DNA 
Restriction enzyme digestion was carried out to create the desired DNA fragment for 
cloning. Also, it was used to confirm the plasmid insertion and orientation of the inserted 
DNA during the generation of recombinant plasmid. A reaction mixture for digestions was 
made of 5-10 U of selected restriction enzyme, 1/10 volume of the accompanying 10x 
restriction enzyme buffer, 1-2µg DNA, 0.1µg/ml BSA if required and volume completed to 
20µl with dH2O. The reaction mixture was incubated for 1 hour at the recommended 
temperature for the enzyme. For double digest, which requires the use of two different 
enzymes, the buffer was selected based on the highest activity by both enzymes. The 
digested DNA was analysed on an 0.8-1 % agarose gel (2.3.2.1). Plasmids with the desired 
inserts were then processed for sequencing to confirm the presence of the correct sequence 
(2.3.5). 
2.3.3.4 Ligation 
After confirming the correct DNA sequence was present in the TOPO vector this DNA was 
digested to remove the insert for ligation into expression vector. The desired fragments 
were cut and the gel was purified as explained (2.3.2.2). Then, a small amount of the 
extracted DNA was run on the gel to determine the DNA concentration required for the 
ligation. 
Based on the gel result, ligations were performed in a 1:3 vector to insert ratio. The reaction 
was performed with vector DNA, inserts DNA (3 times vector concentration), 1µl of 400U 
T4 DNA ligase, 1µl of 1x ligase buffer and was made up to 10 µl with dH2O. As control, a 
vector only ligation was also setup. The ligation mixtures were incubated at 4°C overnight. 
Then MACH1 cells were transformed with ligated DNA as described in section (2.3.3.2). 
Single colonies were expanded and plasmid DNA was prepared and verified for the correct 
insertion by restriction digestion. Bacteria with a correct plasmid were streaked on 
ampicillin plates for plasmid maxiprep (2.3.4.2). 
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2.3.4 Plasmid DNA isolation and purification 
2.3.4.1 Minipreparation for plasmid DNA (Miniprep) 
Miniprep purification was done for all small-scale plasmid preparation using Wizard® Plus 
SV Miniprep DNA purification System as specified in the kit’s protocol. Briefly, 2 ml of 
bacterial culture was centrifuged for 5 minutes at 10,000 x g. Supernatant was discarded 
and pellet was resuspended in 250 µl of the Cell Resuspention Solution. Subsequently, cells 
were lysed in 250 µl of the Cell Lysis Solution and mixed by inverting the tube 4-5 times 
followed by the addition of 10 µl of Alkaline Protease Solution and again mixed by 
inverting the tube 4-5 times. After 5 minutes incubation at room temperature, reaction was 
neutralized by adding 350 µl of Neutralization Solution and mixed immediately by 
inverting 4-5 times then centrifuged for 10 minutes at 13,000 x g. After centrifugation, the 
cleared supernatant was transferred to the Spin Column and centrifuged at 13,000x g for 1 
minute. The flow through was discarded and the column was washed with 750 µl Column 
Wash Solution, and centrifuged at 13,000 x g for 1 minute. The washing step was repeated 
with 250 µl Column wash Solution and was centrifuged for 2 minutes at 13,000 x g. After 
transferring the column into a new 1.5ml micocentrifuge tube, 100µl dH2O was loaded on 
the column and centrifuged at 13,000 x g for 1 minute to elute the plasmid DNA. 
2.3.4.2 Maxipreparation for plasmid DNA (Maxiprep) 
A single colony from the plate streaked with the bacteria containing the correct plasmid 
was picked and grown in 150 ml LB medium with 150µl Carbenicillin (50 µg/ml) and 
incubated overnight shaking at 250 rpm at 37°C in shaking incubator. Cells were harvested 
and plasmid was extracted using a GenElute™ High Performance (HP) Plasmid Maxiprep 
Kit, from Sigma following the manufacturer’s protocol. Bacterial cells were centrifuged for 
15 minutes at 6000xg at 4°C. The bacterial pellet was resuspended in 12 ml of 
Resuspention/ RNase A Solution and mixed well until pellet completely dissolved. Then 
cell suspension was lysed with 12 ml Lysis Solution; mixed gently by inverting 4-6 times, 
and followed by incubation at room temperature for 5 minutes until the solution becomes 
clear and viscous. Lysed cell were neutralized by mixing with 12 ml of chilled 
Neutralization Solution; mixed by inverting 4 to 6 times. 9 ml of Binding Solution was 
mixed with the solution by inverting 1-2 times then suspension was immediately poured 
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into the barrel of a filter syringe and incubated for 5 minutes. During the 5 minutes 
incubation, the GenElute HP Maxiprep Binding Column was placed into 50 ml collection 
tube and washed with 12 ml of the Column Preparation Solution and centrifuged for 2 
minutes at 3000 x g. The cell lysate was expelled into the column by passing through the 
syringe filter using the plunger. Half of the lysate filled the column and was centrifuged for 
2 minutes at 3000x g then the rest of the lysate was processed similarly. After passing all 
sample suspension through the column, the column was washed with 12 ml Wash Solution 
1 and centrifuged for 2 minutes at 3000 x g, the eluted solution was discarded. Then 
column was washed with 12 ml Wash Solution 2 and centrifuged for 5 minutes at 3000 x g. 
Transfer the column to a new 50 ml collection tube and plasmid DNA was then eluted with 
3 ml Elution Solution and was centrifuged at 3000 x g for 5 minutes. 
The eluted DNA was sterile filtered and aliquoted under sterile conditions. A small amount 
of DNA was checked and digested with the same enzyme that had been used for digesting 
the ligated plasmid. The recovered DNAs were stored in -20°C. 
2.3.5 DNA Sequencing 
Sequencing started with a PCR amplification reaction. It was performed in a total volume 
of 20µl in a 96 well plate from ABI. The reaction mixture was composed of the following: 
Template DNA (100-300ng/µl   Xµl     
5x sequencing buffer                  4 µl 
*Big Dye terminator v3.1           1 µl 
Primer (5 µM)                            2 µl 
H2O                                           to 20 µl 
* Big dye is a pre-mix of Dye, dNTPs, chain terminators and enzymes that are required for 
sequencing. 
The prepared plate was placed on the PCR machine and the cycle conditions illustrated in 
Table 2.3 were applied. 
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The X-terminator purification reaction was subsequently performed to remove 
unincorporated dye by shaking for 30 minutes at 2000 rpm in Mix Mate shaker from 
eppendorf after which the plate was loaded into the ABI 3130/3130xl genetic analyser. 
The resulting sequences were blast analysed via NCBI nucleotide Blast 
(http://www.ncbi.nlm.nih.gov/). 
 
Table 2.3: Sequencing cycle condition 
Stage  Temperature °C Duration Cycle 
1 96 1       min 1 
2 96 10     sec X 5 
 
 55 5       sec 
60 1.15  min 
3 96 10    sec X5 
55 5      sec 
60 1.30  min 
4 96 10    sec X5 
55 5      sec 
60 2      min 




2.3.6 Cell Culture 
2.3.6.1 Culturing of cell lines 
Adherent cells (MCF7, HeLa, HepG2, HCT-116 and HCT-116p53-/-) were cultured in 
DMEM media supplemented with 10% (v/v) FBS, 1% (v/v) L- Glutamine, penicillin-
streptomycin, and 1% (v/v) sodium pyruvate. Cells were cultured under humidified 
condition at 37°C in 5% CO2. Cells were harvested by removing the DMEM medium and 
washing the culturing surface with EDTA solution. Then, cells were trypsined by using 1x 
Trypsin and incubated for 5 minutes at 37°C to allow the cells to detach from the culture 
surface. To neutralise the trypsin, DMEM was added in greater volume; then cells pelleted 
at 300 x g for 5 minutes. Supernatant was removed and cell pellet resuspended in a suitable 
volume of culturing medium at a specific densities for seeding, determined after counting 
the cells.  
Trypsinisation of cells was also done using TrypLE™ Express (1X), Phenol Red.  It 
reduces the damage to the cells due to the specific action of a single enzyme that cleaves 
the peptide bonds on the c-terminal sides of lysine and Arginine. Its exceptional purity 
increases specificity and reduces damage to cells that can be caused by other enzymes 
present in some trypsin extracts (Lori Nestler et al. 2004). This trypsin solution was used 
with very sticky and clumpy cells such as HCT-116. 
Using TrypLE™ Express did not require a wash with EDTA, it was added directly to the 
cells after removing the culture medium and incubated for 5-10 minutes. Then, the cell 
suspension was collected and pelleted by centrifugation at 300 x g for 5 minutes. 
Suspension cells (K562, KG-1, HEL and U937) were cultured in RPMI medium 
supplemented with 10% FBS, 1% L-Glutamine, penicillin-streptomycin, and 1% sodium 
pyruvate. Cells were harvested by centrifugation of the entire culture medium for 5 minutes 
at 300 x g. Then, cell pellet was resuspended in the culture medium similarly as for the 
adherent cells. HEL cell line is suspension cells but it has a tendency to stick to the culture 
surface, therefore a cell-scraper was used to detach the cells from the surface. 
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2.3.6.2 Cell Counting 
Cell suspension was mixed with Trypan Blue dye in 1:1 ration to distinguish live and dead 
cells. Then, 10 µl from the stained cells was load into Haemocytometer (Neubauer cell 
counting champer, depth 0.1µl) to count the cells.   When counting, only the healthy 
unstained cells, which represent the live cells, were counted. Cells from 4 corner squares 
were counted the cell number per ml was determined following this calculation: 
Cells/ml= average cell count from 4 squares x10-3 x dilution factor 
2.3.6.3 Cryo-preservation of Cell lines 
Adherent cells trypsinised as described earlier (2.3.6.1) then centrifuged at 300 x g for 5 
minutes and suspension cells were centrifuged directly. Cell pellet was resuspended in 
suitable freezing media i.e. DMEM freezing medium for adherent and RPMI freezing 
medium for suspension cells, at a density of 1-2x106/ml. The freezing vials were frozen at -
80°C in a Cryo Freezing Container (Nalgene Mr Frosty) overnight, then vials were 
transferred to liquid nitrogen for longer storage. 
2.3.6.4 Coomassie Blue staining 
To assess cell viability and drug resistance or sensitivity, adherent cells were stained with 
Coomassie Blue. First, when cells in the culture reached the desired stage, the culture 
medium was removed. Cells were washed twice with PBS and fixed by adding adequate 
amount of 4% paraformaldehyde, and incubated for 10 minutes at room temperature. After 
removing the fixation solution, cells were washed twice with PBS and stained for 10 
minutes with Coomassie Brilliant stain. Finally, staining solution was removed and the 
culture surface was rinsed with dH2O and dried at room temperature. 
2.3.6.5 Isolation of CD34+ from human buffy coat 
All CD34+ cells were isolated from peripheral blood mononuclear cells (PBMCs), which 
were isolated from buffy coats using Ficoll density-gradient centrifugation. Buffy coat was 
extracted from leukocyte cones, obtained from the National Blood Service. Leukocytes 
were diluted 4x with PBS in 50 ml Ficoll tube to facilitate cells separation.  Cell suspension 
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was layered on top of 20 ml of Histopaque (1077 density) and was separated by 
centrifugation at 560 x g for 30 minutes without braking. PBMCs that were concentrated at 
the interphase were carefully removed to a new tubed using a Pasteur pipette, resuspended 
in 50 ml PBS and centrifuged at 400 x g for 10 minutes. Supernatant was discarded and cell 
pellet was washed twice in 50 ml PBS with 2% (v/v) FBS and spun at 200 x g for 10 
minutes. Then, to proceed to CD34+ isolation, cells were counted as explained in (2.3.6.2) 
and centrifuged for 10 minutes at 300 x g.  
CD34+ isolation was performed using CD34 MicroBead Kit following the manufacture’s 
protocol. Briefly, for up to 108 total cells, cell pellet was resuspended in 300 µl MACS 
Rinsing Solution, 100µl of FcR Blocking Reagent (Human IgG) and 100µl of CD34 
MicroBeads (conjugated to monoclonal mouse anti-human CD34 antibodies). Cell mixture 
was incubated for 30 minutes at 4 °C. Subsequently, 5 ml of MACS buffer was added to the 
cell suspension and centrifuged for 10 minutes at 300 x g. Cell pellets were resuspended in 
500 µl MACS buffer and magnetic separation was performed using MACS columns. 
Columns were selected depending on the total number of cells, (MS for 2x108 total cells or 
LS 2x109 column). Columns were placed in the suitable MACS Separator. The columns 
were rinsed with the recommended amount of MACS buffer based on the used column size 
according to the manufacture’s protocol. Following that, the cell suspension was loaded 
onto the column; the unlabeled cells were run through. The columns were washed with the 
appropriate volume of MACS buffer. Subsequently, column was removed from the 
magnetic field; the labeled CD34+ cells were eluted to a new clean tube with the 
recommend volume of MACS buffer. Then the cell suspension was centrifuged for 10 
minutes at 300 x g followed by washing the cell pellet with the StemSpan™ Hematopoietic 
Cell Expansion Media and centrifuged at 300 x g for 10 minutes. Subsequently, cells were 
grown according to the hematopoietic progenitor cells culture system. 
2.3.6.6 Hematopoietic progenitor cell culture 
CD34+ cells were cultured under certain condition to induce erythroid differentiation using 
specific cytokines. Cells were cultured in Serum-Free Medium supplemented with 100U/ml 
penicillin/streptomycin, 2mM glutamine, 100 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6 and 
0.5U/ml EPO. Cells were seeded into 24 wells plate in 1 ml medium per well and kept at a 
density of 5x105 to 1x106 cells/well. Cells were counted every 48 hours and they were 
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expanded and grown in a larger well based on the cell number. On day 6, two different 
liquid culture differentiation systems were applied. Cells were counted and aliquots for 
RNA and protein extraction were collected, the remaining cells were split into two cultures 
and centrifuged at 300 x g for 5 minutes. In one culture, cells were induced to differentiate 
to both erythroid and megakaryocytic lineage by addition of EPO (3 U/ml) and 50ng/ml 
TPO. To induce erythroid and myeloid differentiation, 3 U/ml EPO, 15 ng/ml G-CSF and 
40 ng/ml FLT3 was added. Cells were harvested on day 10 or 11 (day 4 of the 
differentiation cycle) and stained for flow cytometrey analysis.  
For flow cytometrey the cells were washed with PBS and centrifuged at 300 x g for 5 
minutes. Cell pellets were resuspended in 1ml PBS and mixed with 1µl of live dead stain  
(eFluor® 780) and incubated in the dark for 30 minutes. Following that, cells were washed 
twice with FACS buffer and centrifuged for 10 minutes at 300 x g. Supernatant was 
removed and cell pellet was resuspended in 200 µl FACS buffer and stained with the 
marker antibodies and incubated for 30 minutes in the dark. Cells were washed twice with 
FACS buffer and centrifuged at 300x g for 10 minutes. Supernatant was removed and cell 
pellet was resuspended in 500 µl FACS buffer and analyzed by FACS scan. 
2.3.7 Transfections of cells 
2.3.7.1 Transfection by lipofectamine 
Adherent cells were seeded into 24 well plates at a density of 2x105 per well in 500 µl of 
DMEM complete medium 24 hours prior to transfection. Suspension cells were seeded in 
1ml RPMI complete medium at the same density on the same date. Transfection was 
carried out using RNAiMAX or Lipofectamine LTX according to the manufacture’s 
protocol. For siRNA, RNAiMAX was used and different concentrations of siRNA were 
used (100nmol-250nmol), siRNA was diluted with OPTIMEM medium to bring the final 
volume to 50µl. 5µl of RNAiMAX was diluted with 45µl OPTIMEM. Both solutions were 
mixed and incubated at room temperature for 10 minutes then 50µl from the mixture was 
mixed with the cells. At relevant time points, cells were harvested as described in (2.3.6.1) 
and RNA and protein samples were collected. 
For plasmid DNA and shRNA transfections Lipofectamine LTX reagent was used. Cells 
were seeded similarly as above. The plasmid or shRNA concentration was adjusted to 10 
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µg and diluted with 50 µl OPTIMEM. The transfection reagent was prepared by mixing 5µl 
plus reagent with 10µl lipofectamin solution then diluted with OPTIMEM. The two 
diluents were mixed and incubated at room temperature for 10 minutes then 50µl was 
mixed with cells. After 24 hour,  adherent cells were transferred to a T75 flask containing 
20ml culture medium. Puromycin selection was performed 48 hours post transfection and 
samples collected for analysis on day 6 or 7 post transfection.  
2.3.7.2 Transfection by Nucleofection 
Cells were harvested as explained earlier in (2.3.6.1). After harvesting and counting the 
cells, 2x106 cells were prepared per transfection. Cells were washed once with PBS, 
centrifuged at 300 x g for 5 minutes; supernatant was discarded and cell pellets were 
resuspended in 100 µl of the appropriate Nucleofection solution. 5µl (2µg) of plasmid 
DNA/shRNA or siRNA 100nmol-250nmol was added to the mixture. The cell suspension 
was transferred to a Nucleofector cuvette, which was then placed in the Nucleofector II 
device. Transfection programme was selected based on the cell type. The transfected cells 
were immediately transferred to tissue culture flasks based on the cell number and 
experiment type i.e adherent cells were cultured in T175 flask, suspension cells were 
cultured in 6 well plates and siRNA experiments were carried out in 24 well plates.  
2.3.8 Lentivirus ShRNA Virus Particle Production 
2.3.8.1 Lentiviral packaging 
The human embryonic kidney cell line (293T) was used to package lentiviral particles for 
transduction of target cells. Cells were seeded at a density of 3x106 per 100mm culture 
dishes and cultured in 10ml complete DMEM and incubated overnight in humidified 
incubator at 37°C, 5%CO2. Plasmid constructs expressing the components for lentiviral 
packaging (pLKO.1-shRNA) were then transfected using CaPO4 co-precipitation method. 
The transfection complex was made up of three plasmids: 3µg pMD2.G (encoding VSV-
G), 7µg pCMV8.9 (gag/pol) (These were kindly provided by Dr. David Darling) and 10µg 
of vector plasmid [pLKO.1 empty, pLKO.1 RPS14 shRNA (kindly provided by Dr. Jie 
jiang) pLKO.1 RPL27A shRNA and pLKO.1 RPL5 shRNA], shRNA sequences  are listed 
in (2.1.14). The plasmids were diluted to a total volume of 500µl with dH2O and mixed 
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with 500µl 0.5 M CaCl2. Subsequently, 1ml of 2x HEBS buffer was added drop wise whilst 
the tube was vortexed. The mixture was incubated for 30 minutes at room temperature to 
allow DNA precipitation. The mixture was added drop wise to the 293 cells. Two 
transfections were carried out per shRNA plasmid. After overnight culture, medium was 
changed and fresh 10 ml DMEM medium was used.  Cells were then cultured for further 
24hrs, and the lentivirus containing culture medium was collected and filtered through a 
0.45µm filter. Lentiviral particles were aliquoted in smaller volume and stored at -80°C. 
2.3.8.2 Lentiviral concentration 
Lentiviral particles (vector supernatants) were concentrated by centrifugation using an SW 
41Ti rotor at 100,000 x g for 2 hours at 4°C. To make 100x concentrated lentiviral pellets 
were resuspended in 100µl of suitable culture medium and incubated for 30 minutes at 4°C.  
The suspension was aliquoted in smaller volume and stored at -80°C. 
 2.3.8.3 Lentiviral transduction 
Adherent cells were seeded in 24 well plates at density of 4-5x105 cells per well in 1ml of 
DMEM 24 hours prior to transduction. Suspension cells were seeded at the same density in 
1ml RPMI and transduced on the same day. Viral particles (100µl) were added to the cells 
and 4µg/ml polybrene was added. After 24 hours, cells were transferred into a T75 flask 
containing 20 ml of DMEM. Culture medium was supplemented with puromycin (2 µg /ml) 
and maintained for 6-10 days. 
2.3.9 DNA and RNA Extraction and Concentration Determination 
2.3.9.1 Genomic DNA extraction 
Genomic DNA was extracted using the QIAamp DNA Mini Kit according to the kit’s 
instruction. Cells for DNA extraction were pelleted and preserved in 200µl PBS. 20µl 
Qiagen Protease (or Proteinase K) was mixed with the cell suspension. 200µl of Buffer AL 
(lysis buffer) was mixed with the suspension and incubated at 56°C in a heat block for 1 
hour. The tube was centrifuged briefly to bring everything down. 200µl of 100% ethanol 
was added to the mixture and the mixture was applied to a QIAamp Mini spin column in 
2ml collection tube. Column was centrifuged at 6000xg for 1 minute and the supernatant 
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was discarded. Subsequently, 500 µl Buffer AW1 was applied to the column and 
centrifuged at 6000 x g for 1 minute. Then, the column was washed with 500µl of Buffer 
AW2 and centrifuged at full speed (13,000 x g) for 3 minutes.  Column was transferred into 
a new collection tube and centrifuged again at full speed for 1 minute to eliminate any 
possible carryover from AW2. After transferring the column into a new 1.5ml 
microcentrifuge tube, DNA elution was carried out with 50µl water or elution buffer which 
was applied to the column and incubated for 5 minutes then centrifuged for 1 minute at 
6000 x g. Isolated DNA was stored at -20°C and DNA concentration was determined using 
NanoDrop (2.3.9.4). 
2.3.9.2 RNA Extraction using TRIZOL  
5x10 5 to 2x10 6 cells from culture were centrifuged at 300 x g for 5 minutes and the 
supernatant was discarded.  The cell pellet was resuspended in 500 µl of Trizol for less than 
1x10 6 cells to 1 ml Trizol for 2x10 6 cells; mixed well by pipetting and stored at -80 °C. 
For extraction, manufacture’s protocol was applied. Briefly, samples were thawed at room 
temperature for 5 minutes till the sample was completely defrosted. Per 1ml Trizol, 200µl 
of chloroform was added to the sample; the mixture was mixed vigorously for 15 seconds 
and incubated at room temperature for 2-3 minutes. Then the mixture was transferred to a 
gel phase lock tubes to facilitate sample separation followed by centrifugation at 12,000 x g 
for 15 minutes at 4°C. The sample mixture was separated into three layers, a lower (red, 
phenol-chloroform, phase), an interphase and the upper (colourless aqueous phase). The 
upper aqueous phase was transferred to a clean centrifuge tube and mixed with 500µl 
isopropanol to precipitate RNA. Samples were incubated for 10 minutes at room 
temperature then they were centrifuged at 12,000 x g for 10 minutes at 4°C.  Supernatant 
was removed from all samples and the invisible RNA precipitate was washed with 1ml 
75% (v/v) ethanol and vortexed. Samples were centrifuged at 7,600 x g for 5 minutes at 
4°C.  Supernatant was discarded and the remaining ethanol was removed carefully and 
RNA pellet was air dried at room temperature for 10-20 minutes. The dried pellet was 
dissolved in 30-45µl RNase-free dH2O. The RNA concentration was determined by 
Nanodrop, as described in 2.3.9.4 and RNA was stored at -80°C. 
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2.3.9.3 RNA extraction using RNeasy Micro kit 
RNA from patient’s CD34+ or CD34+ cultured cells were isolated using RNeasy Micro kit 
from Qiagen following the kit’s protocol. First, cells were processed similarly as explained 
in (2.3.9.2) until the chlorophorm separation step. Once the aqueous layer was collected, it 
was mixed with 70% (v/v) ethanol then the suspension was transferred into RNeasy column 
and centrifuged for 15 second at 7,000 x g at 4°C. The flow through was discarded and the 
washing with ethanol was repeated. Subsequently, column was washed with 800µl RW1 
washing buffer and centrifuged at 8000 x g for 15 seconds. The column was placed into a 
new collection tube and washed twice with 500 µl of RPE buffer and centrifuged at 8000 x 
g for 30 seconds. Finely, column was transferred to a clean 1.5 ml microcentrifuge tube and 
the RNA was eluted with RNase free water by adding 20-30µl of the water on top of the 
column membrane and column was centrifuged for 2 minutes at 8000 x g. RNA samples 
were stored at -80°C and the concentration was determined by NanoDrop (2.3.9.4).  
2.3.9.4 Determination of nucleic acid concentration by NanoDrop 
RNA and DNA concentration was determined by NanoDrop spectrophotometry (Thermo 
Scientific). Nanodrop optical surfaces were first cleaned with 70% (v/v) ethanol then 1µl of 
nucleic acid free water was placed on the lower optical surface to initialize the instrument, 
following the instrument’s instructions. Following that, both optical surfaces were wiped 
with tissue and blanking was performed by loading1µl of the sample elution solution i.e. 
dH2O or elution buffer on the NanoDrop and blank the instrument. After cleaning the 
surfaces, nucleic acid type was selected, either DNA or RNA, and 1µl of each sample was 
loaded onto the optical surface and the concentration measurement was performed. Sample 
quality was determined based on the 260nm/280nm ratio and the accepted purity had to be 
above 1.6. RNA samples were kept on ice during the concentration measurement to avoid 
RNA degradation. 
2.3.10 Quantitative Real time PCR (qRT-PCR) 
2.3.10.1 miRNA reverse transcription (RT) 
miRNA Reverse Transcription kit was used and the manufacture’s protocol was followed.  
RT master mix of 15µl volume was made up of 7µl master mix, 3µl 5x RT primer of 
individual miRNA and 5µl RNA sample. 
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Master mix was prepared on ice and it was composed of: 
Component Volume 
100mM dNTPs 0.15 µl 
MultiScribe Reverse Transcriptase, 50 U/µl.    1µl 
10x Reverse Transcription Buffer 1.5 µl 
RNase Inhibitor, 20U/ µl 0.19µl 
Nucease-free water 4.16µl 
Master mix was mixed in microcentrifuge tube and centrifuged for 15 seconds at 300 x g to 
bring the solution down. Subsequently, the master mix was combined with 5µl total RNA 
of 5-10 ng/ml concentration. The 12µl reaction mix was loaded into a 96 well palate. For 
every miRNA, master mix of each RNA sample was doubled; one volume was mixed with 
the miRNA primer and the other was mixed with the non \coding RNA control primer. 
5xRT primer was thawed on ice and tube was vortexed and centrifuged for few seconds to 
bring the primer solution to the bottom of the tube.  3µl of 5xRT primer from each assay 
(i.e. each miRNA and control non coding RNA primers) was mixed with the 12µl RT 
master mix containing the RNA. Plate was sealed and centrifuged for two minutes at 300 x 
g to bring the solution to the bottom of the well. Following that, plate was placed on the 
thermal cycler and incubation was carried out according to the following conditions: 
Hold 30 minutes     at 16 °C 
Hold 30 minutes     at 42 °C 
Hold 5   minutes     at 85 °C 
Hold        ∞              at 4 °C 
Reaction was stored at -20°C if not processed immediately to PCR amplification. 
2.3.10.2 miRNA quantitative PCR amplification 
qPCR reaction was performed according to the manufacture’s recommendations. 20µl 
reaction was made for each sample in triplicate. The qPCR reaction mix was made 





TaqMan® Small RNA Assay (20X) 1µl 
Product from RT reaction 1.33 µl 
TaqMan® Universal PCR Mix II (2X) 10 µl 
Nuclease free water 7.67µl 
Total volume 20 µl 
 
qPCR Reaction mix (20µl) was loaded in triplicate for each miRNA or control non coding 
RNA into MicroAmp™ Fast Optical 96 well reactions Plate with Barcode and sealed with 
the appropriate plate caps and was centrifuged for 2 minutes at 300 x g.  The plate was 
loaded into an ABI PRISM 7700 instrument (Applied biosystem) and the following cycling 
condition was applied: 
qPCR cycling condition 
Stage Temperature Duration Cycle 
1 50°C 2 minutes 1 
2 95 °C 10 minutes 1 
3 95 °C 
60 °C 
15    sec 




2.3.10.3 cDNA synthesis  
The first strand cDNA was generated from 1 µg of total RNA using SuperScript® VILO™ 
cDNA Synthesis Kit following manufacture’s protocol. The RT reaction was made on ice 
and it was composed of 2µl 10x Super Script ®III Enzyme Blend, which contains: 
SuperScript® III RT, RNase OUT Recombinant Ribonuclease Inhibitor, and a proprietary 
helper protein. Enzyme was mixed with 4µl 5x VILO™ Reaction Mix, which composed of 
random primers, MgCl2, and dNTPs. The mixture was mixed with 1µg RNA (100-500ng of 
total RNA was used when RNA concentration was very low), and the volume was made up 
to 20 µl with RNAse free water. 
All reaction mixtures were centrifuged, to bring down the suspension mixture, and several 
incubations were carried out on thermal cycler according to the following condition: 
RT samples were incubated at 25°C for 2 minutes. Followed by 60 minutes incubation at 
42°C. Then reaction was terminated by 5 minutes incubation at 85°C. cDNA samples were 
stored at -20°C if was not used immediately for qPCR. 
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2.3.10.4 Determination of mRNA relative expression by qRT-PCR 
Quantitative Real time PCR was performed using Universal Probe Library (UPL) from 
Roche, which is based on analyses of any gene in the genome by using a specific probe 
(short fluorescently-labelled hydrolysis probe) from the library in addition to a pair of gene 
specific PCR primers. 
The PCR primers were designed using a LightCycler® Probe Design Software 2.0 which is 
available at the Roche website. This software provides the primer sequences and the 
compatible UPL probe, which are optimal for amplifying the target DNA by RT-PCR using 
the light cycler instrument. 
Reaction mixtures of 20 µl were made for each cDNA in triplicate. cDNA was diluted 
according to the initial RNA concentration i.e. for 1µg RNA, cDNA diluted as 1:100. The 
reaction master mix was prepared according to the following: 
Component Volume 
Diluted cDNA 5 µl 
Forward primer (100µM) 1 µl 
Reverse primer (100µM) 1 µl 
UPL probe 0.25 µl 
Fast start master mix 10 µl 
dH2O 3.75 µl 
Total 20 µl 
Real time PCR reaction mixtures were loaded into MicroAmp™ Fast Optical 96 well 
reactions Plate with Barcode and sealed with optical tube cabs. Then plate was centrifuged 
at 2000 x g for 2 minutes. Then PCR plate was placed on an ABI PRISM 7700 instrument 
(Applied biosystem) and the same cycling condition described in (2.3.10.4) was applied. 
The comparative cycle threshold (CT) method was used also called 2(- ΔΔCT) to determine 
the mRNA relative expression. First, the ΔCT value for each sample was calculated by 
determining the difference between the CT mean of the target gene and the CT mean of the 
endogenous control gene such as GAPDH. Then, ΔΔCT was determined by calculating the 
differences of the ΔCT value of the calibrator samples and the test samples. The fold 
change or the mRNA expression level was calculated according to this formula: 2 - ΔΔ CT 
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2.3.11 Western Blotting 
2.3.11.1Protein extraction 
Total cell protein was extracted from cells growing in the culture. The cell culture medium 
was removed and cells were harvested as explained in (2.3.6.1). The cell pellet was washed 
once with PBS and then resuspended in protein lysis buffer. The volume of the lysis buffer 
was based on the cell number, 50 µl lysis buffer was used for 2x 105 cells. Lysates was 
incubated at 95°C for 5 minutes then stored at -20°C. 
2.3.11.2 SDS- Polyacrylamide gel electrophoresis (Nu-PAGE) 
Nu-polyacrylamide gel (4-12% Bis -Tris Gel) was placed in the electrophoresis tank and 
the comb was removed. Subsequently, the tank was filled with 1x running buffer and 
protein samples were loaded. Novex sharp pre-stained protein standard (Novex) was run 
simultaneously with samples to determine protein size. Electrophoresis was carried out at a 
constant voltage (200V) until the dye reached the bottom of the gel. 
2.3.11.3 Protein transfer to nitrocellulose membrane 
Separated proteins were transferred onto a 0.45µm pore nitrocellulose membrane 
(Amersham) using Xcell™ blot module. Before transferring, Blotting pads, filter papers 
and nitrocellulose membrane were pre –soaked in 1x transfer buffer. On the cathode (-) 
core of the transfer module, three soaked fibre pad were placed followed by filter paper, the 
gel, the nitrocellulose membrane, again filter paper and a fibre pads. The nitrocellulose 
paper was cut to the size of the gel. Once the anode core was placed on top of the pad, the 
module was placed in the transfer tank and filled with 1x transfer buffer. The outer tank 
was filled with dH2O and transfer was performed on ice for 2 hours at 25 volts. 
2.3.11.4 Probing of western blot and detection by Enhanced Chemi-
Luminescence 
The transferred nitrocellulose membrane was blocked in blocking solution for 1 hour at 
room temperature or overnight at 4 °C. Subsequently, the membrane was incubated with 
primary antibody overnight at 4 °C. The membrane was rinsed with TBST and washed 
three times for 10 minutes each. Then, the membrane was incubated with secondary 
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antibody for 1 hour at room temperature. Following that, another three washes with TBST 
were performed. Protein bands were detected using the ECL™ western blot analysis system 
following manufacture’s protocol.  The blot was incubated for 4-5 minutes in the reaction 
solution, then drained and sealed in Saran wrap. The nitrocellulose membrane was then 
exposed to Hyper film™ECL™ for the preferable time and subsequently developed. 
2.3.11.5 Co- immunoprecipitation (Co-IP) 
5-7 x 10 6 Cells were centrifuged at 3000x g for 5 minutes. Cell pellets were lysed in 1 ml 
cold IP buffer with fresh protease inhibitor. Cell suspension was incubated on ice for 10 
minutes then centrifuged for 10 minutes at 10,000 x g at 4°C. The supernatant was 
collected from each cell lysate tube and an aliquot of 20µl was stored as IN PUT at -20°C 
and the rest of the supernatant was divided over two tubes. In one tube 10 µl of primary 
antibody was added and in the other tube, which is the control tube, 5µl secondary antibody 
was added. Subsequently, tubes were incubated overnight, rotating at 4°C. For the pull 
down protein A/G beads were used, 35µl of beads used per tube which means 70µl used for 
sample and control tubes. Beads were washed twice with IP buffer and briefly spun for 15 
second at 10,000 x g. The third wash of the beads was performed with RIPA buffer and 
beads resuspended in 70µl RIPA buffer. 35 µl of bead suspension was added to each of the 
cell lysate samples and the samples were incubated for 1 hour rotating in the cold room. 
Then lysate was washed three times with RIPA buffer, and spun for 15 seconds each time. 
Laemmli buffer was thawed in a water bath and was diluted with RIPA buffer to reach a 1 x 
concentration by mixing 30 µl of 2 x laemmli buffer with 30 µl of RIPA buffer. Then, 30 µl 
of the mixture was used to resuspend the lysate pellet after the third wash. Subsequently, 
tubes were heated on the heat block at 100 °C for 5 minutes and stored at -20 °C. To 
analysis the samples, samples were loaded directly on polyacrylamide gel and regular 
western blot protocol (2.3.11) was followed. For the In Put sample, which is run as a 
control, the sample was mixed with the 2 x laemmli buffer in a volume equal to the sample 
volume to reach a 1x concentration, sample was processed similarly as the other samples 
regarding heating and storing condition. 
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2.3.11.6 Immunofluorescence Assay 
 5x104 cells were re-suspended in 200µl PBS and cells were spun onto slides using a 
Cytospin at 300 rpm for 5 minutes. The slides were marked and left to dry at room 
temperature. Subsequently, cells were fixed with 100µl 4% PFA in PBS for 15 minutes at 
room temperature. Slides were washed three times with PBS for 5 minutes each with 
continuous shaking on the shaker. The cells were permeabilised in 100µl 0.1% Triton x-100 
in PBS. Then, slide was washed three times with PBS for 5 minutes each. Followed by 
blocking for 1 hour with 100µl  (1% BSA, 5% (v/v) sheep serum in PBS), cells were 
washed briefly in PBS.  Subsequently, cells were incubated for 1hour at room temperature 
with primary antibody at 1:200 dilutions in TPBS. Cells were washed twice in TPBS for 10 
minutes and incubated in the secondary antibody conjugated with fluorescent dye at a 
dilution of 1:200 in TPBS for 1hour at room temperature. Cells were washed twice for 10 
minute each and stained with 100µl DAPI for 5 minutes at room temperature. Slides were 
washed with TBS for 10 minutes and air dried for 4 minutes at room temperature. 10µl 
mounting media was applied on the slide and covered with 22 x22 mm coverslip. Slides 
were analysed with confocal microscopy to visualize signals on the nucleolus. Confocal 
microscopic analysis has been performed in Cambridge university-MRC-Lab with the help 
of Dr. Shengjiang Tan. 
2.3.12 Polyribosome Fractionation 
Polyribosome experiment was performed in Cambridge University in the lab of prof. Alan 
Warren. All the reagents and the assay materials were kindly provided by them and all the 
work was done with the help of Dr. Shengjiang Tan. 
Cyclohexamide was added to the cells in the culture to a final concentration of 100 µg/ml 
and incubated for 15 minutes in a tissue culture incubator. Cyclohexamide is an inhibitor of 
protein synthesis; it blocks the translation elongation and holds ribosomes on the mRNA. 
After incubations, 1-10x106 cells were harvested as explained (2.3.6.1) and centrifuged for 
5 minutes at 300 x g, medium was aspirated completely and cell pellet was washed with 
PBS containing 50 µg/ml cyclohexamide. Supernatant was completely discarded and cell 
pellet was frozen at -80°C.  All these steps were carried out on ice; both cells and solution 
were kept on ice, to avoid translation elongation. Samples were transferred to MRC lab-
Cambridge University in dry ice and processed immediately upon arrival. 
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Cell pellet was partially defrosted on ice and transferred to a 1.5 ml microcentrifuge tube, 
for consistency approximate similar pellet sizes were collected from all samples. Cells were 
lysed in polysome lysis buffer according to the pellet size. Cells were resuspended in 200-
250µl of lysis buffer and were incubated on ice for 15 minutes and mixed several times by 
vortexing. Subsequently, lysed cells were centrifuged at 10,000 x g for 10 minutes at 4 °C. 
After centrifugation, cytoplasmic extract was transferred to a new collection tube from 
which 10µl was used to measure the concentration using a spectrophotometer. The 
concentration of the nucleic acid in the lysate was determined by mixing 10µl of the lysate 
with 490µl of dH2O and blank was made by mixing 10µl of lysis buffer with 490µl dH2O 
and reading the OD 260 with a spectrophotometer. Equal lysate should be loaded on the 
sucrose gradient, thus all lysates were adjusted corresponding to the lowest OD and the 
volume of each sample was made up to 200 µl with lysis buffer. Then, the 200 µl of the 
cytoplasmic extract was layered on top of 10-50 % (w/v) sucrose gradient, which was 
prepared by Dr. Shengjiang Tan. The sucrose gradient was placed in SW41Ti rotor bucket 
and kept in the refrigerator, to reduce possible RNAse activity, until the lysate fractions 
were collected. The cytoplasmic extract was separated by centrifugation for 1 hour and 57 
minutes at 40,000 x g at 4°C in a SW41Ti rotor (Beckman). The sucrose gradient tubes 
were carefully removed from the centrifuge and placed on the ice. To avoid disturbing 
gradient, tube wells in the ice were premade with an empty tube.  The gradients were 
fractionated using the polysome profile fractionator, which is composed of syringe pump, 
UV monitor, amplifier (amplifying the signals to enhance the resolution), fractionator and 
data acquisition module. Figure 2.1 shows the polysome fractionator in prof. Warren’s 
laboratory. Gradient was placed in the fractionator (tube holder), the top of the tube was 
connected to the outlet and the bottom of the tube was placed on a stage in which needle 
penetrate the bottom of the tube. Then, the gradient underwent an upward movement with 
55% (w/v) sucrose, which was placed in the syringe pump.  Polysome profiles signals were 
detected using UV monitor at A254 and these signals were translated into a digital format, 
which can be viewed and saved on a PC using the data acquisition software. The monitor 
was recording signals starting with free materials followed by 40S ribosomal subunit, 60S 
ribosomal subunit and polyribosome complexes. Fractions from each subunit were 
collected through the outlet in 1.5 ml tube as 1ml/ tube. Fraction tubes were stored in -
20°C.  
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2.3.13 Cell cycle 
Cells were counted and 2-5 x105 cells were pelleted by centrifugation at 300 x g for 5 
minutes.  Supernatant was aspirated and cells were fixed in 1ml 70% (v/v) ice cold ethanol 
which was added drop wise while vortexing then stored at -20°C. For cell cycle analysis, 
ethanol-suspended cells were centrifuged for 5 minutes at 300 x g.  Ethanol was decanted 
and cell pellet was washed in PBS twice and centrifuged in FACS tubes at 300 x g for 10 
minutes. Pellets were resuspended in 500 µl of cell cycle staining buffer and incubated in 
the dark for 15-30 minutes at 37°C. Cell cycle analysis was performed by flow cytometric 
analysis using Canto 2. The data was analysed using FlowJo. To exclude artefact and 
double cells, doublet discrimination gate was performed with forward scatter Area(FSC-A) 
against width (FSC-W) and another doublet discrimination gate was performed similarly 








Figure 2.1: polysome fractinationationa and profiling.  
Syring was filed with 50 ml 55% (w/v) sucrose and placed on the pump holder. Ruber tube was 
attached to the syring and to the metal needle attched to the underside of the black circular knob. 
Pump motor was turned on using the Reverese flow rapid setting to accommodate the syring. Then, 
Forword flow was done to  get the air puple out of the rubber tubing, once the scrouse comse throgh 
the needel, power was turned off. Sucrose tube was assembeled on the tube holder attched to the 
optical unit and the needle on the knob was  adjusted to be centered  beneath the tube. Then, screw 
on the top of the hloder was tighten around the tube to hold it and the stage was adjusted to allow 
the needle to come throgh the botom of the tube.Forward option was turnd up with high sensitivy 
adjustment on the UV detector. A rubber tube was connected  from the optical unit to the fractinator 
and 1.5ml tubes were placed on the fractinator for samples collection with setting  which was 
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2.3.14 Annexin V staining 
Annexin V is a cellular protein that binds with phosphatidylserine (PS), which is normally 
located in the inner plasma membrane. During apoptosis, PS translocates to the 
extracellular membrane which makes it target for phagocytosis and can be detected by 
fluorescently labelled Annexin V (Koopman et al. 1994). To stain the cells, cell pellets of 
2-5 x105 cells were washed in ice cold PBS and centrifuged at 300 x g for 5 minutes. Then, 
cells were washed with 1x Binding buffer, and spun in FACS tube at 300 x g. The pellet 
was resuspended in 250µl of 1x Binding buffer and stained with 3-5 µl of Annexin V, based 
on the cell number, and incubated in the dark at room temperature for 10 minutes. The 
stained cells were then washed twice with the binding buffer and spun at 300 x g for 10 
minutes and cells were resuspended in 250-500µl binding buffer. Before analysing the cells 
on the flow cytometer, the cell suspension was stained with 3µl of fluorescently labelled 7-
ADD. 7-ADD can penetrate the membrane of dying cells and stain them to discriminate 
between dead and live cells and in apoptotic assay it is used to distinguish necrotic cells 
from apoptotic cells. FACS analysis was performed in FACS Canto 2. And the data was 
analysed using FlowJo. 
 2.3.15 MTT assay 
MTT assay was used to assess cell viability, which is based on determining the metabolic 
activity of the cells. The yellow MTT is reduced by NAD(P)H dependent oxidoreductase 
enzyme in metabolically active cells to generate a purple insoluble formazan products. This 
assay was performed by seeding the cells in 96 well plates (Flat bottom) at density of 1000-
5000 cells/ 100µl of medium. Cells from each sample were plated in triplicate and three 
wells were filled with medium alone and were used as a control. 20µl of 5mg/ml MTT was 
mixed with each well, then the plate was incubated for 2-4 hours, until purple particle were 
visible, in a humidified incubator 5% CO2 at 37°C. After this incubation 150 µl of 
solubilisation solution was added to each well including control wells and the plate was 
incubated in the incubator in the dark for a further 2-4 hours or overnight. The absorbance 
of each well was measured at 610 nm in a microtiter plate reader. If the readings were very 
low the plates were incubated for longer. Data was analysed by calculating the average 
value from the triplicate readings, then it was normalized with the blank by subtracting the 
average value of the blank. 
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2.3.16 Colony forming cell assay using methylcellulose 
This assay was used to study the potential of haematopoietic progenitor cells to proliferate 
and differentiate into colonies in semi-solid media under the stimulation of cytokines. The 
media bottle was thawed at 2°C to 8 °C overnight.  After the media completely thawed, it 
was liquated as 3ml in 15ml falcon tube, which is the amount required for a single 
experiments and stored at -20C.until use. Aliquots were thawed again at 2°C to 8 °C 
overnight and mixed with cell suspension. Cells were counted and the required number 
which was (3-5x103, was spun at 300 x g for 5 minutes. The cell pellet was resuspended in 
100 μl STSFM and mixed with the methylcellulose media. Subsequently, cell suspension 
was vortexed vigorously and incubated for 30 minutes at room temperature to allow air 
bubbles escaped.  The 3ml suspension was layered on 6 well tissue culture plate using a 
5ml syringe fitted with 16 gauge needle. One well was filled with 3-4 ml sterile water to 
avoid drying. The plate was placed in larger dish filled with sterile water and covered to 
preserve humidity. Plate was incubated for 14-16 days in a humidified incubator 5% CO2 at 
37°C to allow colony formation and the analyses was performed according to the cell 
morphology. 
2.3.17 Statistical analysis 
The significance of the experimental results was calculated using Student’s t-test. If other 
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MicroRNAs play a vital role in regulating a large number of normal biological processes 
including cell proliferation, differentiation, development and apoptosis (Ambros 2004). 
Therefore, dysregulation of miRNAs expression contributes to a variety of cancers 
(Lujambio et al. 2012, Mendell et al. 2012). There has been a lot of progress regarding the 
understanding of the mechanism of action of miRNA and the identification of miRNAs 
targets, which is a key step in understanding miRNA cellular function. Despite the progress 
in miRNA target prediction methods, including bioinformatics approaches and biological 
experiments; these methods which have been explained in the Introductory Chapter, have a 
major drawback. The most common feature in the available target prediction methods is 
based on the base pairing between the miRNA and the complementary sequence(s), which 
are often in the 3’ UTR of mRNA (Didiano et al. 2006, Brodersen et al. 2009). 
Computational algorithms are based on seed pairing, the seed region being the interaction 
region of the miRNA, which is a 6-8 nucleotides-long stretch at the 5’ end of the miRNA. 
However, this seed matching principle is not applicable to all miRNA-target interactions 
and therefore algorithms based on this, result in the prediction of thousands of false positive 
targets (John et al. 2004, Witkos et al. 2011). There were many examples showing that 
perfectly matched seed pairing is not necessary and the interaction between miRNA and 
mRNA can be located at any other region. For example, miR-24 and miR-146a regulate 
their target genes by binding outside the seed region (Lal et al. 2009, Lu et al. 2010). 
However, due to the low sensitivity of the available target identification assays, most 
miRNAs targets have not been identified. At the time of the research the last miRBase 
Release 16 in Sept 2010, showed 1,048 identified human miRNAs and only 206 of them 
have validated targets, either by western blot or expression array, based on the last update 
in miRecords at that time (http://mirecords.umn.edu/miRecords/). These findings had not 
much changed in the last miRBase release (Release 20, June 2013), there are 1872 
precursors and 2578 mature human miRNAs; only 286 of them have validated targets based 
on the last update from miRecords (April 27, 2013). Accordingly, novel experimental 
assays are urgently required for an efficient screening and the identification of miRNAs 
targets (Thomas et al. 2010). 
Therefore, Dr. Joop Gäken has developed a novel functional assay, which has the potential 
for rapid and specific detection of targets for a given miRNA in a single assay (Gaken et al. 
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2012). This methodology relies on the functional activity of a miRNA via positive/negative 
selection, which will overcome the limitations in the other methodologies, which use 
miRNAs target predictions that are mostly based on the perfect complementary of the seed 
sequence with target binding sites. Another advantage of this methodology is the ability to 
identify targets that are either downregulated by mRNA cleavage or translation inhibition.  
This assay is based on the directional cloning of a cDNA library (Sigma) derived from 10 
different human tissues and 10 human cell lines, representing 16,923 unique genes, 
downstream of a TKzeo fusion gene in plasmid p3’TKzeo conferring zeocin resistance and 
Ganciclovir sensitivity. The assay is illustrated in Figure 3.1. The library was introduced 
into a cell line selected based on the miRNA expression profile data of 470 miRNAs in 
several adherent cell lines (293T, HeLa, CHO, MCF7, COS7, NIH/3T3, TE671, HepG2 
and Saos2) using Illumina bead assay.This work was performed by the company 
Geneservice. Normalised expression levels were between 1 (no expression) and 60,000 and 
therefore Dr. Gäken decided to take a 500-fold change as the cut-off point for expression of 
the miRNA of interest. This was based on the qRT-PCR results of the miRNA expression, 
which had shown a strong correlation between the qRT-PCR and the array profiling data. 
For example, miR-10a expression was tested in several of the above cell lines and was 
found to be very low in MCF7 cells in both assays. These results were obtained by 
Dr.Gäken before the start of this project and the data obtained were used for selecting 
miRNAs for this project. 
However, to better understand the genomic complexity of MDS with abnormal 
chromosome 7, I chose to focus on miRNAs localised to this chromosome. Previous studies 
have shown differences in disease progression between patients with monosomy 7 and 
those with del 7q (Cordoba et al. 2012, Jerez et al. 2012). Loss of genetic material from this 
region, suggests its importance in disease progression and transformation. In order to 
identify the miRNA relevant to MDS pathogenesis in MDS with chromosome 7 
abnormalities, I selected miRNAs from the long arm of chromosome 7 that are either not 
expressed on the MCF7 cell line, the functional assay cell line, or are expressed below 500 
as explained above. Therefore I selected 4  miRNA’s that are expressed at very low levels 
in MCF7 cells i.e; miR-489 and miR-653 which are localized on 7q21, miR-671 at 7q36.1 
and miR-595 at 7q36.3. 
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Figure 3.2 shows some of the miRNAs that are located on 7q and the miRNAs with low 
expression in all cell lines have been highlighted 
Furthermore, I was interested in the miRNAs located on the terminal of chromosome 
7(q36.1-q36.3). This region is part of the commonly deleted region of 7q- as determined by 
SNP array karyotyping, as identified by Wang et al (7q22–7q36.3) (Wang et al. 2008) and 
by Ernst et al (7q22.3-7qter) (Ernst et al. 2010). This part of chromosome 7 contains the 
EZH2 gene; EZH2 mutations recurrently occur in MDS patients with -7/7q- as explained in 
the introduction (Ernst et al. 2010, Makishima et al. 2010). Also, haploinsufficiency of 
EZH2 and other genes located at 7q have been identified in MDS patients that had a 
cytogenetically normal chromosome 7, which implies that other genetic or epigenetic 
changes may down-regulate the expression of these genes (Jerez et al. 2012). Therefore, all 
the selected miRNAs were cloned into pBabePuro vector and the most terminal (7q36.3) 
miRNA (miR-595) was the first miRNA used in the functional assay. 
3.2 Aim 
• Application of novel functional assay to identify putative targets for the selected 
miRNAs located on the long arm of chromosome 7. 






Figure 3.1: Principal of functional assay. 
Transfect MCF7 cells with plasmid library with thymidine kinase-zeocin fusion protein (TKzeo). 
Transfected cells are selected with zeocin for 10 days. Zeocin resistance cells are transfected with 
pBabePuro expressing the miRNA and after 48 hrs cells are selected in puromycin. After 96 hrs, 
cells are treated with GCV and only cells in which the miRNA has downregulated the Tkzeo 
expression should survive. Genomic DNA isolated from the GCV resistant cells are PCR-amplified, 







Figure 3.2: Common microRNAs located on the q arm of chromosome 7. 
miRNAs highlighted in red  are not expressed or are very low expressed in the adherent cell lines 
profiled for expression of 470 miRNAs, including 293T, HeLa, CHO, MCF7, COS7, NIH/3T3, 




3.3.1 Plasmid construction 
The primary sequences of selected miRNAs (80-100bp) were obtained from the miRBase 
web resource (http://www.miRbase.org/). This sequence was BLAST analysed via the 
NCBI nucleotide BLAST (http://www.ncbi.nlm.nih.gov/) to find the complementary 
genomic region to the miRNA sequence, and the ~4Kb size was selected. Primer3 software 
(http://frodo.wi.mit.edu/) was used to design primers for amplification of a  ~1Kb fragment 
containing the pre-miRNA hairpin sequence, miR-595 primer sequence is available in the 
Appendix A1.1. Restriction sites were incorporated into the primer sequences to facilitate 
cloning and enzymes were selected based on the NEB cutter from the New England Biolab 
database (http://tools.neb.com/NEBcutter2/index.php). The primers sequence and 
restriction enzymes are given in Section 2.1.16. 
For PCR amplification, MCF7 genomic DNA was used to obtain genomic fragments 
containing the miRNA of interest. PCR products were checked on an 0.8% (w/v) agarose 
gel and the correct fragment was purified and cloned into the PCR II-TOPO vector (PCR 
set up, DNA extraction from agarose gel and TOPO cloning were described in Sections 
2.3.1, 2.3.2 and 2.3.3). 
All plasmid colonies were screened by restriction endonuclease digestion to search for the 
presence of a correctly sized insert (the amounts of the enzyme, DNA, type of buffer and 
reaction temperature followed the manufacture’s recommendations). Plasmids with the 
desired inserts were then processed for sequencing as described in Section 2.3.5. After 
confirming the desired DNA sequence, this DNA was digested to cut the insert for 
subcloning and was cloned into the pBabePuro retroviral vector plasmid (Morgenstern et 
al. 1990). This plasmid acts as a mammalian retroviral vector conferring puromycin 
resistance, which is useful for mammalian selection. Figure 3.3 shows the plasmid clone 
map and indicates the insert cloning site. pBabePuro was digested with the same restriction 
enzyme to leave compatible ends to the insert. The desired fragments were cut and the gel 
was purified, as previously explained. Then, a small amount of the extracted DNA was run 
on the gel to determine the DNA concentration required for ligation. 
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Then MACH1 cells were transformed with ligated DNA as described in Section 2.3.3. A 
single colony was expanded by plasmid miniprep and plasmid DNA was prepared. The 
correct insertion was verified by restriction digestion. The bacteria with a correct insert 
were streaked on an ampicillin plate to obtain single colony to start a maxiprep of plasmid 
DNA. Plasmid amplification by mini prep and maxi prep are explained in Section 2.3.4.  
 
Figure 3.3: pBabePuro vector map 
The genomic DNA containing mir-595 inserted into pBabePuro vector via its restriction sites 
BamHI and EcoRI. 
3.3.2 Library construction 
3’UTR cDNA library (Sigma, MREH01) derived from 10 different human tissues and 10 
human cell lines and representing 16,923 unique genes was cloned downstream of the 
TKzeo fusion gene into Sfi1 sites in p3’TKzeo vector. p3’TKzeo contains two different Sfi1 
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sites (bold) that are different in their interpalindromic sequence (underlined) to allow 
directional cloning (TCGAGGCCATTAAGGCCGGCCGCCTCGGCCCACTTC )  
The cloned library was electroporated into MegaX DH10BTM T1R ElectrocompTM Cells by 
electroporation following the manufacturer’s protocol. Approximately one million 
individual colonies were isolated from 25 square 20x20 cm2 plates; they were scraped off, 
pooled and expanded by maxi prep. The isolated plasmid library DNA was used for 
transfection into MCF7 cell line. 
Figure 3.4: P3’ Tkzeo vector map. 
A human cDNA library was inserted directionally downstream of a TKzeo fusion gene via 2 SfiI 
sites that are different in their interpalindromic sequence. (http://www.sigmaaldrich.com)  
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3.3.3 Transfection and selection 
For library transfection, a Lonza nucleofector kit was used and the kit’s protocol was 
followed (Amaxa Cell Line Nucleofector Kit V for MCF7, VCA-1003). 25 transfections 
were required for each miRNA with 2x106 cells/ transfection. To approach this number of 
cells, MCF7 cells were grown and expanded in five T-175 flasks to give a sufficient 
number of cells for transfection. Cells were trypsinized at 80-90% confluence and counted, 
and 2x106 cells were centrifuged at 300xg for 5 minutes. The pellet was resuspended in 
100µl Nucleofector solution per transfection and mixed with 5µl Library DNA. The 
transfection was carried out using Neuclofector according to the method described in 
Section 2.3.7.2. Electroporated cells were grown in large flasks filled with 40 ml medium. 
After 48 hours, cells were selected with zeocin (500 µg/ml) for 10 days. Transfected cells 
should express the TKzeo fusion protein, and confer zeocin resistance. After zeocin 
selection, ~100,000 colonies were obtained, expanded and stored in liquid nitrogen. 
3.3.4 miRNA transfection 
For miRNA transfection, MCF7 cells containing the library were transfected, using 
Nucleofector (as explained in Section 2.3.7.2), with a pBabePuro plasmid expressing miR-
595 (24 transfections). Furthermore, empty vector pBabePuro was transfected into another 
aliquot of the library-transduced cells to act as a control (1 transfection). After 48 hours, 
cells were treated with puromycin (2 µg/ml) to enable the selection of the transduced cells. 
96 hours after the start of puromycin selection, cells were selected with GCV (8µM). The 
control cells transfected with pBabePuro, were divided into two and either selected with 
puromycin only to determine the transfection efficiency or selected with puromycin and 
GCV to determine the false positive rate. Dr.Gäken has determined the concentration for all 
drugs previously in a ‘lethal dose’ screening that was applied to the same cell line. After 10 
days under GCV selection, DNA from the remaining GCV resistant cells were extracted 
separately from each of the 24 flasks for PCR amplification and sequencing for target 
identification.  
3.3.5 PCR amplification of DNA from GCV resistant colonies and sequencing 
DNA was extracted according to the manufacturer’s instruction and amplified by PCR as 
explained in 2.3.1.2. 
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To optimize the PCR amplification several primer pairs flanking the SfiI sites were tested. 
The differences between these primers (Table 3.1) are only a few base pairs; primer 
alignment in TKzeo sequence is illustrated in the Appendix (A1.4). Also, annealing 
temperature was selected after examining 6 gradients with each primer pair. After the last 
optimization, PCR amplification for all isolated DNAs was performed with the preferred 
pair of primers (3 forward and 10 reverse) using the cycling conditions given in Table 3.2.  
To obtain sufficient DNA for sequencing, the PCR volume was increased to 50 µl instead 
of 20µl. PCR products were run on 2% (w/v) agarose gel and bands of different fragment 
sizes were cut and purified as explained previously. The sequencing process with PCR 
primers was done and processed as mentioned earlier in Section 2.3.5. 
Table 3.1: p3’TKzeo primers used for PCR optimization. 
miRNA Primer Sequence Restriction 
Enzyme site 





9 F ATGGATCCGATGCGCCCTCGATCTTC 79°C 56°C 
11 F CCTTAGGCCATTAAGGCC 61°C 56°C 
13F CCTCGAATCCTTAGGCCA 54°C 56°C 
14F TCGACCTCGAATCCTTAG 52°C 54°C 
15F GGGTCGACCTCGAATCC 55°C 56°C 
3F GGGTCGACCTCGAATCCTTA 56°C 62°C 
10R CGAGGCGGCCGACATGTTT 61°C 62°C 
  
Table 3.2: PCR cycle conditions for DNA extracted from transfected cells. 
Stage Temperature Duration Cycles 











3 72 5 min 1 
4 4 Infinity - 
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3.3.6 Western blot 
Western blot experiments were performed as described in Section 2.3.11, and 
immuneblotting was done with the following primary antibodies: RPL27A and HSPA14 in 
addition to the loading control antibody which was γ tubulin. 
3.3.7 qRT-PCR 
Total RNA was isolated from 0.5-1x106 cells using Tri-reagent following the protocol 
described in Section 2.3.9.2 and RNA concentration was measured by Nanodrop (see 
Section 2.3.9.4). cDNA for miRNA amplification was generated from 5ng of RNA using 
specific primers for the miRNA of interest and primers for two endogenous controls 
RNU6B and RNU48 following the TaqMan Universal Mastermix-NoUNG manufacturer’s 
protocol, as described in Section 2.3.10.1. The relative expression of the miRNA was 
calculated using ΔΔ CT method after normalization with endogenous control. 
cDNA for gene expression was synthesized according to the protocol described in section 
2.3.10.3. For qRT-PCR specific gene primers and probes were used (The primer sequences 
and probe details are listed in 2.1.16). Relative expression was determined using ΔΔ CT 
method after normalization to GAPDH.  
3.3.8 miRNA knockdown 
HeLa cells transfected with miR-595-pBabePuro using Nucleofection as described earlier, 
were transfected with MIRIDIAN hairpin miR-595 inhibitors (25nM final concentration) 
and control inhibitor (Dharmacon) following Nucleofection protocol as well. Also, as a 
control, wild type HeLa cells were transfected similarly with miR-595 inhibitors and 
control inhibitors. Cells were cultured for 48hrs after which RNA and protein extracts were 




The first miRNA used in the functional assay was mir-595 and all the data presented in this 
chapter is related to this miRNA. 
3.4.1 TOPO cloning of PCR amplified miRNA 
The isolated DNA fragment was cloned into the TOPO vector and transformed into 
chemically competent cells. The isolated plasmid DNA was examined in order to confirm 
the presence of the miR-595 insert by restriction digestion. EcoRI was used because it cuts 
the PCR II-TOPO vector flanking the insert, releasing a 4000 bp and a 976bp fragments, 
which represent the PCR II-TOPO vector and the inserted DNA encoding miR-595 
respectively. Figure 3.5 shows the EcoRI digestion for three plasmids containing miR-595. 
3.4.2 Sequencing of plasmid DNA 
The three plasmids were sequenced using the Sanger chain termination method. Data were 
analysed with an ABI 3130/3130xl genetic analyser. The analysed sequences were aligned 
to the human genome with NCBI BLAST (http://blast.ncbi.nlm.nih.gov/).  
The sequence reads did not cover the complete amplified DNA fragment; therefore, new 
internal primers were designed and used in sequencing. The new oligonucleotides are listed 
in Table 3.3 
Table 3.3: New primers for miR-595  
miRNA Primer Sequence Annealing Temp 
595F2 AGCCATCAAGATGGTCTGC 62 °C 
595R2 CCGGGACATGATGTGATTAG 63 °C 
There was a single base change detected in the pre- miRNA sequence in all three plasmids. 
This base change turned out to be a known SNP after analysis with the UCSC genome 
browser (http://genome.ucsc.edu/). The sequencing results are available in the Appendix 
Section A1.2. Whilst the influence of this SNP on miR-595 expression and function is not 
clear, we decided to re-amplify this miRNA from a different source of genomic DNA, 
namely HeLa cells. The new mir-595 PCR product that came from HeLa cells was Topo 
cloned as described previously. The sequencing of two plasmids confirmed the presence of 
the correct insert without the SNP present in genomic DNA that is derived from MCF7 
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cells, sequencing results are available in the Appendix Section A1.3. Figure 3.6 shows the 
digestion products of TOPO cloned miR-595 amplified from HeLa cells. 
3.4.3 Subcloning and amplification 
The miR-595 sequence was released from the PCR II-TOPO vector by EcoRI and BamHI 
digestion, gel purified and ligated into pBabePuro, which was digested with the same 
restriction enzymes EcoRI/BamHI, at 4oC overnight. The ligated mixture was used to 
transform MACHI bacteria. Plasmid DNA was isolated and verified by restriction digestion 
(SmaI); this enzyme should cut the pBabePuro-miR-595 construct in three positions 
resulting in bands of 2514, 1867 and 1554 bp. The digestion products were assessed by gel 
electrophoreses and gave the predicted restriction pattern, confirming the correct insertion 
of miR-595 into pBabePuro. The digestion result is shown in Figure 3.6. Bacteria 
containing the correct plasmid were streaked for single colony and maxi prepped, and the 














Figure 3.5: Digestion result of plasmid containing miR-595 DNA from MCF7 cells. 
PCR amplification of a 976bp product from genomic DNA from MCF7 cells containing the miR-
595 sequence was cloned into the PCR II-TOPO vector. Following bacterial transformation, 
isolated DNA was digested by EcoRI. The three lanes represent a digestion of plasmid derived from 
three different colonies. EcoRI digestion cut the plasmid to two fragments, vector at 4000 bp and 
















Figure 3.6: Digestion result of plasmid containing miR-595 DNA from HeLa cells 
The PCR amplification of a 976bp product from genomic DNA from HeLa cells containing the 
miR-595 sequence was cloned into the PCR II-TOPO vector. Following bacterial transformation, 
isolated DNA was digested by EcoRI. The four lanes represent a digestion of plasmid derived from 
four different colonies. EcoRI digestion cut the plasmid to two fragments, vector at 4000 bp and the 











Figure 3.7: Digestion of DNA encoding miR-595 ligated into pBabePuro 
This image shows SmaI digestion of isolated plasmids derived from ligation of pBabePuro and 
miR-595. SmaI cuts once within the miR-595 sequence and twice in the vector resulting in three 
fragments: 2514, 1867 and 1554bp respectively (arrowed in the figure).    
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3.4.4 Library cloning and transfection 
The cDNA library inserted downstream of TKzeo fusion gene in the p3’TKzeo vector was 
electroporated into electrocompetent DH10α bacteria and plated on 25 (20 x 20 cm) square 
plates. Around 1x106 colonies were recovered and they were scrapped off the plates and 
maxi prepped. The MCF7 cell line that does not express miR-595, was transfected with 
library DNA. 24 independent transfections were performed using nucleofection which 
require 2 x106 cells/transfection. Subsequently, the transfected cells were put under zeocin 
selection. After expansion of the zeocin resistant cells, pBabePuro expressing miR-595 and 
empty pBabePuro were introduced into the library transfected MCF7 cells and after 48 
hours the cells were placed under puromycin selection. GCV was added after 96 hours of 
puromycin selection. After 10 days of GCV selection, genomic DNA was extracted from 
the surviving cells in individual flasks; there were about ~600 surviving colonies after GCV 
selection in 21 out of the original 24 transfections with a range of 4 to 58 colonies per flask.  
3.4.5 Targets amplification and detection 
The colonies in individual flasks were expanded and genomic DNA was isolated and PCR 
amplified. DNA extraction was performed separately for colonies isolated from each flask. 
Several primer pairs were tested for their ability to generate optimal amplification of target 
sites, and primer 3 forward combined with primer 10 reverse were subsequently used for 
PCR amplification of all DNAs. During PCR optimization all other primers failed to 
amplify the isolated DNA and with some of them the amplification resulted in amplifying 
region from the TKzeo vector. Therefore, the last designed pairs, which were very closed to 
Sfi1 sites overcome this problem. The gel image in Figure 3.8 shows a typical result of PCR 
amplification and the presence of many bands at different lengths, with the majority being 
between 500-1000bp. 20 bands of different sizes were isolated and sequenced. Sequencing 
of 8 bands failed. The remaining sequences (12 sequenced bands) were aligned to the 
human gene bank sequences using the program BLAST. The alignment identified matches 
with the human genome sequences in 12 blasted sequences. Two of them were identified 
with high homology to two different transcripts; RPL27A (ribosomal protein L27A) and 
HSPA14 (heat shock protein 14). Apart from RPL27A and HSPA14, a number of other 
sequences were analysed that mapped to chromosomes 3, 6 and 7 in positions without 
known genes or in positions close to some genes such as: Neuregulin 3 (NRG3), 10q23.1, 
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glutamate receptor metabotropic 5 (GRM5), 11q14.3, and translocation protein (SEC63), 
6q21. 
Furthermore, a DNA mixture derived from DNA from all flasks was prepared by mixing 
the same amount of template DNA and then amplifying it with primer 3 forward and 10 
reverse; the PCR result of this DNA showed an amplification of the common bands 
presents in the other DNA and some distinct bands which were seen in some of the DNA 
were not observed in the DNA mix.  
3.4.6 Computationally predicted targets   
The miRecords website allows to predict miRNA targets with 7 different prediction 
programs. This website was used to search for miR-595 targets; there are no validated 
targets for miR-595 as yet, whereas there are more than 3,000 targets predicted by at least 
one program (http://miRecords.biolead.org/). This website provides a filtering option to 
compare target prediction by multiple programs. Using the 5 programs targetscan, 
rnahybrid, pita, miRtarget 2 and Miranda a shorter list of 133 predicted targets was 
generated. Table 3.4 shows the 133 predicted targets. RPL27A and HSPA14 are not present 
in this list, they were not predicted by any program. However, another software program 
RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/), which relies on finding the 
minimum free energy (MFE) of hybridization between a mature miRNA sequence and the 
predicted target sequence, was used to identify the binding energy between miR-595 and 
the identified targets (RPL27A and HSPA14) as shown in Figure 3.9. The lower the energy 
(<-20kcal/mol) is the more likely that a miRNA binds to the putative target site. The 
binding between the mature miR-595 sequence and its putative target gene sequences was 
good because the MFE value for binding with RPL27A was -29.3 kcal/mol and -30.1 
kcal/mol for binding with HSPA14. These values are comparable to those obtained for the 
binding of other miRNAs to their known validated targets. 
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Figure 3.8: A typical result of PCR amplification of genomic DNA extracted from 
GCV resistant cells. 
After transfecting pBabePuro expressing miR-595 into MCF7 cells containing the TKzeo library, 
puromycin and GCV selection was applied. Genomic DNAs were isolated from GCV resistant cells 
from 21 flasks and PCR amplified using vector specific primers. PCR products were visualized on a 
2% (w/v) agarose gel and the gel image shows the PCR products of individual flasks. Each lane 
represents a DNA from one flask. Some of the bands are present in multiple samples and might 
represent identical targets in different transfections. Bands of different sizes were purified and 
sequenced. A BLAST search of the sequences obtained identified two transcripts; RPL27A 
(≈500bp) and HSPA14 (≈800bp) as indicated. DNA mix (a combination of isolated DNAs from all 




Table 3.4: list of miR-595 predicted target by 5 programs: targetscan, rnahybrid, pita, mirtarget2 and 
miranda 
 
Gene$Symbol Description Gene$Symbol Description
SH3YL1 SH3$domain$containing,$Ysc84=like$1$(S.$cerevisiae) C18orf19 chromosome$18$open$reading$frame$19
TCL6 T=cell$leukemia/lymphoma$6 SLC16A12 solute$carrier$family$16,$member$12$(monocarboxylic$acid$transporter$12)
DECR2 2,4=dienoyl$CoA$reductase$2,$peroxisomal TIPARP TCDD=inducible$poly(ADP=ribose)$polymerase
SLC24A3 solute$carrier$family$24$(sodium/potassium/calcium$exchanger),$member$3 GNRHR gonadotropin=releasing$hormone$receptor
RNF150 ring$finger$protein$150 DARS aspartyl=tRNA$synthetase
KIAA1377 KIAA1377 FMO2 flavin$containing$monooxygenase$2$(non=functional)
ZNF273 zinc$finger$protein$273 CAPN2 calpain$2,$(m/II)$large$subunit
ZNF708 zinc$finger$protein$708 CTNNA1 catenin$(cadherin=associated$protein),$alpha$1,$102kDa
GREM2 gremlin$2,$cysteine$knot$superfamily,$homolog$(Xenopus$laevis) DPT dermatopontin
CCDC21 coiled=coil$domain$containing$21 AFF2 AF4/FMR2$family,$member$2
USP46 ubiquitin$specific$peptidase$46 PRELP proline/arginine=rich$end$leucine=rich$repeat$protein
MLF1IP MLF1$interacting$protein RASA1 RAS$p21$protein$activator$(GTPase$activating$protein)$1
NAT11 N=acetyltransferase$11 SNRPB2 small$nuclear$ribonucleoprotein$polypeptide$B""
PPP1R14C protein$phosphatase$1,$regulatory$(inhibitor)$subunit$14C UBE2G2 ubiquitin=conjugating$enzyme$E2G$2$(UBC7$homolog,$yeast)
TMEM133 transmembrane$protein$133 USP4 ubiquitin$specific$peptidase$4$(proto=oncogene)
LYRM2 LYR$motif$containing$2 CUL5 cullin$5
CHST7 carbohydrate$(N=acetylglucosamine$6=O)$sulfotransferase$7 RGS5 regulator$of$G=protein$signaling$5
WDR45L WDR45=like CREG1 cellular$repressor$of$E1A=stimulated$genes$1
NSFL1C NSFL1$(p97)$cofactor$(p47) BCL2L1 BCL2=like$1
HSD17B11 hydroxysteroid$(17=beta)$dehydrogenase$11 ADCY9 adenylate$cyclase$9
GDE1 glycerophosphodiester$phosphodiesterase$1 REPS2 RALBP1$associated$Eps$domain$containing$2
ZC3H7B zinc$finger$CCCH=type$containing$7B FGA fibrinogen$alpha$chain
KIF21A kinesin$family$member$21A NCAM1 neural$cell$adhesion$molecule$1
MTMR10 myotubularin$related$protein$10 DCK deoxycytidine$kinase
SLC35A5 solute$carrier$family$35,$member$A5 GABRA1 gamma=aminobutyric$acid$(GABA)$A$receptor,$alpha$1
TMEM106B transmembrane$protein$106B PRRG1 proline$rich$Gla$(G=carboxyglutamic$acid)$1
LSG1 large$subunit$GTPase$1$homolog$(S.$cerevisiae) CLEC6A C=type$lectin$domain$family$6,$member$A
ANLN anillin,$actin$binding$protein FLJ46838 FLJ46838$protein
CTTNBP2NL CTTNBP2$N=terminal$like ARHGAP28 Rho$GTPase$activating$protein$28
AJAP1 adherens$junctions$associated$protein$1 DUXA double$homeobox$A
TBC1D16 TBC1$domain$family,$member$16 LRRC66 leucine$rich$repeat$containing$66
RBM47 RNA$binding$motif$protein$47 GLUL glutamate=ammonia$ligase$(glutamine$synthetase)
FAM172A family$with$sequence$similarity$172,$member$A MDH1B malate$dehydrogenase$1B,$NAD$(soluble)
B3GNT5 UDP=GlcNAc:betaGal$beta=1,3=N=acetylglucosaminyltransferase$5 CLDND1 claudin$domain$containing$1
SPRED1 sprouty=related,$EVH1$domain$containing$1 C6orf91 chromosome$6$open$reading$frame$91
LCORL ligand$dependent$nuclear$receptor$corepressor=like CDKL2 cyclin=dependent$kinase=like$2$(CDC2=related$kinase)
REXO1L1 REX1,$RNA$exonuclease$1$homolog$(S.$cerevisiae)=like$1 FGF12 fibroblast$growth$factor$12
CACNA2D4 calcium$channel,$voltage=dependent,$alpha$2/delta$subunit$4 LYVE1 lymphatic$vessel$endothelial$hyaluronan$receptor$1
C11orf47 chromosome$11$open$reading$frame$47 DDX52 DEAD$(Asp=Glu=Ala=Asp)$box$polypeptide$52
SLC30A8 solute$carrier$family$30$(zinc$transporter),$member$8 KIF3A kinesin$family$member$3A
KRT28 keratin$28 MACF1 microtubule=actin$crosslinking$factor$1
C2orf50 chromosome$2$open$reading$frame$50 TLK1 tousled=like$kinase$1
FAM33A family$with$sequence$similarity$33,$member$A C11orf58 chromosome$11$open$reading$frame$58
RNF212 ring$finger$protein$212 C1orf107 chromosome$1$open$reading$frame$107
C6orf167 chromosome$6$open$reading$frame$167 AFF4 AF4/FMR2$family,$member$4
TPRG1 tumor$protein$p63$regulated$1 TOR1B torsin$family$1,$member$B$(torsin$B)
GJB7 gap$junction$protein,$beta$7,$25kDa VASH1 vasohibin$1
TMEM215 transmembrane$protein$215 CPEB3 cytoplasmic$polyadenylation$element$binding$protein$3
ZNF417 zinc$finger$protein$417 SORCS3 sortilin=related$VPS10$domain$containing$receptor$3
WDR21C WD$repeat$domain$21C GLT25D2 glycosyltransferase$25$domain$containing$2
C2orf63 chromosome$2$open$reading$frame$63 TRIM2 tripartite$motif=containing$2
DSEL dermatan$sulfate$epimerase=like NTS neurotensin
C15orf41 chromosome$15$open$reading$frame$41 AFF1 AF4/FMR2$family,$member$1
UBASH3B ubiquitin$associated$and$SH3$domain$containing,$B ABI2 abl$interactor$2
PCDH11X protocadherin$11$X=linked ARHGAP1 Rho$GTPase$activating$protein$1
PCDH11Y protocadherin$11$Y=linked CYP8B1 cytochrome$P450,$family$8,$subfamily$B,$polypeptide$1
ZFP91 zinc$finger$protein$91$homolog$(mouse) GPC5 glypican$5
GRIN3A glutamate$receptor,$ionotropic,$N=methyl=D=aspartate$3A USP6 ubiquitin$specific$peptidase$6$(Tre=2$oncogene)
ZNF431 zinc$finger$protein$431 FOXK2 forkhead$box$K2
NUS1 nuclear$undecaprenyl$pyrophosphate$synthase$1$homolog$(S.$cerevisiae) LRP2 low$density$lipoprotein=related$protein$2
ADAMTS16 ADAM$metallopeptidase$with$thrombospondin$type$1$motif,$16 USP9Y ubiquitin$specific$peptidase$9,$Y=linked$(fat$facets=like,$Drosophila)
MAPK1IP1L mitogen=activated$protein$kinase$1$interacting$protein$1=like EIF2AK3 eukaryotic$translation$initiation$factor$2=alpha$kinase$3
TTC30A tetratricopeptide$repeat$domain$30A SEL1L sel=1$suppressor$of$lin=12=like$(C.$elegans)
SCYL1BP1 SCY1=like$1$binding$protein$1 H3F3B H3$histone,$family$3B$(H3.3B)
ABCA1 ATP=binding$cassette,$sub=family$A$(ABC1),$member$1 HINT1 histidine$triad$nucleotide$binding$protein$1




Figure 3.9: Binding between miR-595 and its identified targets based on the 
hybridization energy.  
RNAhybrid software was used to determine the minimum free energy (MFE) of hybridization of the 
mature miR-595 sequence with RPL27A and HSPA14 sequences. The values obtained as shown in 
the image indicate favourable binding. 
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3.4.7 Target validation  
Several experiments have been done to validate the putative targets for miR-595 (RPL27A 
and HSPA14). First, the expression level of miR-595 was examined in different cell lines 
including HeLa, HepG2 (human liver carcinoma cell line), KG-1 (acute myelogenous 
leukemia) and K562 (human erythroleukemic cell line) to decide which validation method 
will be applied, that is either knocking down miR-595 in the cells that express the miRNA, 
or introducing the miRNA into cells that do not express or express the miRNA at very low 
level and then examining the effect of the miRNA knockdown/overexpression on the 
putative targets.  
RNA was isolated from all selected cell lines (from 1x106 cells) using the Trizol extraction 
method and the concentration was measured by Nanodrop as described in Section 2.3.10.4. 
To make cDNA for miR-595, 10 ng/ml from the RNA was used and miRNA Taq man assay 
was applied as explained in Section 2.3.10.2. Two endogenous controls were used (RNU6b 
and RNU48) and miRNA expression level in each cell line was calculated using ΔCT; 
results are presented in Figure 3.10-A. The Taq man assay showed that the expression level 
of miR-595 is absent or very low in these four cell lines. Therefore, the selected method for 
target validation was the ectopic expression of miR-595 in these cell lines. Also, before 
introducing the miRNA in the cell lines, the expression level of RPL27A and HSPA14 was 
also examined in the same cell lines to ensure that these genes are expressed in all of them. 
For qRT-PCR, 1µg RNA was used to make cDNA, which was then diluted to 1:100 for 
qRT-PCR, and then the data was normalized with GAPDH. The mRNA expression showed 
that RPL27A and HSPA14 are expressed in all selected cell lines at variable levels based on 
ΔCT fold change calculation; results are shown in Figure 3.10-B and C. 
Hence, based on the expression result of miR-595 and its putative target, cell lines were 
transfected with pBabepuro-miR-595 and empty vector pBabePuro (control) using the 
Nucleofection method as explained previously. Cells were selected with 2µg/ml puromycin 
at 48hrs post transfection, except KG-1 which had shown high sensitivity to puromycin and 
it was therefore selected with 1µg/ml puromycin. After introducing the miRNA into the cell 
lines, the miR-595 expression was examined by qRT-PCR in all of them to confirm that 
they express the miRNA. The screening confirmed the increases in miR-595 expression 
level as shown in Figure 3.11-A. The expression level was increased on average of 60-80% 
in all cell lines in comparison with wild type cells. 
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Samples for qRT-PCR and the western blot were isolated on day 6 post-transfection. RNA 
was extracted from all cells from three independent experiments and analysed by qRT-
PCR. The RPL27A expression in all cell lines was downregulated as a result of miR-595 
overexpression in comparison with untransfected cells or cells transfected with an empty 
vector. The RPL27A expression level was decreased by 83% in KG-1, 73% in K562, 88% 
in HeLa and 55% in HepG2, see Figure 3.11-B. The percentages were determined by 
comparing the RNA expression levels from cells expressing miR-595 to cells transfected 
with the empty pBabePuro plasmid. 
Protein extracts from HeLa and HepG2 cells were isolated from 2.5x105 cells lysed in 40 µl 
lysis buffer; they were probed with antibodies to RPL27A (ABCAM), HSPA14 (ABCAM) 
and γ-tubulin as loading control (Santa Cruz). The protein levels in cells expressing the 
miRNA were down-regulated in comparison with proteins from wild type cells and cells 
transfected with empty pBabePuro, see Figure 3.11-C.  
These results confirmed that RPL27A is a real target for miR-595 as the overexpression of 
miR-595 resulted in a clear down regulation of RPL27A at both mRNA and translational 
level. Also, HSPA14 was validated as a real target for miR-595 on the protein level by 
western blot. 
To further investigate RPL27A as a target for miR-595, HeLa cells (wild type cells), and 
HeLa cells transfected with miR-595, were transfected with hairpin inhibitor directed 
against miR-595 (MIRIDIAN) and a control hairpin inhibitor (Dharmacon). Cells were 
transfected using Nucleofection and analysed after 48hrs for mRNA and protein expression 
(Figure 3.12). Wild type HeLa cells (the control) showed no or minor changes on RPL27A 
expression level as a result of inhibitor transfection which showed the specificity of the 
inhibitors because the expression of miR-595 is absent or very low in normal HeLa cells as 
shown earlier in Figure 3.11-A, whereas HeLa cells transfected with miR-595 showed 
reduced expression of RPL27A which could be restored to normal levels by treatment with 
miR-595 inhibitor and resulted in a 4 to 5 fold upregulation of RPL27A on both mRNA and 




Figure 3.10 Expression levels of endogenous miR-595 and RPL27A in different cell 
lines  
Endogenous levels of miR-595, RPL27A and HSPA14 mRNA were determined by qRT-PCR in 
HeLa, HepG2, KG-1 and K562. A) Total RNA isolated from each cell line and miR-595 expression 
level was quantified by qRT-PCR. The expression level, which was normalized to the endogenous 
control (RNU6B) showed no expression in HeLa cell line and very low expression level in the other 
cell lines. B &C) Total RNA isolated from each cell line; RPL27A & HSPA14 mRNA expressions 
were determined by qRT-PCR. After normalizing to GAPDH, expression level was determined by 















































































                        
Figure 3.11: Validation of RPL27A and HSPA14 as a target for miR-595 by qRT-PCR 
and western blot analysis.  
Endogenous mRNA and protein level for RPL27A in addition to the protein level for HSPA14, 
were all determined in untransfected, pBabe (pBabePuro empty vector), and miR-595 (pBabePuro-
miR-595) transfected cells. Transfection was done by Nucleofection and samples were collected 
after 4 days from puromycin selection. A) miR-595 expression level was determined in four 
different cell lines 48hrs after miRNA transfection. The result confirmed that all the cell lines were 
expressing miR-595 after the transfection. B) To investigate if miR-595 overexpression will down 
regulate RPL27A, mRNA was quantified by qRT-PCR on untransfected cells, cells transfected with 
empty vector and cells transfected with miR-595 from three independent experiments. The result 
was determined after normalization to GAPDH and relative expression was calculated by 2-∆∆CT. 
RPL27A was down regulated in all cell lines that are expressing miR-595 in comparison with cells 
transfected with pBabe or untransfected cells. C) Proteins Isolated from HeLa and HepG2 that were 
transfected with empty vector and miR-595, were probed with RPL27A, HSPA14 antibodies and 
loading control tubulin antibody. The results showed that RPL27A and HSPA14 were 































































































































































Figure 3.12: Inhibition of miR-595 expression by MIRIDIAN hairpin inhibitor. 
HeLa cells which do not express miR-595 were transfected with control inhibitors (HeLa+C) and 
miR-595 inhibitor (HeLa+ miR-595Inh). Also, HeLa cells were transfected with miR-595 to 
examine the effect of the inhibitors in the cells expressing the miRNA. HeLa cells that are 
expressing miR-595 were also transfected with hairpin control and inhibitor against miR-595. A) 
RPL27A mRNA expression level quantified by qRT-PCR showed up-regulation for RPL27A in 
HeLa cells expressing miR-595 which was transfected with miR-595 inhibitor. B) RPL27A protein 
expression was determined by western blot using RPL27A antibody and tubulin control antibody. 
RPL27A overexpression was observed in HeLa cells with miR-595 and miR-595 inhibitor, 
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3.5 Discussion 
Several studies have shown an association between microRNA expression and MDS 
pathogenesis as illustrated in the introduction. MDS patients with chromosome 7 
abnormalities, specifically monosomy 7, are considered as a poor prognostic class and a 
high-risk group. To the best of my knowledge, no single study has examined the 
contribution of miRNAs in MDS with chromosome 7 abnormalities. Studying the 
expression of miRNAs encoded by chromosome 7 and their targets might clarify the 
pathogenesis of MDS with -7/7q-.  
Since the discovery of the miRNA in 1993 (Lee et al. 1993) rapid developments in miRNA 
target prediction assays, mainly bioinformatics, have led to the identification of many new 
miRNAs and a very large number of predicted possible targets. However, only a very small 
proportion of these predicted targets have been experimentally validated. Based on the last 
miRBase release (Release 20, June 2013), there are 1872 precursors and 2578 mature 
human miRNAs; only 286 of them have validated targets based on the last update from 
miRecords (April 27, 2013). The main obstacle in miRNAs research is the accurate 
detection of target genes at the post-transcriptional level without relying on the homology 
to a putative target. Therefore, the application of our novel functional assay allows an 
efficient identification of miRNA targets that interact with or without a seed sequence with 
their targets. This assay has the potential to identify down-regulated targets at both mRNA 
and protein levels. However, the identified number of putative targets by this assay is 
smaller than the number of target predicted by computational algorithms and expression 
arrays. The assay isolates only the targets that are significantly down-regulated which 
therefore can be considered as the most crucial targets (Gäken et al, 2012). 
The novel functional assay relies on using a large cDNA library, representing 
approximately 77% of the human transcriptome, inserted downstream of a fusion gene 
(TKzeo). The presence of this large library will increase the possibility of identifying many 
targets for many miRNAs.  
As mentioned earlier in this chapter, several miRNAs were initially selected because they 
were located in the 7q region. The four selected miRNAs were: miR-489 and miR-653, 
which are located on 7q21, miR-671 at 7q36.1 and the most terminal miR-595 at 7q36.3. 
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These miRNAs were cloned into pBabePuro and the functional assay was started with miR-
595.  
Literature searches on miR-595 revealed no studies that specifically discuss the differential 
expression of this particular miRNA in certain diseases. However, a few studies have 
shown the differential expression of miR-595 by microRNA profiling. Using microarray 
analysis, Liu et al. showed that overexpression of miR-595 was accompanied by a reduction 
of PRODH/POX (Proline Oxidase) in a renal cancer cell line as compared to a normal renal 
cell line, (Liu et al. 2010). POX is a mitochondrial inner membrane enzyme that has been 
identified as a mitochondrial tumour suppressor that is functionally involved in promoting 
apoptosis by secreting ROS (Reactive Oxygen Species) and minimizing the signalling of 
HIF (Hypoxia-Inducible Factor) (Liu et al. 2009). This target might be of interest in our 
study, as it was reported that POX upregulation is possibly driven by p53 mutation (Donald 
et al. 2001), and p53 mutations are noted for their contribution to MDS pathogenesis 
(Kitagawa et al. 1994). POX was not predicted as a target for miR-595 neither by any of 
the prediction algorithms nor by the applied functional assay and this is probably due to the 
low frequency of POX in the used library (only 126 reads) as deduced from the next 
generation sequencing results of the Mission Target ID library (see attached CD).   
Another interesting study has shown that miR-595 was up-regulated in CD4+ cells as 
compared with CD8+ cells in thymocytes at the single positive maturation stage (Ghisi et al. 
2011). This observation implies an interesting correlation between this miRNA and the 
immune system. miRNAs dysregulation has been associated with their effect on innate 
immune signalling, which plays an important role in MDS prognosis and treatment. Recent 
studies on MDS with 5q- showed that the reduction of miR-145 and miR-146a in CD34+ 
bone marrow cells from individuals with del 5q MDS relative to normal controls, was 
inversely associated with the increased expression of TIRAP and TRAF6, which are 
involved in the innate immunity pathway, and activated the innate immunity which caused 
abnormalities in the megakaryocyte (Baltimore et al. 2008, Starczynowski et al. 2010, 
Olnes et al. 2011). A more detailed description of miRNAs contribution and involvement in 
regulation of the immune system has been provided in the introduction.  
The application of the novel functional assay has identified several putative targets for miR-
595 including RPL27A and HSPA14. These targets were present in the DNA isolated from 
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multiple individual flasks. Also, during the optimization of PCR primers, these putative 
targets were also isolated with most of the other primer pairs tested. This is a further 
indication of the sensitivity of the assay. The functional details of RPL27A and HSPA14 are 
described in Table 3.6.  
Interestingly the PCR amplification of the DNA mixture consisting of genomic DNAs from 
all 21 extractions did not show similar results to that from individual DNA. It only showed 
the common bands whilst the other isolated bands from individual DNA were absent. This 
is probably due to the higher abundance of these bands resulting in preferential PCR of 
these fragments.  
To find out if there is any correlation between the miR-595 identified targets RPL27A and 
HSPA14, and the computational algorithm predicted targets, gene clustering was performed 
based on gene function or pathways. David Bioinformatics Resources database was used 
for that purpose (http://david.abcc.ncifcrf.gov/). The 133 genes, identified by 5 different 
computational algorithms, in addition to the two targets identified by our functional assay 
(RPL27A and HSPA14), clustered into 10 different functional groups. Interestingly 
RPL27A clustered under phosphoprotein function, the group in which most (58 of the 133 
predicted targets) of the miR-595 predicted targets cluster. HSPA14 clustered to ATP-
binding function together with 15 other predicted target genes. However, pathway analysis 
did not show any possible involvement of these genes in known pathways.  
Interestingly, analysis of possible binding between miR-595 and its identified targets 
(RPL27A and HSPA14) using RNAhybrid, shows favourable binding between them with 
low MFE comparable to other miRNAs and their validated targets. For example, Garzon et 
al., identified the mRNA encoding Homeobox A1 (HOXA1) as a target for miR-10a 
(Garzon et al. 2006). The binding energy of hybridization of this miRNA with 
HOXA1mRNA is -19.8 Kcal/mol, which is higher than the calculated energy for miR-595 
with its targets, RPL27A (-29.8 Kcal/mol) and HSPA14 (-30.1 Kcal/mol). This further 
indicated that the identified targets by the functional assay are valid targets for miR-595. In 
order to confirm this finding, target validation using functional assays was carried out. 
As mentioned earlier in the introduction, ribosomal protein RPS14 has been identified as an 
important gene involved in the pathogenesis of MDS with 5q-, mainly through its 
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involvement in controlling erythroid differentiation. Therefore, it was of interest to validate 
the ribosomal protein RPL27A, which can be then further investigated in terms of its 
biological function and possible contribution to MDS. 
The validation was carried out in several cell lines, which were chosen based on the several 
reasons. To insure high efficiency for the transfection, two adherent cell lines were used 
(HeLa and HepG2), which are in general easier to transfect than suspension cell lines. Also, 
suspension cell lines were selected due to our interest in studying the miRNA implication 
in myeloid disease. Therefore, two myeloid cell lines were chosen (K562 and KG-1). The 
main reason for using more than one cell line is to rule out the differences in the genetic 
background of each cell line which might affect the miRNA regulation of its target, 
especially if that target is mutated, or regulated by other genetic variants. Although MCF7 
cell line was the assay model, it was excluded from the selected cell lines for the validation 
due to the earlier identification of SNP in miR-595 sequence as mentioned in Section 3.5.2. 
Even though this SNP was not identified with any biological effect it was preferred to 
exclude these cells from the validation experiments.  
Ribosomal protein RPL27A which was isolated from different clones from different flasks 
was validated as a real target for miR-595 regulated at both mRNA and protein level. 
Interestingly, Mendiburu et al have shown that RPL27A is highly overexpressed in MDS 
patients with refractory anaemia with excess blasts (RAEB). This observation relies on 
analysing bone marrow samples by serial analysis of gene expression (SAGE) (Mendiburu 
et al. 2008). Furthermore, it has been found that RPL27A knockdown resulted in the 
induction of p53 in sooty foot ataxia mice (Terzian et al, 2011). This study used mutated 
RPL27A transgenic sooty foot ataxia mice and they showed that the mice developed p53 
phenotype including pancytopenia, epidermal hyperpigmentation and cerebellar ataxia. 
This ribosomal stress, which occurs through changes in the ribosomal proteins level, 
interferes with p53 expression level. The relation between ribosomal protein and p53 was 
first discovered in 1994, when Levine and his group discovered the binding complex 
between RPL5, p53 and its regulator MDM2 (Levine et al, 1994). Since then, several other 
ribosomal proteins have been identified with their effect on the p53-MDM2 pathway and 
their implication in disease pathogenesis. For instance, haploinsufficiency of ribosomal 
gene RPS14, which is localized to the critical deleted region (CDR) in 5q- patients, was 
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associated with p53 overexpression which inhibited erythroid differentiation and 
contributed to the development of 5q- syndrome phenotype, a subtype of MDS (Ebert et al. 
2008, Dutt et al. 2011, McGowan et al. 2011). Therefore, it was of interest to investigate 
the biological function of this ribosomal protein in human cell lines and human 
hematopoietic progenitor stem cells CD34+ to identify the effect on ribosome biogenesis, 
p53 pathway and the biological effect on hematopoietic stem cells, mainly erythroid cells 
differentiation.  
Conclusion 
Deregulation of specific miRNAs correspondingly results in biological changes, which 
might contribute to MDS. Therefore, identification of miRNA targets is essential for 
understanding the function of the miRNA. The application of the functional assay described 
here led to the identification of a biologically relevant target, RPL27A, which has been 
experimentally validated. 
Thus, studying the biological function of this validated target might provide insight into the 
function of miR-595 and its contribution to MDS mainly via its functional effect on p53 
pathway and erythroid differentiation. 
Table 3.5: Predicted genes by sequencing and their biological function and involved pathways. Data 
adapted from www.genecards.org. 
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Ribosomal proteins are a major component of ribosomes; which were first identified in 
Escherichia coli (E.coli) more than 40 years ago (Waller et al. 1961). Ribosomes are 
ribonucleoprotein complex that are responsible for protein synthesis in all living cells and 
consist of two subunits. The primary structure of the ribosome in E.coli identifies three 
ribosomal RNAs (rRNAs) and 54 ribosomal proteins. The rRNA is composed of 5S and 
23S in a large 50S subunit, and 16S in a small 40S subunit. The 54 ribosomal proteins are 
divided into 33 proteins in the large subunit and 21 in the small subunit, reviewed in (Stelzl 
et al. 2001). 
Subsequently, a variety of ribosomal proteins (from 50 to 80 proteins) were identified in 
other organisms; some of which are conserved among pro and eukaryotes, and others are 
organism specific. Initially, separated by two-dimensional polyacrylamide gel 
electrophoresis, which allowed researchers to distinguish ribosomal proteins in all 
organisms (Dzionara et al. 1970, Kaltschmidt et al. 1970). The ribosomal proteins were 
numbered according to their protein sizes on the gel, with the larger proteins having a small 
number, and the smaller proteins with higher number. Approximately 50-60 different 
polypeptides were found in bacteria and archaea ribosomes, and approximately 70 different 
polypeptides have been identified in eukaryotic ribosomes(Strom et al. 1973, Tsurugi et al. 
1977). However, with the advancement that occurred in whole-genome sequencing, a large-
scale study on ribosomal protein genes from 66 genomes from different organism was 
performed. 102 families of ribosomal proteins were identified and only 34 proteins were 
conserved in all organisms (Lecompte et al. 2002).  
4.1.1 Ribosome biogenesis 
The eukaryotic mature ribosome (80S) consists of two subunits, large (60S) and small 
(40S), which together contain four rRNAs, 18S in the small subunit and 5S, 5.8S and 28S 
in the large subunit, along with 80 different ribosomal proteins. Ribosome biogenesis starts 
in the nucleolus by the production of ribosome and synthesis of pre ribosomal particles, 
which are then exported to the cytoplasm for the formation of functional ribosome. This 
process involves the synthesis of four rRNAs, 80 ribosomal proteins, more than 150 other 
supportive proteins and 70 small nuclear RNAs (snoRNAs). The 47S pre-RNA molecules 
transcribed with the action of RNA polymerase I to generate 18S RNA, which is 
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incorporated in the synthesis of the small ribosomal subunit (40S). RNA polymerase II 
transcribed the 47S to release 5.8S and 28S RNAs, where RNA polymerase III transcribed 
5S RNA; all of which are involved in the making of the large ribosomal subunit 60S. These 
subunits are then exported to the cytoplasm and undergo several maturation steps to form 
the 80S ribosome (Warner 1999, Rudra et al. 2004, Rodnina et al. 2009, Panse et al. 2010). 
The 80 ribosomal proteins are transcribed by RNA polymerase II and exported to the 
cytoplasm for translation, then imported into the nucleolus for the assembly of the 
ribosome (Lempiainen et al. 2009). All the reported information about ribosome biogenesis 
was based on the genetic studies of prokaryotic biogenesis. Although, there is a high level 
of conservation on ribosome biogenesis elements between mammalian cells and yeast, 
knowledge acquired about mammalian ribosomes is still somewhat limited. 
4.1.2 Ribosomal proteins functions 
The role of ribosomal proteins in the assembly of eukaryotic ribosomes has been studied 
for several years and shows similarities with prokaryotic ribosome assembly (Ferreira-
Cerca et al. 2007, Budkevich et al. 2008). However, some distinct features in translation 
initiation, termination and recycling were different among different kingdoms. Consistent 
with that, the ribosome from different kingdoms composed of different ribosomal proteins, 
which can modulate specific functions related to the organism. Of the 80 eukaryotic 
ribosomal proteins, some of them are homologous between two or more kingdoms and 
some are eukaryotic specific. The identification of the role of individual ribosomal proteins 
is difficult due to the cooperative role between ribosome components. However, the major 
change in the understanding of ribosomal protein function came in 2003 when Steitz and 
Moore, identified that ribosomal proteins are responsible for ribosome assembly and for the 
accurate folding of rRNA, which is required for the cleavage and processing (Steitz et al. 
2003). Analyses of eukaryotic ribosomal proteins identified that ribosomal proteins have a 
distinct function in ribosome assembly and are required for different steps of ribosome 
biogenesis; for example: some ribosomal proteins are responsible for translational 
accuracy, peptide bond formation and interaction with translation initiation factor 
(Caldarola et al. 2009).   
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Figure 4.1: Ribosome biogenesis (reproduced from (Xue et al. 2012) 
Ribosome biogenesis is a highly coordinated process that is responsible for protein synthesis through a series 
of steps, which mostly take place in the nucleolus. The pre-RNA 47S is transcribed by Pol I and generates 3 
of the 4 rRNAs (18S, 5.8S and 28S) this step occurs in the nucleolus. The fourth rRNA, 5S, is transcribed in 
the nucleus by Pol II. Ribosomal proteins are transcribed by Pol II in the cytoplasm then exported into the 
nucleus and involved in the ribosome assembly. 18S with 32 ribosomal proteins are assembled into the 40S 
small subunit. The other rRNAs (18S, 5.8S and 28S) along with 47 ribosomal proteins are assembled into the 
large subunit, 60S. Both subunits are exported into the cytoplasm to generate the mature ribosomal subunit. 
RPL: large subunit ribosomal proteins, RPS small subunit ribosomal proteins.  
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4.1.3 Ribosomal protein and extra-ribosomal functions 
In addition to their contribution in ribosome biogenesis, ribosomal proteins have been 
identified with extra-ribosomal functions (Wool 1996, Lindstrom 2009). These functions, 
recognized through the damaging defect that occurs in ribosome synthesis and leads to 
apoptosis and cell cycle arrest through ribosomal protein accumulations or 
haploinsufficiency and this is one of the mechanism in carcinogenesis (Montanaro et al. 
2008, Narla et al. 2010).  
Impaired ribosome biogenesis as a result of ribosomal stress causes accumulation of 
ribosomal proteins. Therefore, cell growth and proliferation are affected with changes in 
ribosome activity and production. This accumulation could be due to defective ribosome 
assembly resulting from imbalanced expression of ribosomal proteins and the other 
components of the ribosome machinery and downregulated ribosome activity and protein 
synthesis (Lempiainen et al. 2009). Disruption of ribosomal protein production causes 
defects in ribosome biogenesis and disrupts the survival of the cells, which suggests p53 
involvement, as p53 being the major guardian of the cells (Deisenroth et al. 2010). The 
tumour suppressor protein p53 is known for its ability to induce apoptosis, cell-cycle arrest 
and senescence in response to ribosomal stress, DNA damage and oncogene activation 
(Kruse et al. 2009). 
The p53 pathway plays a major role in preserving the integrity of ribosomes. Disruption of 
ribosomal integrity results in the release of several ribosomal proteins from the nucleolus, 
which interact with murine double-minute 2 (MDM2) called HDM2 in humans, the main 
negative regulator of p53. MDM2 negatively regulates p53 activity by acting as an E3 
ubiquitin ligase, leading to p53 ubiquitination and degradation. Nucleolar stress causes a 
disruption of rRNA synthesis which inhibits the assembly of the ribosome and that results 
in an excess of free ribosomal proteins, which become available to interact with MDM2 
(Zhang et al. 2009). The binding of the ribosomal proteins with MDM2 interferes with its 
transactivation activity, resulting in the stabilization and activation of p53 either by 
protecting p53 from degradation by MDM2 or inducing p53 translation and therefore 
arresting cell cycle progression in a p53 dependent manner (Dai et al. 2004).  
Several ribosomal proteins have extra-ribosomal functions such as binding to MDM2 and 
protecting p53 from degradation. In 1994, it was found that RPL5 and 5S RNA can bind to 
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MDM2 and MDM2-p53 complexes in murine cells (Marechal et al. 1994). Overexpression 
of RPL5 and RPL11 causes an accumulation of p53, which leads to apoptosis and 
consequent G1 arrest through their interaction with MDM2 (Lohrum et al. 2003, Zhang et 
al. 2003, Bhat et al. 2004, Dai et al. 2004). RPL23 can also associate with MDM2 and it’s 
overexpression or suppression leads to cell-cycle arrest and apoptosis (Dai et al. 2004, Jin 
et al. 2004). RPS7 also binds with MDM2-p53 complex, protecting p53 from degradation 
(Chen et al. 2007). Additional MDM2 binding partners were identified such as RPL26 
(Ofir-Rosenfeld et al. 2008), RPS14 (Zhou et al. 2013) and RPS3 (Yadavilli et al. 2009). 
These studies led to unravelling of the RP-MDM2-p53 pathway, which is active in 
responses to ribosomal or nucleolar stress, see Figure 4.2.  
Inhibition of certain ribosomal proteins by small interfering RNA (siRNA) has also been 
shown to induce p53 accumulation. Work on a mouse model has shed light on the induction 
of the RP-MDM2-P53 pathway in response to ribosome imbalance. In mice, mutations in 
ribosomal protein genes or heterozygous deletion have shown a diverse effect on the mice 
phenotype and developmental defects and have been associated with a high p53 phenotype. 
Also, most homozygous mutant ribosomal proteins are embryonic lethal. The differences in 
the identified phenotypes are mainly due to the differences in the basal level of some 
ribosomal proteins, tissue specificity and development stage. Table 4.1 summarizes the 




Figure 4.2:The RP-MDM2-p53 pathways 
In steady state conditions (left side) ribosome biogenesis takes place in the nucleolus and ribosome subunits 
are exported to the cytoplasm for the formation of mature ribosomes and initiation of mRNA translation. 
During this normal phase, MDM2 mediates the attachment of ubiquitin (Ub) molecules to p53 and induces 
p53 degradation, which leads to normal cell proliferation. Under stress condition (right side), ribosomal stress 
impairs ribosome biogenesis and disrupts the ribosome assembly. This causes a release of free ribosomal 
proteins (RP), which interact with MDM2 and block its interaction with p53, resulting in p53 accumulation. 
Subsequently, an activated p53 may cause cell cycle arrest, apoptosis, DNA repair or senescence  
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Table 4.1: Ribosomal protein knockouts and phenotypes in mice (reproduced from(Terzian et al. 2013)) 
Ribosomal 
protein gene 
Mouse phenotype P53 defect 
RPL22 +/-: No phenotype 
-/-: Viable, defect in alpha-beta T-cells 
 
Yes 
RPL24 Bst/+: small body size, bell spot and abnormal skeletal 
and eye morphology 
Bst/Bst: Embryonic lethal 
Yes                              
No 
RPL27A SFA/+: Small body size, Pancytopenia, epidermal 
hypermelanosis, cerebellar ataxia 
SFA/SFA: Embryonic lethal 
Yes 
No 
RPL29 +/-: No phenotype 
-/-: Viable, mild growth retardation 
Yes 
RPL38 Ts/+: Skeletal patterning abnormalities 
Ts/Ts: Embryonic lethal 
No 
N/A 
RPS6 +/-: Embryonic lethal Partial 
RPS7 Zma/+: Small body size, belly spot, skeletal, eye and 
neuro-anatomical defect. 
Zma/Zma: Embryonic lethal 
Mtu/+: Small body size, belly spot, skeletal and neuro-
anatomical defect 





RPS14 CD74-Nid67+/-: Macrocytic anemia 
CD74-Nid67-/-: N/A 
Yes 
RPS19 Dsk3/+: Small body size, belly spot, anemia and 
epidermal hypermelanosis 
Dsk3/Dsk3: Embryonic lethal 
+/-: No Phenotype 





RPS20 Dsk4/+: Small body size, belly spot, anemia and 
epidermal hypermelanosis 




+/_: heterozygous gene deletion, -/-: homozygous gene deletion, Bst: Belly spot, Dsk: Dark skin, SFA: Sooty 
Foot Ataxia,Ts:Tail short, Mtu: Montu: Zma: Zuma 
4.1.4 Ribosomal protein RPL27A 
The human RPL27A gene is a ribosomal protein belongs to the 60S subunit and is localized 
on chromosome 11p15.5 ! p15.1. It composed of 32,349 bases and the mRNA encodes a 
protein of 148 amino acids. 
The importance of RPL27A in haematopoiesis become clear from sooty foot ataxia (SFA) 
mouse models (Terzian et al. 2011). In that report the authors emphasized the importance 
of this gene and the potential need for further investigation of its biological function in the 
human haematopoiesis. Therefore this project focused on the functional importance of 
RPL27A on the ribosome biogenesis and its relation to the MDM2-P53 pathway. 
 132 
4.2 Aim 
The identification of individual ribosomal protein function is challenging due to the 
cooperative role between rRNA and ribosomal proteins and between the ribosomal proteins 
themselves. The role of several ribosomal proteins which was mentioned earlier was 
determined by causing changes in the gene/protein expression level either by inserting a 
mutation that silences the gene or knocking down the gene and examining the effect of 
haploinsufficiency on cell survival. Therefore, I proceeded to study the biological effects 
consequent to RPL27A knockdown. 
In order to examine the effects in detail, I examined the following: 
• Effects of RPL27A knockdown in different human cell lines expressing p53 and p53 
null cells and specifically focused on the effects on p53 pathway.  
• The effects of knockdown on apoptosis, cell cycle and cell viability. 
• The effects of RPL27A knockdown on the ribosome assembly, particularly large 
ribosome subunit. 
• The possible interaction between MDM2 and RPL27A. 
• Overexpression of RPL27A and its effect on cellular function. 
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4.4.1 Production of pSUPER retroviral plasmid expressing RPL27A shRNA and cell 
transduction  
4.4.1.1 RPL27A shRNA cloning in pSUPER retroviral plasmid 
I created a stable knockdown of RPL27A by designing shRNA that could be cloned into 
pSUPER plasmid, which is the standard vector used for delivering small interfering RNA 
(Tuschl 2002).The shRNA sequences were generated from the online shRNA design tool 
(http://www.genelink.com/sirna/shrnai.asp.) The RPL27A mRNA sequence was uploaded 
and several shRNA sequences were generated at different positions in the coding DNA 
sequence (CDS). Three shRNA sequences at 485 (sh-1), 588 (sh-2) and 735 (sh-3) CDS 
were selected, see Section 2.1.14. Restriction sites were incorporated at each end of the 
oligonucleotide to facilitate the subsequent cloning into pSUPER. The manufacture’s 
recommended restriction enzymes are HindIII and BglII but because these sites are close to 
each other (BglII:1447 and HindIII:1441) XhoI (1420) was used instead of HindIII .An 
XhoI site was incorporated into the reverse primer and a BglII site was inserted into the 
forward sequence. 
Each shRNA primer was diluted to 1µg/ml and annealed to create a synthetic DNA 
molecule with XhoI (5’) and BglII (3’) overhangs. The annealing was performed by 
combining 5 µl of each primer (forward and reverse) with 10µl NEB 2 and 80µl dH2O. The 
mixture was placed in a beaker containing hot water (95°C); and left until the water 
temperature cooled to room temperature. This was subsequently ligated into XhoI/BglII 
linearized pSUPER-retro-puro overnight at 4°C. Then, an aliquot from the ligation was 
transformed into MACHI competent cell, as explained in Section 2.3.3.2. Six colonies were 
selected grown overnight and mini prepped (as explained in Section 2.3.4.1). Plasmid DNA 
was verified by restriction digest and sequencing (see, Sections 2.3.3.3 and 2.3.5). The 
result of restriction digest and sequencing of all selected colonies confirmed the successful 
cloning of RPL27A sh-1 and sh2 into pSUPER but not for RPL27A sh-3 which was not 




Figure 4.3: Schematic representation of pSUPER-retro-puro vector (reproduced 
from:www.oligoengine.com)  
The RPL27A shRNA oligo’s inserted into the vector via its restriction sites XhoI and BaglII.  
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4.4.1.2 Efficiency of RPL27A depletion using pSUPER cloned shRNA 
RPL27A knockdown was performed on the MCF7 cell line, which is known for its high 
transfection efficiency, as mentioned in Chapter 3. MCF7 cells were transfected with empty 
pSUPER, RPL27A shRNA-1 and RPL27A shRNA-2 using nucleofection, (see Section 
2.3.7.2) and cells were selected with 2µg/ml puromycin 48 hours post-transfection. RNA 
and protein samples were isolated at two different time points from the three independent 
replicates. Unselected cells were collected on day 2 post-transfection and selected cells 
were harvested on day 10 post-transfection. RNA was extracted, cDNA was synthesized 
and RPL27A mRNA expression was measured by qRT-PCR. The relative expression was 
calculated relative to the untransfected control after normalizing all tested samples with 
GAPDH. The results from three independent experiments showed ineffective silencing of 
RPL27A, with a very small (less than 20%) reduction on the cells transfected with shRNA-
2 and no changes in the cells that were transfected with shRNA-1 compared with the cells 
with empty pSUPER. Also, the analysis of the protein samples by western blotting resulted 
in the same finding of small changes on the protein expression level, which was 
inconsistent within the replicates, see Figure 4.4. To rule out the possibility of inefficient 
transfection, the assay was performed in other cell lines including KG-1, K562 and Jurkat. 
The qRT-PCR and western bolt results confirmed the ineffective silencing of RPL27A 
using these shRNAs. However, the experiment which was performed on KG-1 showed less 
than 30% reduction with RPL27A-sh-1 at both mRNA and protein levels, which was not 
seen in any other cell lines. Therefore, to save time, the plan was modified to try other 
knockdown methods rather than optimizing or cloning more shRNAs into pSUPER.  
4.4.2 RPL27A transient knockdown (RPL27A siRNA) 
RPL27A siRNA was obtained from Santa Cruz and transfection was performed using the 
lipofectamine RNAiMAX method, see Section 2.3.7.1. In a 24 well plate, 2-5x105 cells 
were seeded in 1ml of complete medium. Then the siRNA concentration was optimized for 
a maximal silencing effect, by diluting the stock siRNA (10µM) and testing several 
concentrations (10, 50, 100, and 200 nM) on MCF7 and KG-1 cell lines. Results showed 
variability in the knockdown efficiency at different concentrations and at different time 
points between the two cell lines, Figure 4.5 shows an example of the data obtained from 
two different concentrations which has shown small variations not seen by the other tested 
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concentrations. Also, there was a contradiction seen between qRT-PCR and western blot 
results in the MCF7 cell line, in which the knockdown with 100nM at 48hrs gives 40% 
reduction at mRNA level, which was not detected at the protein level, as shown in Figure 
4.5. Efficient silencing was not achieved with multiple repeats. Therefore, for practical 
reasons, with regard to cell numbers required for multiple assays, stable knockdown was 
required, and I used lentiviral strategy for knockdown, which leads to highly efficient 





















































































































10 days (puromycin selection)
  
Figure 4.4: RPL27A depletion using shRNAs cloned into pSUPER. 
MCF7 and KG-1 cell line were transfected with two different shRNAs against RPL27A in addition 
to an empty vector. A-B) The mRNA expression of RPL27A in MCF7 and KG-1 cells was 
determined at 48hrs and 10 days post transfection, the data were normalized to GAPDH mRNA, 
and were compared with a control empty vector as measured by qRT-PCR. Results are 
representative of the mean ±S.D of three independent experiments. C-D) Cellular proteins were 
isolated from MCF7 and KG-1 cells (wild-type and transfected cells) at day 10 post-transfection, 
then studied by western blots analysis for the expression of RPL27A and γ-tubulin antibody was 













































































































Figure 4.5: Analysis of RPL27A expression in cells transfected with siRNA 
A-B) western blot analysis of RPL27A expression in MCF7 and KG-1 transfected with control 
siRNA and RPL27A siRNA, which was used at two different concentrations: 10nM and 100nM. 
Cells (1-2x105) were lysed 24, 48 and 72 h after transfection and analysed by western blot. RPL27A 
expression was measured by probing with antibodies against RPL27A and γ tubulin, the loading 
control. C) mRNA levels of cells transfected with 100nM RPL27A siRNA were normalized to the 
expression of GAPDH mRNA and the data were calibrated to non transfected cells ( normalized to 
1), The result was based on the comparison with cells transfected with an empty vector and are 
representative of triplicate independent experiments. Bars represent the mean ±S.D 
24h 48h 72h 
A 
C 
24h 48h 72h B 
 140 
4.4.3 RPL27A Lentivirus production and knockdown efficiency 
4.4.3.1 RPL27A lentivirus shRNA production 
Lentiviral infection has the capability of efficient delivery of expression construct with high 
stability in the transduced cells. The pre-designed RPL27A shRNAs (4) expression 
constructs, which were cloned into the lentiviral vector (pLKO.1), (obtained from Open 
Biosystem). As a control, the pLKO.1 empty lentiviral vector was used; this vector was 
kindly gifted by Dr. Jie Jiang. The shRNA sequences are listed in Section 2.1.14 and the 
pLKO.1 vector map is shown in Figure 4.6. 
Before starting any experiment, the cells infectability with lentiviral vectors was examined 
and lentiviral titre was determined. The cell lines used in this experiment were HCT-116 
and HCT-116 p53-/-, which have been used extensively to examine the relationship between 
ribosomal protein depletion and MDM2-p53 pathway. Two other myeloid cell lines were 
selected, HEL and K562, former expresses p53 whereas the later dose not. Lentivirus 
production and titre estimation was performed with the help of Dr. David Darling. Based 
on his experience, the K562 cell line is infectable and therefore infectability was examined 
in the other 3 cell lines. Cells were infected with GFP- lentivirus (Gifted by Dr. David 
Darling).  The infection efficiency in HCT-116 and HEL cell lines was more than 80% at 
48hrs post-infection which is similar to K562 and that indicated the feasibility of delivering 
lentivirus into these cell lines. To determine the required volume of the viral supernatant to 
cause sufficient knockdown, 5x105 HCT-116 cells were seeded into a 24 -well plate in 1ml 
complete medium (DMEM) and transduced by recombinant lentivirus, empty pLKO.1, at 
four different virus dilutions (0.1µl, 1µl, 10µl and 100µl.); virus production and 
transduction were performed as explained in Section 2.3.8, and infections were carried out 
in the presence of 8 µg/ml polybrene. After 24hrs the medium was changes and cells were 
selected with 2µg/ml puromycin. After 10 days of puromycin selection, cells, which were 
transduced with 0.1 µl and 1 µl had all died. The cells transduced with 10 µl viral 
supernatant showed some live cells and the cells transduced with 100µl supernatant showed 
more than 80% transduced cells after 10 days puromycin selection. Therefore, cell lines 
were infected with 100 µl of each shRNA and selected with puromycin. After 6 days, RNA 
and protein samples were isolated from all infected cells to examine the knockdown level. 
The results shown in Figure 4.7-A showed that RPL27A-sh2 caused an 80% reduction in 
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RPL27A expression at both mRNA and protein levels, RPL27A-sh4 caused a reduction of 
50% at mRNA and approximately 30-40% at protein level (Figure 4.7-B). The other two 
shRNAs did not show any significant changes at mRNA by qRT-PCR, so these shRNAs 
were not used any further. Therefore, RPL27A-sh2 and RPL27-sh4 were re-examined in 
K562 and HEL cell lines and the knockdown level was very close to what was seen in 
HCT-116 cell lines, (Figure 4.7-C). Therefore, the rest of the experiments were carried out 
using RPL27A-sh2 and RPL27A-sh4. As a control, knockdown of RPS14 was carried out in 
parallel, RPS14 shRNA was kindly provided by Dr. Jie Jiang. In some experiments, the 
knockdown of RPL5 was also studied. The RPL5 shRNA was obtained from Open 
Biosystem; lentivirus production and transduction were performed as explained in Section 
2.8.3. RPS14 and RPL5 knockdown levels were measured by qRT-PCR and the result 
(Figure 4.8) showed a reduction in RPS14 expression by more than 80% in both HEL and 
K562 cell lines and RPL5 expression was reduced by 80% in HEL cell line and 
approximately 50% reduction in K562 cells. Data was obtained from three independent 




Figure 4.6: pLKO.1 vector map (reproduced from 
www.dharmacon.gelifesciences.com). 
The pLKO.1 vector is the backbone of the RNAi Consortium (TRC) for expressing different 











Figure 4.7: RPL27A depletion using lentivirus shRNA.  
A) RPL27A mRNA expression was examined in HCT-116 and HCT-116 p53-/- infected with four different 
shRNAs, showed a reduction in RPL27A with sh2 and sh4 B) Western blot analysis of proteins collected from 
HCT-116 and HCT-116 p53-/- cells, infected with RPL27A-sh2 and RPL27A- sh4. Antibodies against RPL27A 
and the loading control γ tubulin were used to detected proteins expressions; the results confirmed the qRT-
PCR result and showed a reduction in protein expression by both shRNAs C). RPL27A mRNA expression in 
HEL and K562 cell lines infected with RPL27A-sh2 and RPL27A sh4 also showed a reductions in the gene 
expression by both shRNAs at different levels. mRNA expression was normalized with GAPDH mRNA, 
calibrated to the non infected cells and compared with empty vector. Bars represent the mean ±S.D. from 































































































































































































































































































































Figure 4.8: RPS14 and RPL5 depletion using lentivirus shRNA.  
RPS14 and RPL5 mRNA expression in HEL and K562 cell lines which were infected with RPS14 
shRNA and RPL5 shRNA showed a reduction in the gene expression in both cell lines. mRNA 
expression was normalized with GAPDH mRNA, calibrated to the uninfected cells and compared with empty 







































































































































4.4.4 RPL27A depletion causes p53 activation   
Given the evidence for p53 overexpression in a mouse model with reduced RPL27A 
expression (Terzian et al. 2011), this project examined the effects of reduced RPL27A in 
vitro in a variety of human cell lines including HCT-116, HCT-116-p53-/-, K562 and HEL 
cell lines. HEL and K562 are myeloid cell lines of erythroleukemia type; both have 
different p53 mutations. The K562, human chronic myelogenous leukaemia cell line, is 
known to contain a p53 mutation in exon 5 leading to a frame-shift mutation resulting in an 
inactive truncated p53 (Law et al. 1993). The identified mutation in p53 in the 
erythroleukemic HEL cell line is a homozygous mutation in exon 5 which does not affect 
the p53 expression (Zhao et al. 2012). I examined p53 expression in all selected cell lines at 
both mRNA and protein levels. RNA and protein samples were isolated from the wild type 
cells and qRT-PCR and western blot analyses were performed. p53 expression was 
confirmed in HCT-116 and HEL cell lines and the absence of p53 expression in the other 
cell lines as shown in Figure 4.9. Cells that do not express p53 either due to p53 mutations 
or double knockout termed “null p53 cells” and p53-/- only referred to HCT-116 with p53 
double knockout.  
To investigate the cellular consequences of RPL27A knockdown on the p53 pathway, the 
selected cell lines were infected with control empty lentivirus, two shRNAs targeting 
RPL27A (sh2 and sh4), which were shown earlier to decrease RPL27A expression by 80% 
and 40%-50% respectively at mRNA and protein levels. In addition, RPS14 and RPL5 were 
also knocked down in all cell lines. The reason for choosing RPS14 is because of its 
recognised importance in the pathogenesis of 5q- syndrome, subtype of MDS. RPL5 is a 
ribosomal protein that belongs to the large ribosomal subunit and its depletion does not lead 
to p53 induction (Dai et al. 2004, Teng et al. 2013). Therefore, re- examining the knock 
down effects of these ribosomal proteins alongside with RPL27A will address any 
functional similarities or discrepancies between the different knockdowns.  
Cell lines were infected as explained in Section 2.3.8.3. After 24hrs, infected cells (HCT-
116 and HCT-116-p53-/-) were transferred to 75-mm flasks and selected with 2µg/ml 
puromycin where as K562 and HEL infected cells were transferred to 6 well plate and 
selected with 2µg/ml puromycin as these cells grew better in smaller culture volumes at low 
cell density (density should not exceed 1x106 / ml in any culture vessel). Independent 
experiments were performed in triplicate for each infection of each cell line, two 
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independent biological replicates were performed as single infection for each shRNA. After 
6 days, samples were isolated to investigate the knockdown effect on p53 and its target 
gene p21 (also know as cyclin-dependent kinase inhibitor 1-CDKN1A), Bax (pro apoptotic 
Bcl-2-associated X protein) and MDM2, at mRNA level by qRT-PCR. 1-2 x105 cells were 
preserved in trizol and RNA extraction was performed as explained (see Section 2.3.9.2) 
cDNA synthesis was done on 100-500ng/ml of RNA and the cDNA was diluted 1:10-1:50 
respectively. The qRT-PCR was carried out as explained in Section 2.3.10.4 using primer 
specific probe combinations as listed in 2.1.15. GAPDH mRNA was also quantified and 
was used as endogenous control to normalise signals obtained for each mRNA. Each cDNA 
sample was amplified in triplicate for a total of 40 cycles, and the relative quantification 
analysis was performed by normalizing with GAPDH mRNA and using ΔΔCT method. The 
ΔCT value was calculated as explained in 2.3.10.4. The ΔΔCT value was generated by 
subtracting the ΔCT value of the calibrator sample (the non infected wild type cells) from 
the ΔCT value of the shRNA-infected cells. p53, MDM2 and RPL27A were examined at 
protein level and γtubulin was used as loading control (antibody details are listed in 2.1.13). 
In HCT-116 which express p53, the depletion of RPL27A using sh2 and RPS14 were 
resulted in a significant increase in p53 mRNA level of 2-2.5 fold (RPL27A-sh2 p < 0.005 
and RPS14 shRNA p <0.01). RPL27A-sh4 increased p53 by 1.5 fold, relative to control 
empty vector (p <0.05) as assessed by qRT-PCR, result shown in Figure 4.10-A. On the 
other hand, RPL5 depletion did not cause any changes in p53 level. In the HEL cell line, 
which express p53, no significant changes were detected in p53 expression by any of the 
shRNAs that target ribosomal protein genes (Figure 4.10-A).  
To investigate weather the induction of p53 resulted in transcriptional activation, the 
expression of p53 downstream targets p21 and Bax were examined in HCT-116 and HEL 
cell lines by qRT-PCR. The result in Figure 4.10-B showed that p21 mRNA was 
significantly increased ± 5 fold in HCT-116 by all shRNAs except RPL5 shRNA (p <0.05). 
In the same cell line Bax expression was significantly increased (p <0.05) by 2-3 fold with 
RPL27A-sh2 and RPS14 shRNA. Increased expression with RPL27A-sh4 did not reach 
significance. In the HEL cell line, RPL27A-sh2, RPS14 shRNA and RPL5 shRNA caused a 
significant increase in p21 (p <0.05) by ± 4 fold, whereas RPL27A-sh4 did not increase the 
p21 expression (p =0.2057). A two folds increase in Bax mRNA level occurred in cells 
infected with RPL27A-sh2, RPS14 shRNA and RPL5 shRNA, the difference were 
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statistically significant. RPL27A-sh4 did not show any significant increase in Bax mRNA 
level.  
As expected, for the null p53 cell lines (HCT-116 p53-/- and K562) no changes in p21 and 
Bax levels,with all targeted shRNAs Figure 4.10-D. This indicated that p21 and Bax 
inductions were p53 dependent in the p53 expressing cell lines.  
To verify the p53 induction, p53 expression was examined at the protein level. 1-2 x105 
cells were lysed in 30-50 µl lysis buffer; western blotting analyses was carried out as 
explained in Section 2.3.11. The result in Figure (4.11-A and C) showed that RPL27A-sh2 
and RPS14 shRNA increased the p53 expression compared to control empty vector in both 
HCT-116 and HEL cell lines in three independent experiments. In HEL cell lines, the 
inductions of p21 with RPL27A and RPS14 depletion, did not show significant increase in 
p53 mRNA level, confirming that p53 gene was transcriptionally active. The increase in 
p53 expression with RPL27A-sh4 was not distinguishable when compared with the empty 
vector.  
Interestingly, knockdown of RPS14 also resulted in a decreased expression of RPL27A, the 
reasons for this are unknown as shown by western blot (Figure 4.11). 
Depletion of RPL27A, RPS14 and RPL5 resulted in reduced MDM2 expression at both 
transcriptional and post-transcriptional level in all cell lines tested except K562, which did 
not show a clear reduction at the post-transcriptional level. However, a significant reduction 
of MDM2 was observed in cells infected with RPL27A-sh2 at mRNA 
To determine whether RPL27A interacts directly with MDM2 and the reduction in 
RPL27A inhibited the MDM2- mediated p53 ubiquitination and degradation resulting in 
the induction of p53, co-immunoprecipitation assays with anti-RPL27A and anti-MDM2 
were performed (See 4.4.11). 
In order to determine the effect of RPL27A depletion on the p53 surveillance mechanism, 
proliferation assays, apoptosis and cell cycle analysis were carried out to investigate if there 























Figure 4.9: P53 expression in different human cell lines. 
A) The mRNA expression of p53 in four different cells lines (HCT-116, HCT-116 p53-/-, K562 and 
HEL) relative to GAPDH, as assessed by quantitative real time-PCR. Results showed that p53 is 
expressed in HCT-116 and HEL cell lines only; the result is representative of 2 independent 
experiments and bars represent the mean± S.D. B) Western blot analysis of p53 expression in four 
different cell lines using antibody against p53 and the loading control γ tubulin. The results 






































































Figure 4.10: Decreased expression of RPL27A activates the p53 pathway.  
 A) The mRNA expression of p53 and MDM2 in HCT116 and HEL cell lines relative to GAPDH, 
was measured by qRT- PCR. p53 induction with RPL27A and RPS14 depletion was seen in HCT-
116 cells compared with the control empty vector. Depletion of RPL27A, RPS14 and RPL5 reduced 
MDM2 expression in both cell lines. B) The mRNA expression of p53 target genes p21 and Bax in 
HCT116 and HEL cell line relative to GAPDH, was measured by qRT- PCR, showed increased 
expression of p21 and Bax with RPL27A and RPS14 depletion in both cell lines C-D) The mRNA 
expression of p53 target genes p21, Bax and MDM2 in HCT116 p53-/- and k562 cell line relative to 
GAPDH, as assessed by qRT-PCR, showed a significant reduction in MDM2 only with all 
knockdowns and no changes of the other genes. Results are representative of 3 independent 
experiments and bars represent the mean± S.D. p values were determined using tow tail student t-
















































































































































































































































































































































































































































Figure 4.11: RPL27A depletion increased p53 expression and reduced MDM2 level at 
the post-transcriptional level. 
Protein extracts were collected form wild type cell lines and cells infected with empty vector and 
shRNAs against RPL27A and RPS14 and analysed on 4-12% polyacrylamide gels with antibodies to 
detect RPL27A, p53 and MDM2. Equal protein loading per well was determined by γ tubulin 
loading control. A) HCT-116 cell line, the depletion of RPL27A and RPS14 induced p53 expression 
and reduced MDM2. B) The reduction of RPL27A and RPS14 in HCT-116 p53-/- reduced MDM2 
and p53 were not detected. C) In HEL cells the depletion of RPL27A and RPS14 induced p53 and 
reduced MDM2. D) The reduction of MDM2 in K562 infected with RPL27A shRNA and RPS14 
shRNA was not very distinguishable at the post-transcriptional level. In all cell lines, infection with 

























































































































































































4.4.5 Depletion of RPL27A inhibits cell proliferation and reduces cell viability  
To further study the effect of RPL27A inhibition on cell proliferation and viability،٬ HCT-
116 and HCT-116 p53-/- cells were transduced with the shRNA constructs and counted 
every 48hrs as explained in Section 2.3.6.2. Both cell lines were very clumpy and after 
trypsinization it was very difficult to get an accurate cell count to monitor the knockdown 
effect on the cell proliferation at different time points. Therefore, MTT assay was 
performed to determine the metabolic activity of the shRNA transduced cells compared to 
cells infected with empty vector. On day 6 post infection, 2000 cells in 100µl medium were 
seeded on a 96 well plate (flat bottom) and incubated with 20 µl MTT reagent at 37°C and 
5% CO2. After 2h, formazan crystals were observed under the microscope and 150µl 
solubilisation buffer was added to each well. Each sample was seeded in triplicate and three 
wells were filled with complete medium only, which was used as a blank. The plate was 
analysed after 24hrs with a plate reader set at 630nm. The data was analysed by calculating 
the average of each triplicate and normalizing with the blank average. Fold change was 
determined by dividing the normalized average of the samples by the normalized average 
of the calibrator sample, which is the empty control. The results in Figure 4.12-A and B, 
showed a clear reduction in the metabolic activity relative to the control empty vector in 
both HCT-116 and HCT-116 p53-/- cells infected with RPL27A-sh2 and RPS14 shRNA; 
RPL27A-sh4 caused a small but significant change in HCT116 only. In order to show the 
knock down effect on cell surveillance, HCT-116 cells were stained on day 6 post infection 
(see Section 2.3.6.4). The results in Figure 4.12-C, showed severe cell death in cells treated 
with RPL27A -sh2 and RPS14 shRNA where as RPL27A-sh4 and RPL5-shRNA showed a 
relatively less cell death.  
Although the reduction in the metabolic activity in HCT-116 p53-/- was significant, it was 
less than what was seen in the cell with normal p53. This might be due to the fact that 
HCT-116 p53-/- cells clearly proliferate more slowly than the wild type cells. For example 
after seeding the same cell number in culture flasks, HCT-116 with normal p53 required 
passaging after 72hrs while cells with null p53 needed passaging after 6 days. Also, null 
p53 cells showed an increased sensitivity to trypsinization. The staining result in Figure 
4.12 –D, clearly showed that many p53-/- cells were lost both with the empty control as 
well as with RPL27A-sh2, though more cells were lost with the cells with reduced RPL27A.  
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In K562 and HEL cells the proliferation was determined by counting the cells every 48hrs 
and a reduction in cell number was detected by day 4 which increased over time in cells 
treated with RPL27A-sh-2, RPS14 shRNA and RPL5 shRNA (see Figure 4.13-A and B). 
Cells infected with RPL27A-sh4 showed a reduction in cell number but this was less 
marked. The unexpected observation was that there was no difference in cell death was 
noted between the p53 expressing (HEL) cells and the p53 null (K562) cells. In order to 
investigate this p53 independent effect, which was not clear in the HCT-116 cell lines, I 
chose U937 cells which also do not express p53, due to a large deletion in p53 gene 
(Sugimoto et al. 1992). These cells were infected with RPL27A-sh2 only and compared to 
empty vector, cell numbers were decreased in RPL27A-sh2 infected cells but this was not 
lethal during the assay period as compared to cell lines, which do express p53 (see Figure 
4.13-C). These results suggested that the observed cell death in the null p53 cell line is may 
be due to the defects in the ribosome biogenesis. To further investigate these p53 





Figure 4.12: RPL27A depletion reduces cell viability. 
MTT assay of cells A) HCT-116 and B) HCT-116 p53-/-,, which were infected with RPL27A-sh2, 
sh4 and RPS14 shRNA on day 6 post infection, under puromycin selection. The result showed 
significant reduction in cell viability with RPL27A-sh2 and RPS14 shRNA in both cells at variable 
level. RPL27A-sh4 caused a significant reduction in HCT-116 cells while the reduction in HCT-116 
p53-/-,, was not significant. Results are expressed as fold change mean ±S.D. relative to the control 
empty vector and are representative of three independent experiments each performed in triplicate 
*P<0.05,*P<0.005. C) HCT-116 cells, infected with empty pLKO.1, RPL27A shRNAs, RPS14 
shRNA and RPL5 shRNA stained with coomassie stain on day 6 post infection, results showed a 
marked cell death in cells infected with RPL27A-sh2 and RPS14 shRNA with moderate reduction in 
cell viability in cells infected with RPL27A-sh4 and RPL5 shRNA. D) HCT-116 p53-/- infected with 
empty pLKO.1 and RPL27A-sh2 stained with coomassie stain on day 6 post infection showed small 
differences between the control empty vector and RPL27A-sh2 expressing cells. 
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Figure 4.13: RPL27A reduction decreases cell proliferation 
Cells were counted every 48hrs. A reduction in cell number was noted by day 4 which almost 
resulted in complete cell death by day 10 in cells infected with RPL27A-sh2, RPS14 shRNA and 
RPL5-shRNA in A) K562, B) HEL cell lines. RPL27A–sh4 also decreased the cell count but less 
than the other shRNAs. C) U937 cells, which were infected with control empty vector and RPL27A-
sh2 showed a reduction in cell number but less than the other cell lines. Error bars represent the 































































































4.4.6 RPL27A depletion induces apoptosis independent of p53 
To investigate whether the observed cell death in the cells with depleted RPL27A was due 
to apoptosis and if that was dependent on the p53 induction or not, cells treated with the 
shRNAs used above stained with Annexin-V/7-AAD. On day 6 post infection, 
approximately 1-2x 105 cells from all studied cell lines were stained with Annexin V/7-
AAD to distinguish apoptotic from necrotic cells, staining was performed as explained in 
Section 2.3.14 and cells were analysed by flow cytometry. Annexin-V verses 7-AAD 
analysis revealed four populations: negative for both fluorescence which represent the 
living cells; Annexin V+/7-AAD- which identify early apoptotic cells; Annexin V+/7-AAD+ 
which characterize late stage apoptosis and Annexin V-/7-AAD+ which represent dead cells 
with permeabilized membrane only. To adjust the analysis grids, control staining with 
single dye was performed in cells infected with empty vector and the adjusted alignment 
was applied to all samples from each experiment. This adjustment step was performed with 
every cell line in all replicates. The analysed data showed significant increase in apoptosis 
in all cell lines. HCT-116 cells treated RPL27A-sh2 showed an increased number of cells at 
the early stage of apoptosis as compared to RPS14 shRNA and RPL5 shRNA as assessed 
by the quantification of Annexin V+/7-ADD- staining with an average increase of 55% with 
sh2 and 40%- 35% with RPS14 and RPL5 shRNAs, respectively. The substantial increase 
in apoptotic cells as compared to control vector were significant with the following p-
values RPL27A-sh2 P =0.00052, RPS14 shRNA P =0.00157 and RPL5 shRNA P =0.01804 
as estimated by two tail student t-test. RPL27A-sh4, which caused less than 50% 
knockdown also showed a 25% increase in apoptotic cells compared to the control vector 
(P =0.03126). The number of cells at late stage apoptosis had also increased by an average 
of 10-15% compared to control vector (RPL27A-sh2 P =0.00141, RPL27A-sh4 P =0.0056, 
RPS14 shRNA P=0.001924 and RPL5 shRNA P =0.00238). Interestingly, the p53 null cells 
HCT-116-p53-/- also showed an average increase in apoptotic cells of 15-20% in all 
knockdowns as compared to control at early stage apoptosis and 8-10% increases at late 
stage apoptosis. Even though the increase in apoptotic cells was far less than what was 
observed in cell lines that express p53, these increases were also significant (Early 
Apoptosis: RPL27A-sh2 P =0.00278, RPL27A-sh4 P=0.0516, RPS14 shRNA P =0.00359 
and RPL5 shRNA P =0.00202; Late Apoptosis: RPL27A-sh2 P =0.01707, RPS14 shRNA P 
=0.02747 and RPL5 shRNA P =0.017855). RPL27A-sh4 caused a slight increase of late 
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stage apoptosis but this was not significant, see Figure 4.14. In HEL and K562 cells the 
observed cell death was confirmed to be a result of apoptosis. In the HEL cells there were a 
40-50% increase in apoptotic cells with all the shRNAs infected cells at late stage of 
apoptosis with no differences at early apoptosis as compared to the control vector. The 
increase in apoptotic cells at late stage was significant (RPL27A-sh2: P=0.001024, 
RPL27A-sh4 P=0.000606, RPS14 shRNA P=0.00087 and RPL5 shRNA P =0.000179). 
However, in null p53 K562 cells the depletion of RPL27A, and RPS14 led to an increase in 
apoptotic cells by an average of 15-20 % at both early and late stagse. Therefore, to address 
the p53 independent induction of apoptosis, U937 cells were investigated. The result 
showed a significant increase in apoptosis in cells infected with RPL27A-sh2 but that 















Figure 4.14: RPL27A reduction induces apoptosis in HCT-116 and HCT-116 p53-/- 
 (A) Grid alignment in HCT-116 cells infected with empty pLKO.1 using single stain. B and C) 
HCT116.and HCT-116 p53-/-cells were infected with empty vector, RPL27A shRNAs, RPS14 
shRNA and RPL5 shRNA and selected with puromycin. 6 days after infection, cells were stained 
with Annexin and 7-AAD followed by flow cytometer analysis. Cells on the upper left quadrant 
indicate Annexin positive, early apoptotic cells. The cells in the upper right quadrant indicate 
Annexin-positive/ 7-AAD-positive, late apoptosis. In comparison with empty vector, RPL27A sh-2 
significantly induced apoptosis in both cell lines with effects been more marked in HCT-116. Also, 
RPS14 and RPL5 reductions significantly induced apoptosis in both cell lines with a greater degree 
in HCT-116. RPL27A-sh4 induced significant apoptosis in HCT-116 cells only. D and E) Column 
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Figure 4.15: RPL27A induces apoptosis in K562, HEL and U937 
HEL(A) and K562(B) cells were infected with empty vector, RPL27A shRNAs, RPS14 and RPL5 
shRNAs and selected with puromycin. 6 days after infections, cells were stained with Annexin V 
and 7-AAD followed by flow cytometer analysis. Cells in the upper left quadrant indicate Annexin 
positive, early apoptotic cells. The cells in the upper right quadrant indicate Annexin-positive/ 7-
AAD-positive, late apoptosis. In K562, RPL27A sh-2 and RPL27A-sh4 significantly induced 
apoptosis at early stage and RPL27A-sh2 and RPS14 shRNA induced apoptosis at late stage, 
relative to the control empty vector. In HEL cells, all targeted shRNAs significantly increased late 
stage apoptosis. Column diagram represents the mean of apoptotic cells from three independent 
experiments ±S.D. *P(<0.05), **P(<0.005).C) U937 cells infected with empty vector and RPL27A-
sh2 only, the flow cytometric analysis revealed that RPL27A-sh2 significantly increased the 
percentage of apoptotic cells but less than other cell lines.  
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4.4.7 RPL27A reduction induces cell cycle arrest 
The results described in the previous sections showed that RPL27A depletion induces 
apoptosis and reduces cell viability, which suggesting a possible defect in the cell cycle. 
Therefore, at the same time point, day 6, 1-2x 105 cells were isolated from the uninfected 
cells, control infected with empty vector and cells infected with shRNAs targeting RPL27A, 
RPS14 and RPL5. Subsequently, cells were fixed with 75% ethanol, stained with PI (DNA 
content) and processed as explained in Section 2.3.13. Flow cytometric analysis was 
performed to determine the percentages of cells in each phase of the cell cycle by analysing 
the DNA content. Cell cycle analysis was performed on all cell lines but the data obtained 
for the HEL cell line was unusable probably because the cell population was not very 
homogeneous. Repeated experiments on HEL cell line also failed. In HCT-116, there was a 
considerable reduction in cells in G0/G1 in cells infected with RPL27A-sh2 and RPS14 
shRNA (43.4%± 10% and 47% ± 8% respectively), compared to the control (84.5%± 3%), 
and a smaller reduction 61.7% ± 13%, and 55.9% ± 7%, was observed in cells infected with 
RPL27A-sh4 and RPL5-shRNA, respectively. No changes were observed in either the S or 
G2/M phases in all conditions. However, a high percentage of cells accumulated in the sub-
G1 phase in cells infected with shRNA targeting RPL27A (sh2: 45.2% ± 10%, sh4: 23.1%± 
7%), RPS14 (38%± 10%) and RPL5 (25%± 7%) compared to control empty vector (1.84% 
± 2%), and non-infected cells (2.84% ± 3%) (n=3, mean±S.D.), as shown in Figure 4.16-
A.The increases in sub-G1 is consistent with the induction of apoptosis, which had been 
shown earlier (Section 4.4.6). 
In K562 cells, similar result were observed with a reduction in cell content in G0/G1 phase 
and no changes in S or G2/M with all shRNAs apart from RPL5 shRNA. An increased in 
sub-G1 was observed (Figure 4.16-C). For other p53 null cell lines, (HCT-116 p53-/- and 
U937), there was a reduction in G0/G1 phase as well as an increase in cells in G2/M 
consistent with an increase in the sub-G1 phase. In HCT-116 p53-/-, 26.3% of cells were in 
G0/G1 in RPL27A-sh2 transduced cells, 40.3% in RPS14 shRNA and 39.5% in RPL5 
shRNA infected cells, as compared with control 75.8%. The observed increases in G2/M 
were seen in cells infected with RPL27A-sh2 (23.3% ± 5% ) RPS14 shRNA (9.5% ± 15%) 
and RPL5 shRNA ( 14.9% ± 7% ) compared to the control (5.9% ± 3% ). The observed 
increase in G2/M for cells infected with RPL27A-sh2 and RPL5 shRNA was significant 
(p≤0.005) compared to control; the observed increase with RPS14 did not reach 
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significance (P=0.07) (see Figure 4.16-B). In U937, 43.5% ± 3% of cells infected with 
RPL27A–sh2 were in G0/G1, 10%± 4% in S and 19.6% ± 5% in G2/M, compared with 
64.5%± 5%, 13.5%± 3% and 10.7% ± 1% respectively for cells infected with the control 
empty vector (n=3, mean ±S.D.), see Figure 4.16-D. The observed increase in cells in 
G2/M, which was significant (P=0.0046), suggested that these cells were arrested via 
different pathways independent of p53. However, the observed increase in cell numbers in 
sub-G1 (RPL27A-sh-2 infected cells: 26.5 %± 7% compared with control 10.7%± 2), in the 
null p53 cell lines was less than what was seen in the other cell lines and that is consistent 
with the obtained results from apoptosis analyses (see Section 4.4.6). 
From these results, it was clear that at day 6, the cells undergo apoptosis and it was unclear 
at which phase the cells were arrested. In order to determine whether the cell cycle defect 
occurred at an early time points, I performed the analysis at 24hrs, 48hrs and 72hrs. In 
HCT-116 and HCT-116 p53-/-, the results were not clear and it was difficult to interpreted 
due to clumping of cells resulting in histograms with several spikes making the gating for 
each phase of cell cycle unclear, data not shown (Cell Cycle data was kindly reviewed by 
prof. Shaun Thomas, KCL). These results suggested increase in apoptosis occurs at sub-G1 
phase, which increases with time in the cells that express p53. The null p53 cells did not 
show any significant differences from control cells in sub-G1 at early time points 
suggesting that depletion of RPL27A and RPS14 are p53 dependant at an early time point 
while this effect become independent at a later time points, this was confirmed by 
experiments presented in the Section 4.4.10. The p53 independent effect can be attributed 
to the defect in the ribosome biogenesis. In order to investigate that ribosome profiling and 
nucleolar staining were performed as explained in the following sections. 
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Figure 4.16: Cell cycle analysis in different cell lines infected with shRNAs against 
RPL27A, RPS14 and RPL5. 
Cell cycle analyses of uninfected, control and shRNAs infected cells on day 6 post-infection. The 
cells were fixed with ethanol and stained with PI. Graphs of the percentage of cells in sub-G1, 
G0/G1, S and G2/M phases were determined by flow cytometry. A) Cell cycle results of HCT-116 
cells which were infected with control, RPL27A-sh2 and RPL27A-sh4, RPS14 shRNA and RPL5 
shRNA; this showed increased in subG1 cells in all shRNAs infected cells compared with the 
relevant control. B) Cell cycle result on HCT-116 p53-/- cells which were infected with control, 
RPL27A-sh2 and, RPS14 shRNA and RPL5 shRNA; and showed increased percentage of cells in 
subG1 and G2/M in all shRNAs infected cells compared with the relevant control. C) K562 cells 
were infected with control, RPL27A-sh2 and, RPS14 shRNA and RPL5 shRNA; and showed 
increases of cells in subG1 in all shRNAs infected cells compared to the relevant control. D) U937 
cells were infected with control and RPL27A-sh2; also showed a high percentage of cells in subG1 
and in G2/M in the infected cells compared to the relevant control. The results represent three 
independent experiments  

































































































































































































































































































4.4.8. Effect of RPL27A deficiency on ribosome assembly 
We postulated that a striking abnormality in RPL27A deficient cells may be a consequence 
of a primary defect in the ribosome formation and function and maturation of 60S subunit. 
Therefore, I performed polysome profiling of cells infected with RPL27A shRNA-2 by 
sucrose gradients fractionation. This experiment required a large numbers of cells to 
generate an analysable profiles; approximately 1 µg cell pellet was required. However, due 
to the knockdown effect on cell viability, this experiment was carried out several times to 
find the minimum analysable cells. Therefore, HCT-116, HCT-116-p53-/- , K562 and HEL 
cell lines were infected with empty vector pLKO.1, RPL27A shRNA2 and RPS14 shRNA 
(see Section 2.3.8.3). It has previously been shown that RPS14 depletion results in the 
reduction of the 40S subunit (Ebert et al. 2008), therefore I used this as my control only in 
HCT-116 and HCT-116-p53-/- cells. In each experiment, three infections with the individual 
shRNAs were performed to recover sufficient numbers of cells for the analysis. On day 6 
post-infection, pellets were collected from triplicates and mixed together; the minimum 
collected pellet contained approximately 8x105 cells. Cells were treated with 
cyclohexamide for 15 minutes before collection and stored at -80 °C until analysed. The 
Polysome profiles were performed at the University of Cambridge in Prof. Alan Warren’s 
lab with the help of Dr. Shengjiang Tan. Samples were transferred on Dry Ice and 
processed immediately upon arrival. Samples were lysed; RNA concentration was 
measured and equal concentration was separated by sucrose gradients centrifugation on 10 
to 50% sucrose gradient as described in Section 2.3.12. The polysomes profile was detected 
using a UV monitor at A245 . In HCT-116, HCT-116 p53-/- and K562 the reduction of 
RPL27A resulted in a reduction of the 60S subunit and slight increase in the 40S subunit in 
comparison with the non-infected cells and the cells infected with empty vector (see Figure 
4.17). RPL27A-sh4 was only examined in HCT-116 cell line and showed a small reduction 
in the 60S compared to the control. As expected, the depletion of RPS14 caused a reduction 
in the 40S subunit in HCT-116 and HCT-116 p53-/-. HEL cells analyses failed, the profiling 
result of the sucrose fractions from this cell line did not give any analysable data of the 
cells infected with RPL27A shRNA due mainly to low RNA concentration that was used in 
the fractionation. It is also likely that the high apoptotic level (see Section 4.4.6) also 
contributed to the failure to obtain a ribosomal profile. The profiling experiment was 
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performed in duplicate in all other cell lines and results were similar. Data obtained 





Figure 4.17: Depletion of RPL27A causes defects in 60S subunit maturation. 
Polysomes profile of cells infected with lentivirus-expressing RPL27A shRNA, RPS14 shRNA and 
empty vector pLKO.1 on day 6 post-infection. Polysomes profiling was performed by sucrose 
gradient fractionation on a 10% to 50% sucrose gradient. Polysomes were detected at A245 using a 
UV monitor. Ribosome native subunits 40S, 60S and 80S  monosomes are indicated. A, B) In HCT-
116 and HCT-116 p53-/-, RPL27A depletion reduced the 60S subunit, where RPS14 shRNA 
reduced the 40S subunit compared to the relative control. C) K562 cells infected with RPL27A 
































































































































































4.4.9 Depletion of RPL27A, RPS14 and RPL5 disrupts nucleolar signals 
In order to examine if the deficiency of RPL27A and the other ribosomal proteins were 
involved in the alteration of nucleolar structure or the synthesis of ribosomes, which 
normally occurs in the nucleolus, nucleolar staining was performed. The nucleolus is 
composed of three main components: one of them is a dense fibrillar component, which can 
be visualized by staining with nucleolar protein, fibrillarin. 
In this experiment, HCT-116 and HCT-116 p53-/- infected with empty vector pLKO.1, 
RPL27A-sh2, RPS14-shRNA and RPL5-shRNA, cells were puromycin selected and on day 
6 post- infection, cells were fixed on slides and stained with anti fibrillarin antibody (see 
Section 2.3.11.5). Depletion of RPL27A, RPS14 and RPL5 resulted in abnormal staining of 
fibrillarin in all cell lines (Figure 4.18). Ribosomal protein depleted cells showed dispersion 
of fibrillarin in the nucleolus whereas cells treated with control empty vector (pLKO.1) did 
not show this disruption by screening at least three different positions in each slide. These 
results suggesting the importance of these ribosomal proteins in maintaining the nucleolar 
integrity and might explain the observed p53-independent effects described in previous 
sections. This experiment was performed in duplicate in each cell lines and analysed by 
confocal microscopy in Prof Warren’s lab, Cambridge, the analyses was performed by the 
















Figure 4.18: RPL27A, RPS14 and RPL5 are required for nucleolar organization.   
A) HCT-116 and B) HCT-116 p53 -/- cells, infected with empty vector (the top panel) and the 
ribosomal protein shRNAs, were fixed on slides and stained with anti fibrillarin antibody (green: 
nucleolar marker) on day 6 post infection. The nucleus was stained with DAPI (blue). The slides 
were analysed using 40x objective Zeiss LSM780 confocal microscopy, ZEN 2010 software. The 
results represent n=2 experiments and showed disruption of nucleolar fibrillarin staining in cells 














4.4.10 Depletion of RPL27A and RPS14 causes p53 dependent effect at an early time 
point 
In order to investigate the effect of RPL27A depletion at early time points, some of the 
experiments were repeated on HCT-116 and HCT-116 p53-/- cells 48hrs post infection. 
HCT-116 and HCT-116 p53-/- cells were infected with RPL27A shRNAs, RPS14 shRNA 
and RPL5 shRNA as explained in Section 2.8.3.8. Samples for apoptosis, MTT assay and 
ribosome profiling were collected as explained earlier.  
Apoptosis assays were performed using double staining with Annexin V and 7-AAD on 
1x105 cells collected from cells which were infected with RPL27A shRNAs, RPS14 shRNA 
and RPL5 shRNA compared to cells infected with control empty vector. RPL27A-sh2, 
RPS14 shRNA and RPL5 shRNA infection induced p53 dependent apoptosis, see Figure 
4.19.The observed induction of apoptosis was significant based on the p value derived by a 
two tail student t-test. There were no significant changes in apoptosis observed in the p53 
null cell line. 
MTT assay was performed on 2000 cells suspended in 100µl complete culture medium and 
seeded into 96 well plates. Subsequently, MTT reagent was added to the cells and to the 
blank wells as explained earlier in Section 4.4.5. After overnight incubation plates were 
read on a platereader and the obtained data was analysed as explained in Section 4.4.5. The 
results showed a reduction in cell viability in cells infected with RPL27A shRNA and 
RPS14 shRNA only in the p53 expressing cell line but RPL5 depletion did not affect the 
cell viability in both cell lines as shown in Figure 4.20-A. 
Polysomes profiling was performed on the HCT-116 cell line. Cells were infected with 
empty pLKO.1 and RPL27A-sh2 in triplicate and approximately 1x 106 cells were collected 
after cyclohexamide treatment. Ribosome profiling and analysis was performed as 
explained in Section 4.4.8. The result showed that RPL27A depletion reduced the 60S 
subunit compared to the control empty vector, see Figure 4.20-B. However, the reduction in 
the 60S subunit was less than what was seen on day 6 suggesting that the reduction in the 
60S ribosomal subunit increased with time, implying a p53 independent effect, which 
















Figure 4.19: RPL27A deficiency resulted in apoptotic p53 dependent defect at 48hrs 
post infection. 
HCT-116 and HCT-116 p53-/- cells were infected with control empty vector and shRNA against RPL27A, 
RPS14 and RPL5. Then at 48hrs post infections samples were collected for several assays.  Cells were stained 
with Annexin and 7-AAD and followed by flow cytometer analysis. Cells on the upper left quadrant indicate 
Annexin positive, early apoptotic cells. The cells in the upper right quadrant indicate Annexin-positive/ 7-
AAD-positive, late apoptosis. In comparison with empty vector, RPL27A sh-2, RPS14 shRNA and RPL5 
shRNA significantly induced apoptosis in HCT-116 only. Column diagram represents the mean of apoptotic 
cells from three independent experiments ±S.D. *P(<0.05), **P(<0.005).   







































































































































































































































































Figure 4.20: RPL27A deficiency resulted in p53 dependent defect at 48hrs post 
infection. 
HCT-116 and HCT-116 p53-/- cells were infected with control empty vector and shRNA against RPL27A, 
RPS14 and RPL5. Then at 48hrs post infections samples were collected for several assays. A) MTT assay to 
examine the knockdown effect on cell viability, the result showed significant reduction in cell viability with 
RPL27A-sh2, sh4 and RPS14 shRNA in HCT-116 only. Results are expressed as fold change mean ±,S.D. 
relative to the control empty vector and are representative of three independent experiments each performed 
in triplicate *P<0.05,*P<0.005. B) Polysomes profiles were performed only in HCT-116 with RPL27A-sh2 
and control empty vector only. Polysomes separation was performed by sucrose gradient fractionation on a 
10% to 50% sucrose gradient. Polysomes were detected at A245 using UV monitor. Ribosome native subunit 
(40S and 60S) and 80S monosomes are indicated. RPL27A depletion reduced the 60S subunit compared with 

















































































































4.4.11 RPL27A interacts with MDM2 and RPL5 in cells 
The fact that several ribosomal proteins cause p53 induction through their interaction with 
MDM2 suggests that RPL27A might also interact with MDM2. This is strengthened by my 
observation that RPL27A depletion reduced MDM2 levels. To examine the possible 
interaction between RPL27A and MDM2 co-immunoprecipitation (IP)-immunoblot (IB) 
assays were performed as explained in 2.3.11.5. 
The HCT-116 cell line was cultured and expanded until it almost reached confluence; 
5x106 cells were collected for each pull down assay and IgG control, IP assay was 
performed as explained in Section 2.3.11.5. Cells were lysed and incubated overnight with 
the appropriate antibodies; the pull down was performed with RPL27A antibody, the 
relevant IgG rabbit antibody, MDM2 antibody and the mouse IgG control. Also, a small 
aliquot from cell lysate without antibodies was stored at -20°C and used as a total input 
sample in western blot analysis. Following the overnight incubation with the antibodies at 
4°C, lysed proteins were immobilised on protein A/G beads and incubated for 1hrs at 4°C. 
Subsequently, several washes were carried out followed by western blot analysis to 
determine the possible binding between RPL27A and MDM2. Interestingly, the 
endogenous MDM2 could be immuneprecipitated with RPL27A (Figure 4.21). However, 
the RPL27A pull down with MDM2 could not be confirmed due to the overlap with light 
chain, which was predicted to be of the same size as RPL27A (20KDa). Several attempts 
were made to address this including: changing the composition of IP lysis buffer, lysing the 
protein without using reducing agent in the lysis buffer, running the IB on a higher 
acrylamide gel, 20% instead of 14%, which should separate smaller bands better and finally 
using commercial secondary antibodies against light chain such as easy blot. All of these 
measures failed in overcoming this problem and no further optimizations were performed. 
Although it has been reported that RPL5 binds to MDM2, so I performed western blot 
analysis for RPL5 and its interaction with MDM2 and RPL27A by probing MDM2 pull 
down lysate and RPL27A pull down lysate with RPL5 antibody. This was done to 
investigate whether the association of RPL27A with MDM2 in cells might be indirect via 
other ribosomal proteins. The result in Figure (4.21) showed that endogenous RPL5 bound 
to MDM2 as well as RPL27A. Suggesting a possible indirect interaction between RPL27A 
and MDM2. Further investigations to determine the binding site on MDM2 needs be 




















Figure 4.21: RPL27A interacts with MDM2 and RPL5 in cells. 
Endogenous RPL27A interacts with endogenous MDM2 and RPL5 in HCT-116 cells. Cell lysate 
(5x106 cells) were prepared and IP was performed with anti-RPL27A or rabbit IgG and anti-MDM2 
or mouse IgG followed by IB with anti-MDM2, anti-RPL27A and anti-RPL5. Experiments were 
performed at least two times. The result showed that MDM2 and RPL5 proteins are co-precipitated 










4.4.12 RPL27A overexpression has no effect on cell survival 
It has been previously shown that the ribosomal proteins that interact with MDM2 inhibit 
MDM2 –E3 liagase activity and stabilize p53. To test this, I cloned RPL27A into FLAG 
expressing vector as explained in 2.3.3 
The plasmid p3xFLAG-myc-CMV empty vector and p3xFLAG-RPL27A were introduced 
into HCT-116 cells using the lipofectamine transfection method as explained in Section 
2.3.7.1. Transfections were performed in 24 well plate and 48 hrs post transfection cells 
were transferred to 175 cm2 flask; cells were selected with G418 and samples were 
collected on day 14 post-selection. Samples for RNA, western blot and cell cycle analysis 
were collected. mRNA level of RPL27A was investigated as explained earlier and the result 
was normalized with GAPDH and compared with the empty vector (p3xFLAG-myc-CMV). 
The relative RPL27A expression was calculated using ΔΔCT and the result in Figure 4.22-
A, showed an approximately 2 folds increase in cells transfected with RPL27A constructs 
compared to the empty vector. In order to investigate the overexpression effect on p53 and 
MDM2, the mRNA expression levels for both of them was determined. RPL27A 
overexpression had no effect on p53 and MDM2 expression was only slightly increased in 
accordance with RPL27A overexpression. Protein samples were analysed by western blot as 
explained earlier. RPL27A antibody was used in addition to loading control antibody, 
which was γ tubulin. The result showed overexpression of RPL27A as compared to the 
control, Figure, 4.22-B.  
For cell cycle analysis 2x 105 cells were fixed in ethanol and stained with PI (DNA content) 
and analysed by flow cytometer. The results showed normal cell cycle profile in cells 





Figure 4.22: Effect of RPL27A overexpression  
HCT-116 cells were mock transfected, and transfected with empty vector p3X FLAG and 
p3xFLAG RPL27A constructs. Cells were selected with G418 and after 14 days under selection 
cells were collected to examine the RPL27A overexpression level and its effect on p53 and cell 
cycle. A) mRNA relative expression of RPL27A, p53 and MDM2 normalised to GAPDH in cells 
transfected with RPL27A compared with cells transfected with empty vector. Bars represent three 
independent experiments mean± S.D. B) Western blot analyses of protein samples collected from 
cells transduced with RPL27A and empty vector. Samples were probed with RPL27A antibody and 
tubulin was used as loading control. C) Cell cycle analysis of cells transfected with empty (p3x 
FLAG) and FLAG-RPL27A. Cells were fixed in ethanol and DNA content was stained with PI and 
analysed by flow cytometrey. There were no significant changes on the cell cycle phases from three 












































































































































Impaired ribosome biogenesis caused by ribosomal protein mutations and 
haploinsufficiency can cause nuclear stress. This phenomenon leads to the development of 
a clinical entitities collectively known as “ribosomepathies” which refer to the ribosomal 
defect that is associated with several congenital diseases and bone marrow failure 
syndromes, such as Diamond Blackfan Anaemia (DBA), Shwachman-Diamond syndrome 
(SDS), Dyskeratosis Congentia (DS) and Cartilage-Hair Hypoplasia(CHH) in addition to 
acquired MDS sub type 5q- syndrome (Liu et al. 2006, Narla et al. 2010).  
It is recognised that ribosomal stress is leads to p53 accumulation, although the 
mechanisms that underlie this phenomenon are not fully understood. Marechal and co-
workers were the first to show a link between ribosomal stress and p53 in 1994. They 
identified the complex interaction between RPL5, p53 and MDM2 (Marechal et al. 1994). 
Other studies followed and identified other ribosomal proteins also interact with MDM2 
and increase the expression level of p53. Reduction of RPS6 (Panic et al. 2006), RPL22 
(Anderson et al. 2007), RPL24 (Barkic et al. 2009), RPS19 (Danilova et al. 2008), RPS14 
(Ebert et al. 2008) and RPL23 (Jin et al. 2004) all have been shown to increase the p53 
levels while the reduction of other ribosomal proteins including RPL11 (Zhang et al. 2003), 
RPL5 (Dai et al. 2004) decrease the p53 level. By contrast the overexpression of RPL5(Dai 
et al. 2004), RPL26 (Takagi et al. 2005) and RPL11 (Lohrum et al. 2003, Zhang et al. 
2003, Bhat et al. 2004) and other ribosomal proteins, induced p53. Uniquely, however, 
RPL23 and RPS14 reduction and overexpression increase p53 expression (Jin et al. 2004, 
Zhou et al. 2013). 
Various studies on ribosomal protein depletion, including RPL27A have been done in mice 
and showed different phenotypes, as summarized in Table 4.1. The RPL27A study on mice 
is the only available study of this ribosomal protein; all other information about this 
ribosomal protein comes from expression array data and profiling results of different 
diseases (Terzian et al. 2011). Terzian et al, discovered the effect of reduced expression of 
RPL27A in sooty foot ataxia (SFA) mice on the p53 pathway. They isolated a SFA mutation 
and, by using mitotic mapping, they identified 13 genes within that mutation. The scan for 
the mutations of SFA heterozygous mice identified a point mutation within the RPL27A 
gene: an A>G at position 15 in the final splice acceptor of intron 4. Terzian and co-workers 
identified a phenotype similar to the high p53 mouse model and those with reduced MDM2 
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and MDM4.This phenotype includes the four major p53-dependent phenotypes: cerebellar 
ataxia, pancytopenia and epidermal hyperpigmentation and radio sensitivity. The reduction 
of RPL27A increase p53 levels and affected survival, and decreased number of 
haematopoietic stem cells (HSC) in the bone marrow in the severely affected mice. Also, 
downregulation of c-Kit and increased apoptosis was observed mainly in the mice with 
reduced HSC leading to postnatal lethality, which was attributed to a p53-dependent effect. 
Terzian et al, indicated the importance of RPL27A in maintaining p53 levels and suggested 
that the severity of depleted RPL27A depends on the expression levels of RPL27A and the 
affected tissue type, as well as the development stage.  
Therefore, in the current study, the effect of RPL27A depletion on ribosome biogenesis, cell 
proliferation and survival in comparison with other ribosomal proteins was investigated. 
The conducted experiments in this chapter were performed on different cancer cell lines 
that included cells expressing p53 and cells null for p53. Using lentiviral strategies, the 
achieved knockdown level was more than 80% with one shRNA (shRNA-2) and 
approximately 40-50% with another shRNA (shRNA-4).  
In relation to p53, it has been shown that deficiency of RPS14 and other ribosomal proteins 
as mentioned earlier lead to activation of p53 in vivo and in vitro. That activation was 
accompanied with p53-dependent apoptotic cell death and cell -cycle arrest, which are 
mediated through induction of p53 targets such as p21 and Bax. Thus, RPS14 knockdown 
was performed and used as positive control. RPL5, which has been known with inducing 
p53 by its upregulation, was also knocked down. The knockdown level for RPS14 and 
RPPL5 was more than 80%. Therefore, the knockdown levels of these ribosomal proteins 
were comparable with RPL27A-sh2. 
RPL27A depletion was carried out in different cell lines to investigate the effect on the p53 
pathway, as mentioned earlier, and the reduction of RPL27A was carried out using the two 
shRNAs. The expression levels of p53 were measured at mRNA and protein level and the 
result showed an induction of p53 at variable levels in both transcriptional and protein 
levels. As expected RPS14 depletion also led to the increased levels of p53. To validate 
whether p53 is active or not, the expression levels of some of the known p53 target genes 
were examined including p21 and Bax. In the p53+/+ cell lines the expression levels of these 
genes were increased significantly in comparison with the control empty vector in cells 
deficient for RPL27A. This increase in the expression of p53 target genes was also 
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associated with RPS14 depletion, which was in agreement with other studies (Dutt et al. 
2011). However, in the null p53 cell lines, the expression level of p21 and Bax did not 
change. This implies that RPL27A is similar to other ribosomal proteins, functioning 
through a p53-dependent mechanism.  
However, the induction of p53 at the mRNA level was not detectable in the HEL cell line 
that expresses p53; though the p53 targets p21 and Bax were increased, which indicates 
p53-dependent induction. The undetectable induction of p53 at mRNA level could be due 
to the global translation inhibition caused by RPL27A depletion. A similar finding was 
reported when RPS19 and RPL5 were knocked down in CD34+ cells (Dutt et al. 2011). In 
the study by Dutt et al, p53 induction was only observed at the protein level and the failure 
to detect changes at the p53 mRNA level was thought to be due to general translation 
inhibition. Similar finding was also reported by Mu-Shui and Hua Lu who found that p53 
induction as a result of RPL5 overexpression was only detected at protein level and not at 
the mRNA level but they were able to detect increases in p21 at mRNA level (Dai et al. 
2004). 
The expression level of MDM2 was also investigated to study the effect of ribosomal 
protein depletion on p53 to determine whether these effects are through MDM2 or through 
independent mechanism. Interestingly, MDM2 expression was reduced in all cell lines 
suggesting that RPL27A inhibit MDM2-mediated p53 degradation resulting in increased 
levels of p53. MDM2 is a key regulator of p53 and plays an important role in cell survival 
(Manfredi 2010).  
In order to investigate the knockdown effect on the cell survival mechanism, cell 
proliferation, apoptosis and cell cycle were investigated. Silencing of RPL27A, RPS14 and 
RPL5 reduced the proliferation of HEL and K562 cells. The reduction of proliferation in 
K562 was surprising, as K562 does not express p53 and the effect was similar to that seen 
in the HEL cell line resulting in complete cell death by day 10. For HCT-116 cells, as 
explained in section 4.2.4, the proliferation monitoring based on cell count was not reliable. 
Therefore an MTT assay was performed which showed a significant reduction in cell 
metabolic activity on day 6, detectable in both p53+/+ and p53 -/- cells, but the reduction was 
less in p53-/- cells. Therefore, to verify the p53-independent effect, another cell line U937 
(null p53) was obtained and results of RPL27A depletion in these cells proliferation showed 
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a moderate reduction in proliferation suggesting a p53 independent mechanisms that could 
result from defects in ribosome biogenesis. 
To investigate whether the reduction in cell proliferation is due to apoptosis, Annexin V 
and 7-AAD double-staining was performed. RPL27A (sh2 and sh4), RPS14 and RPL5 
reduction was associated with increased apoptosis in both p53+/+ and p53-/- cells. These 
results are similar to what was observed in the proliferation assay, the increase in apoptosis 
was highest in the HEL and K562 cell lines. However, a significant increase in apoptosis 
was still seen in HCT-116-/- and U937 cell lines, but it was less than in HEL and K562. 
Also, the cell cycle analysis results confirmed the findings in the apoptosis assay namely 
accumulation of cells in the sub-G1 phase and a considerable cell death. However, G2/M 
arrest was observed in U937 and HCT-116 p53-/- at day 6, which is suggested to be caused 
by p53 independent mechanisms.  
It was surprising to find that, upon reduction of RPL27A, RPS14 and RPL5 in both p53+/+ 
and p53 -/- cells, there was a significant induction of apoptosis in the null p53 cells lines in 
addition to the reduction in cell proliferation. This suggests the existence of p53-
independent mechanisms that affect the biological process in the long run. The independent 
effect by RPL27A was also seen in vivo by Terzian and co-workers study. In the SFA an 
association was found between RPL27A reduction and tumour transformation and 
prevention independent of p53. They tested the effect of tumour formation and overall 
survival in mice with p53+/- and mice with p53+/-:SFA/+ with reduced RPL27A. The 
depleted RPL27A mice had a higher risk of metastasis compared with p53+/-mice. This 
metastatic effect implies the p53-independent effect of RPL27A. The fact that the same 
investigation was performed in another study using RPL24 knockout mice with a p53+/- 
background and in this study no differences were noticed either in tumour development or 
metastasis emphasizing the specificity of this effect to RPL27A, which cannot be 
generalized to other ribosomal proteins. The observed independent damage emphasizes the 
importance of this ribosomal protein in mutant p53 cancer. In contrast, the depletion of 
RPL5 does not lead to induction of p53 in the literatures, but it has been reported that 
reduction of RPL5 decreased the 60S ribosomal subunit with a concomitant increase in 
40S. This had an inhibitory effect on ribosome biogenesis and global protein translation, 
which caused a delay in proliferation independent of p53 (Teng et al. 2013). This 
observation could explain the observed defect on proliferation and increased apoptosis 
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independent of p53, as observed by day 6. Further supportive evidence of the effect of 
RPL5 deficiency on apoptosis induction is consistent with what was seen in other studies of 
RPL5 and RPL11 depletion in CD34+-derived erythroid cells. Normally to induce erythroid 
differentiation the experiments are carried out in long-term culture procedures, therefore 
after 10 days on culture the depletion of RPL5 showed significant induction of apoptosis. 
These findings suggest the importance of a p53- independent mechanism in the onset of 
tumourgenesis mainly in tumours with non -functional p53. 
The observed cell death in myeloid erythro-leukaemia cell lines (HEL-K562) could be 
attributed to either a cell type -specific effect, which would be an effect against erythroid 
cells, or it could be a cell line-specific genetic defect (k562 is a BCR-Abl cell line and HEL 
carries JAK2 mutation). 
Given that the effects appear to be erythroid specific, several reports have pointed to the 
involvement of ribosomal defects in erythroid differentiation such as the effect of RPS19 
and further11 ribosomal proteins mutations, which reduced the genes expression, in the 
erythroid cells in DBA patients and the association of RPS14 haploinsufficiency with 
erythroid depletion in 5q-syndrome (Narla et al. 2010, Dutt et al. 2011). 
Goetz and co-workers reported that the presence of BCR-Abl control the MDM2 level and 
keep it at high levels. They have shown that BCR-Abl-positive cells, which are normally 
resistant to apoptosis and cell death caused by pro-apoptotic stimuli such as cytotoxic 
agents and growth factors deficiency, are not resistant to cell death caused by MDM2 
depletion (Goetz et al. 2001). This could explain the observed high apoptotic in K562 cell 
line, which is a BCR-Abl positive cell line, as a result of the decreased expression of 
RPL27A, RPS14 and RPL5, which reduced the expression of MDM2. 
The RPL27A depletion using shRNA-4, which caused less than 50 % knockdown, has no 
significant effect on the null p53 cell lines (HCT-116 p53-/-) and the observed effect on the 
p53 cell lines (HCT-116 and HEL) was less than what was seen with shRNA-2. This 
indicated that although a 50 % reduction led to the induction of p53, but this reduction is 
insufficient to induce cell death. This is supported by the knockout studies in mice, which 
showed that ribosomal protein deficiency by heterozygous mutations in mice had no 
adverse effect on the mice whereas mice homozygous for several mutated ribosomal 
proteins, including RPS19 and RPL27A, were embryonic lethal as summarised in Table 4.1. 
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Also, the complete loss of RPS14 lead to cell death as seen in yeast (Ferreira-Cerca et al. 
2005).This homozygous deletion of RPS14 is not seen in 5q- patients (Ebert et al. 2008). 
This also could explains the rescued phenotype in mice with heterozygous deletion of 
RPL27A (Terzian et al. 2011) RPS14 (Barlow et al. 2010) and RPS19 (Devlin et al. 2010) 
in these models, a normal cellular phenotype was restored. 
To my knowledge, thus far, no studies have shown the importance of RPL27A on the 
ribosome assembly and ribosome biogenesis in humans. Therefore, in this project ribosome 
profiling was performed on three cell lines (including HCT-116, HCT-116 p53-/- and 
K562) with reduced RPL27A.The knockdown using RPL27A-sh2 caused a depletion in the 
large subunit, accompanied by an increase in the 40S subunit in comparison with the 
control and the non-infected cells. Also, the knockdown of RPS14 caused a reduction in the 
40S subunit and resulted in accumulation in the 60S subunit, which is in agreement with 
what was seen in the Ebert et al (Ebert et al. 2008). The above results were obtained from 
samples isolated on day 6 post-infection. To confirm the presence of the effect at an earlier 
time point, the experiment was repeated in one cell line (HCT-116) 48hrs post –infection. 
The result showed a reduction of 60S ribosomal subunit, but this was less than what was 
observed on day 6; this indicated that the ribosomal defect was not a consequent of cell 
death and apoptosis; it was a specific defect of RPL27A deficiency. This finding contradicts 
what was reported in Terzian et al study, that RPL27A has no effect on ribosome 
biogenesis. In the Terzian study, the maximum knockdown level was 40% in cerebellum 
and approximately 30% and 20% in bone marrow and skin respectively. These low levels 
of knockdown are the reason they did not observe any defect in ribosome biogenesis; in this 
study the knockdown with RPL27A-sh4, which caused 40-50% knockdown resulted in only 
a very small reduction of the 60S subunit. These findings taken together and suggests that 
RPL27A impairs ribosome assembly only when the depletion exceeds 50%.  
The knockdown of RPL27A caused a reduction in the large subunit, which in turn caused a 
reduction in other proteins that are part of the large subunit assembly such as RPL5, which 
is probably a response to the global translation inhibition. This is in agreement with what 
was observed with knockdown of RPS19, which caused a dramatic reduction in the 
ribosomal proteins that are part of the same subunit (Badhai et al. 2009). The regulation of 
other ribosomal proteins important for p53-MDM2 pathway might be involved indirectly 
with the induction of p53 and impaired ribosome biogenesis.   
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Activation of p53 as a result of ribosomal dysfunction has been attributed to two pathways, 
either via increased expression of RPL11 or nucleolar stress, which affects the nucleolar 
structure. The current study showed that the reduction in RPL27A, RPS14 and RPL5 caused 
a disruption of the nucleolar marker, fibrillarin, in HCT-116 and HCT-116 p53-/- on day 6 
post infection. This indicates that these ribosomal proteins could activate p53 through 
nucleolar stress suggesting their importance for ribosome biogenesis. The current study 
contradicts another study that investigated the effect of RPS14 deficiency on the nucleoli 
(Dutt et al. 2011). Dutt et al, showed that both RPS14 and RPS19 knockdown did not affect 
the nucleolar integrity by staining with the nucleophosmin (B23). Dutt et al, discussed the 
similarity of their finding with another study on RPS6; the effect of RPS6 depletion on p53 
induction is caused by an increase in the expression levels of RPL11. This occurred without 
affecting the nucleolar integrity, which was observed by staining with another nucleolar 
protein marker, nucleolin (Fumagalli et al. 2009). Increases in RPL11 translation elevated 
the binding of RPL11 to MDM2 and therefore increased the expression of p53 (Lohrum et 
al. 2003). This contradiction with the data presented here can be explained in several ways. 
First, the nucleolar staining was performed with different nucleolar markers, i.e. fibrillarin 
in the current study and two different markers in the other studies. Second, the duration of 
the experiments was different between the studies mentioned and as shown in this thesis 
timing plays a crucial role to observe the effect of ribosomal protein knockdown on 
ribosome biogenesis. The experiments performed in the other studies were terminated 
within 48 -72hrs post- depletion, while in the current study it was measured on day 6 post-
infection. In this study some experiments were carried out 48hrs post transduction and it 
was very clear that the effect on the ribosome profiling was moderate and the reduction of 
the 60S subunit was much less than what was seen by day 6. Therefore the majority of the 
damaging effects seen at a late stage are mainly due to the disruption of ribosome 
biogenesis. These findings show the importance of these ribosomal proteins on the 
ribosome machinery and ribosomal structure. 
Regulation of MDM2 activity is a complex process due to the abundance of interacting 
ribosomal proteins that can modulate MDM2 function following ribosomal or nucleolar 
stress (Deisenroth et al. 2010). Co-immunoprecipitation of RPL27A identified the possible 
interaction with MDM2 in HCT-116 cells. The pull-down experiment showed that RPL27A 
interacts with MDM2 and RPL5.  The function of this interaction might be the prevention 
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of p53 ubiquitination and degradation by MDM2. However, to further investigate whether 
the RPL27A interaction with MDM2 was mediated through other ribosomal proteins, 
further experiments should be carried out to identify binding sites of ribosomal proteins on 
MDM2. 
Finally, overexpression of RPL27A was carried out and showed no effect on the p53 
pathway and showed normal cell proliferation and a normal cell cycle profile. However, the 
effect of RPL27A overexpression on the p53 pathway and cell survival cannot be 
conclusive, because the increase in the expression level was only 2-folds. Therefore, the 
effect of RPL27A overexpression levels has to be ascertained by increasing the expression 
level, in order to assess the relation between RPL27A overexpression and other cellular 
mechanisms. However, the achieved upregulation, which has no effect on cell surveillance 
mechanism, and is supported by the observations from other studies, which showed 
increases in the expression level of RPL27A in different tumours and human cancer cell 
lines (Ross et al. 2000). 
The results described in this chapter shed light on the mechanism of cell death following 
depletion of RPL27A and the subsequent defect in ribosome biogenesis due to a reduction 
of the 60S ribosomal subunit. It became clear that RPL27A depletion leads to a severe 
cellular insult, and there is a possibility that RPL27A deficiency leads to an activation of 
several cell death pathways, including the p53 pathway and global translation inhibition.  
The results seen in the erythroid cell lines seem to indicate that RPL27A plays a role in 
erythroid cell survival. To confirm this and to identify whether RPL27A is another 
ribosomal protein that controls erythropoiesis similar to RPS14, RPS19 and RPL5, the aim 
of the following chapter was to perform RPL27A knockdown on CD34+ cells - derived 
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The deletions or mutations of genes, which are able to encode ribosomal proteins, have 
been identified in haematological diseases, particularly 5q- MDS and inherited 
hypoproliferative anaemia DBA. This has led to a new terminology “ribosomopathies”, 
which is used to refer to disorders caused by impaired ribosome biogenesis and function 
(Narla et al. 2010). DBA is the first known disease to be caused by mutations in ribosomal 
protein genes, and it leads to impairment of erythropoiesis and the development of a disease 
specific phenotype (Draptchinskaia et al. 1999). DBA is a congenital bone marrow failure 
syndrome, characterised by red blood cell aplasia; a model disease for erythroid 
differentiation. Half of DBA patients have heterozygous mutations in multiple ribosomal 
protein genes, leading to defects in ribosome function (Boria et al. 2010). The RPS19 
mutation was the first discovered, and the most frequent mutation in DBA patients, as it 
represents around 25% (Draptchinskaia et al. 1999, Choesmel et al. 2007). Later, several 
other ribosomal protein gene mutations were identified in DBA patients including RPS24 
(Choesmel et al. 2008), RPS17 (Cmejla et al. 2007) and RPL35a (Farrar et al. 2008). This 
is in addition to mutations in RPL5 and RPL11 (Gazda et al. 2008), which have been 
identified in 11.4% of DBA patients. A large-scale study of DBA patients identified 
mutations in other ribosomal protein genes such as RPS27A, RPS7, RPS15 and RPL36 
(Gazda et al. 2008).  
Mutations in other genes which are required for ribosome synthesis have been implicated in 
different congenital bone marrow failure syndromes such as SDS, DC and CHH (Liu et al. 
2006). 
In addition to congenital disease, ribosomal proteins have also been implicated in acquired 
disorders such as 5q– syndrome, which is a subtype of MDS, as described in Chapter 1. 5q– 
syndrome is characterised by a defect in erythropoiesis, which leads to macrocytic anaemia, 
patients usually have a normal or elevated platelet count. The potential importance of 
ribosomal protein genes in 5q- MDS is derived from the findings of Ebert and colleagues 
(Ebert et al. 2008). The haploinsufficiency of RPS14, localised to 5q segment, in normal 
haematopoietic progenitor cells leads to the characteristic disease phenotype. A decrease in 
the expression of RPS14 has been identified in patients with 5q- syndrome (Ebert et al. 
2008, Pellagatti et al. 2008). RPS14 deficiency results in impairment of the pre-RNA 
processing of 18S RNA, and causes a reduction of the 40S subunit. This is similar to what 
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was observed with RPS19 deficient cells in DBA patients, which links the 5q- syndrome 
pathophysiology to defects in ribosomal proteins function, in a similar way to congenital 
bone marrow failure syndromes (Choesmel et al. 2007, Ebert et al. 2008). 
The association between ribosomal protein mutations and the development of specific 
defects, throughout the haematological systems, can be attributed to various mechanisms. 
The main mechanism is attributed to the activation of the p53 pathway, which is described 
in the Chapter 4 (Figure 4.2). The disruption of ribosome biogenesis leads to the release of 
free ribosomal proteins, which interact with MDM2 and prevent the degradation of p53. 
The accumulation of p53 leads to apoptosis and cell cycle arrest, and inhibits cell 
proliferation, leading to anaemia (McGowan et al. 2008, Fumagalli et al. 2009). 
The other suggested mechanism is inherently linked to the active proliferative machinery 
seen in erythroid cells. Erythroid cell maturation and differentiation, which is also known 
as erythropoiesis, is a dynamic process regulated by different proteins, with the power to 
cause the developmental changes required by specific lineages. These changes affect the 
development of progenitor erythroid cells into mature erythrocyte (Weissman 2000, 
Flygare et al. 2007). Erythroid progenitor cells are notable for their high proliferation rate, 
which double every 12 to 24 hours, and require elevated ribosomal activity and ribosome 
biogenesis (Lajtha et al. 1961, Narla et al. 2010). The insufficiency of ribosomal protein 
causes ribosomal stress, which affects globin synthesis and leads to the release of excess 
free haem, resulting in apoptosis of erythroid cells and leading to anaemia (Quigley et al. 
2005, Keel et al. 2008, Narla et al. 2010). 
The identification of the genes involved in erythroid differentiation provides an insight into 
understanding the biology of erythrocyte and erythroid disease. Therefore, the aim of this 
chapter is to study the effects of RPL27A deficiency on normal haematopoietic progenitor 
cells, and particularly on erythropoiesis. According to the findings from the previous 
chapter, about the effects of RPL27A knockdown on ribosome biogenesis, cell proliferation 
and apoptosis, it was of interest to investigate the extra ribosomal function of this ribosomal 
protein gene on erythropoiesis mainly through p53 activation and to demonstrate if there 
are any functional similarities with other ribosomal protein genes or any possible links with 
bone marrow failure syndrome. 
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5.2 Aim  
•  Investigate RPL27A Knockdown in normal haematopoietic progenitor cells using 
lentiviral shRNA. 
• Investigate the consequent effects of RPL27A deficiency on the p53 pathway. 
• Examine the knockdown effect of haematopoietic subpopulations mainly on 
erythroid differentiation.  
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5.4 1 RPL27A knockdown in BM CD34+ inhibits cellular proliferation  
The knockdown experiment was first performed on CD34+ cells from viably frozen BM 
cells, which were obtained from Lonza. The cells (1 × 106 cells) were defrosted at room 
temperature and cultured to induce erythroid differentiation in a two-phase liquid culture 
systems, as explained in Section 2.3.6.6. In Phase I, cells were cultured in Serum-Free 
Expansion Medium supplemented with penicillin/streptomycin, glutamine, 100 ng/ml SCF, 
10 ng/ml IL-3, 10 ng/ml IL-6 and 0.5 IU/ml Epo. After 6–7 days, the cells were induced to 
differentiate into two lineages; erythroid-myeloid and erythroid-megakaryocyte. Therefore, 
the same culture medium used in Phase I was used with the addition of 3 IU Epo, 40 ng/ml 
FLT3 and 15 ng/ml G-CSF to induce the cells to differentiate along the erythroid and 
myeloid lineages. On the other hand, to induce megakaryocyte differentiation, Phase I 
culture medium was used and was supplemented with 3 IU Epo and 50 ng/ml TPO.  
During Phase I, which is the expansion phase, the recovered CD34+ cells were cultured in 1 
ml medium in a 24-well plate. After one day in the culture, the cells were counted and 
divided into three wells (with 3–4 × 105 cells/ml/ well). One of the wells was left as mock 
(non-infected cells), and the other two wells were infected with retroviral plasmid. One was 
infected with 10 µl of the 100× concentrated lentiviral empty pLKO.1 and the other one 
infected with 10 µl of the 100× concentrated lentiviral expressing RPL27A shRNA-2 as 
explained in Section 2.3.6.6. After 24 hrs, cells were selected using puromycin. The cell 
count was monitored every 2 days using trypan blue staining, and due to increases in the 
cell count, cells were transferred to a 6-well plate on day 3 (post infection), with cell 
density preserved at 1 × 106/ ml. On day 6 (post infection), cells were transferred to Phase 
II in the culture system. The cells in each well were divided into two culture conditions 
using different cytokine cocktails, as explained earlier, and the two different linages were 
induced. This experiment was repeated several times, until the final optimisation condition 
was achieved. This led to the loss of several BM samples. As such, the following result is a 
preliminary result generated from only one BM CD34+ sample. The knockdown level was 
examined on day 6 (post infection), by qRT-PCR and western blot analysis. The levels of 
RPL27A mRNA and protein were decreased by 40% and 80%, respectively, as shown in 
Figure 5.1 A and C. Also, p53 expression levels were examined and showed an induction 
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of p53 at both the transcriptional and post-transcription levels, (Figure 5.1 A). The 
activation of p53 was confirmed with the upregulation of p53 targets p21 and Bax by qRT-
PCR (Figure 5.1 B). The knockdown effect on cell proliferation was assessed based on the 
cell count, every 48hrs. The reduction of RPL27A expression led to a reduction in the cell 
count by day 4, and this reduction continued with time. Accordingly, RPL27A deficiency 
blocked cell proliferation and led to cellular death within 10 days, compared to the control 
empty pLKO.1 and the mock (Figure 5.1 D). The cells were cultured until day 10 (which is 
day 4-5 of Phase II), when cell death dramatically increased. At this point, the cells were 
harvested and FACS analysis was performed on protein surface markers of different 
lineages, in order to investigate the knockdown effect on erythroid, myeloid, and 
megakaryocytic lineages. However, on day 10 there were very few live cells in RPL27A sh-
2, excepting cells, which were harvested for FACS analysis (approximately < 5 × 104 cells). 
The FACS result was not very clear, due to the small cell number and small number of 
recorded events. Whilst there was a clear reduction in erythroid cells, relative to the 
myeloid and megakaryocytic lineages, this data had to be further validated (Figure 5.2).  
Therefore, these experiments were repeated on CD34+ cells, isolated from PBMCs. The 
reason for changing from the marrow to the blood was primarily due to the practical 
difficulties and cost implications surrounding the acquirement of normal bone marrow 




Figure 5.1: RPL27A knockdown in normal BM CD34+ leads to p53 activation. 
A) RNA samples collected on day 6 (post-infection) and the mRNA expression of RPL27A and 
P53, relative to GAPDH, was measured by quantitative real time PCR and showed an induction of 
p53, associated with the reduction of RPL27A. B) The mRNA expression of p53 target genes p21 
and Bax, relative to GAPDH, was measured by quantitative real time PCR, and showed increased 
expression of p21 and Bax in cells with depleted RPL27A. All qRT-PCR results were compared to 
cells infected with empty vector. C) Protein extracts were collected on day 6 from non-infected 
cells and cells infected with empty vector and shRNAs, against RPL27A, and analysed on 4–12% 
polyacrylamide gels probed with antibodies, in order to detect RPL27A and p53. Equal protein 
loading per well was determined by Υ tubulin loading control. The reduction of RPL27A was very 
high and resulted in p53 induction. D) Cells were counted every 48 h, and the results showed a 
reduction in cell numbers by day 4, reaching complete cell death by day 10 in cells infected with 
RPL27A-sh2, compared with control, empty vector and non-infected cells. The presented data is 
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Figure 5.2: RPL27A knockdown in normal BM CD34+ blocks HSC proliferation and 
differentiation. 
Cells were harvested on day 10–11, after retroviral infection for flow cytometry. Approximately 
0.5–1 × 105 cells were labelled with a mixture of conjugated antibodies, including live/dead staining 
with (780), immature erythroid (CD71), mature erythroid (GlyA), myeloid (CD11b) and 
megakaryocyte (CD41). A) Identical gating was applied in all examined cells, and showed that cells 
expressing RPL27A shRNA were less viable. B) Comparing immature and mature erythroid did not 
show a clear effect on terminal erythroid differentiation, as assessed by flow cytometry using 
antibodies against CD71 and GlyA. C) RPL27A knockdown blocks erythroid, relative to 
megakaryocyte differentiation, compared to a control empty vector and non-infected cells. The ratio 
of cells from erythroid and megakaryocytic lineages was assessed by flow cytometry, using 
immature and mature erythroid antibodies (CD71 (right-bottom) GlyA (left-bottom)) against 
megakaryocyte (CD41 antibodies). D) RPL27A knockdown reduces erythroid, relative to myeloid 
differentiation, and the ratio was assessed using immature and mature erythroid antibodies (CD71 
(right-bottom) GlyA (left-bottom)) against myeloid antibody (CD11b). In all panels, the effect was 
compared to the control empty vector and the non-infected cells. 
  






























































































































































































































































































































5.4.2 RPL27A knockdown in CD34+ cells isolated from PBMCs reduces cell 
proliferation and induces p53 
Peripheral blood CD34+ cells have been used in other studies, in order to examine the 
consequent effect of ribosomal protein gene knockdown on haematopoietic subpopulations 
(Ohene-Abuakwa et al. 2005, Dutt et al. 2011). Therefore, the experiment performed on the 
bone marrow CD34+ was repeated on CD34+ cells isolated from four blood samples. 
CD34+ cells were isolated from PBMCs, using leukocyte cones, as described in Section 
2.3.6.5. Mononuclear cells were collected after histopaque separation from the interface 
layer, then CD34+ cells were isolated using the MACS-LS separation columns and the 
CD34+ microbead kit. The isolated CD34+ cells were counted (the cell count was in the 
range of 1 to 1.5 × 10 6 cells) and cultured, in the same way as described in the previous 
section. The cells were counted and divided as 2.5–3 × 105 cells/ml for each experiment, 
which were mock (non-infected cells) and cells infected with either empty vector pLKO.1 
or targeted shRNAs against RPL27A and RPS14 shRNA. After 24 h, the infected cells were 
selected with puromycin, and cells were transferred to larger wells due to the rapid increase 
in cell density. Similar to what was observed in BM CD34+ cells, the growth rate of cells 
expressing the shRNAs targeting RPL27A was reduced, relative to empty vector control, by 
day 4. This is based on cell counts, and the same observation was noted in RPS14 shRNA. 
Therefore, cells were harvested on day 6, and cells from each experiment were divided for 
several more experiments including qRT-PCR, protein analysis, Phase II culture and colony 
forming assay. The knockdown efficiency of RPL27A and RPS14 was determined by qRT-
PCR and western blot. RNA was purified from cells preserved in Trizol, and cDNA was 
produced using Superscript II reverse transcriptase; qRT-PCR was carried out as described 
in Section 2.3.10.3. RPL27A mRNA levels were normalised with GAPDH, and relative 
expression in cells expressing RPL27A-shRNA was calculated relative to the expression 
level in the control empty vector. The qRT-PCR results showed approximately 70% 
reduction in the expression level of RPL27A and RPS14 in cells infected with RPL27A 
shRNA and RPS14 shRNA, respectively relative to the control empty vector (Figure 5.3-A). 
Furthermore, the reduction of RPL27A and RPS14 caused a significant reduction in RPL5 
expression (P= 0.0055 and P=0.0120, respectively), whereas RPL27A reduction did not 
significantly affect the RPS14 expression, or vice versa. RPL27A expression was further 
validated by western blot analysis, which showed a clear reduction in the protein 
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expression, as shown in Figure 5.3 C. The expression level of p53 was determined by qRT-
PCR and western blot analysis. The mRNA expression of p53 was surprisingly decreased 
in both RPL27A and RPS14 depleted cells, whilst the protein expression showed increases 
in p53 protein expression (Figure 5.3 B and C). This was further confirmed with the 
detection of significant increases in the expression level of p53 targets. The mRNA relative 
expression of p21, in both RPL27A and RPS14 deficient cells compared to the empty 
vector, was significantly increased with P=0.00062 and P =0.01732, respectively. Bax 
expression was also significantly increased in both RPL27A and RPS14 deficient cells, 
compared to the empty vector (P =0.00156 and P =0.00610, respectively) (Figure 5.3-B). 
To investigate the effects on cell cycle, cell cycle marker RB was used (pRB antibody was 
kindly provided by Prof. Shaun Thomas). The western blot analysis, using phosphorylated 
RB, showed hypophosphorylation in the cells infected with RPL27A shRNA, as well as 
RPS14 shRNA. This indicates an arrest within the cell cycle (Figure 5.3-C). The reason for 
not investigating the cell cycle profile, and only screening the cell cycle marker, was the 
limitation in cell number. The cells, which were infected with targeted shRNA, were 
apoptotic and all the live cells were used for FACS analyses. 
In order to investigate the knockdown effect on cell proliferation, cell counting was carried 
out every 48 h. It showed a dramatic reduction in cell count, which increased in both 
RPL27A shRNA and RPS14 shRNA expressing cells, compared to the control and non-
infected cells, as shown in Figure 5.3-D. 
On day 10/11 in culture, very few viable cells from the knocked down cells were left. 
Therefore, the effect of RPL27A knockdown on erythroid, myeloid and megakaryocytic 
linages was only assessed by flow cytometry, using specific cell surface markers. Cells 
were stained, as explained in Section 2.3.6.6. Erythroid differentiation was assessed by 
measuring the expression of erythroid- specific surface proteins CD71 and GlyA. Myeloid 
cells were assessed using CD11b, and the megakaryocytes cells were determined by CD41. 
The analysis was performed using Flowjo, and single cell gating was first performed. Then, 
live/dead discrimination was conducted, according to the live/dead staining within 780 
markers. This staining showed a dramatic reduction in the percentage of cells in the live-
gated populations of cells expressing RPL27A shRNA(17.6%) and RPS14 shRNA(9.09%), 
compared to control (79.2%) and non-infected cells (80.9%), see Figure 5.4-A. The 
analysis of erythroid cells within the live population showed a massive reduction in the 
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production of both immature and mature erythroid cells in both RPL27A and RPS14 
deficient cells (CD71+/GlyA+: ±5.8% and ± 3.3%, respectively), compared to the relevant 
control (CD71+/GlyA+: ±74.9% in empty vector infected cells and ±64.8% in mock non 
infected cells), Figure5.4-B. The staining, relative to myeloid and megakaryocyte lineages, 
was not conclusive due to insufficient induction of both lineages. To assess whether or not 
the cell death was a result of apoptosis, annexin V staining was performed on day 6 (post 
infection), and cells were stained with CD71 to determine the apoptosis effect relative to 
erythroid cells. RPL27A shRNA and RPS14 shRNA significantly induced apoptosis 






Figure 5.3: RPL27A knockdown in CD34+ form PBMC’S 
A) RNA samples collected on day 6 (post infection) and the mRNA expression of RPL27A, RPS14 
and RPL5, relative to GAPDH, was measured by quantitative real time PCR. It showed a significant 
reduction of RPL27A and RPL5, in cells expressing RPL27A-shRNA and RPS14, and and RPL5 
reduction in cells expressing RPS14 shRNA B) The mRNA expression of p53 and its target genes 
p21 and Bax, relative to GAPDH, was measured by quantitative real time PCR, and showed a 
reduction in p53 expression, with increased expression of p21 and Bax in cells with depleted 
RPL27A and RPS14. All qRT-PCR results were compared to cells infected with empty vector. C) 
Protein extracts were collected on day 6 from non-infected cells and cells infected with empty 
vector and shRNAs, against RPL27A and RPS14. They were analysed on 4–12% polyacrylamide 
gels, and probed with antibodies to detect RPL27A, p53 and pRb. Equal protein loading per well 
was determined by Υ tubulin loading control. The depletion of RPL27A and RPS14 resulted in p53 
induction and hypophosphorylation of pRB. D) Cells were counted every 48 h and the result 
showed a reduction in cell number by day 4, reaching massive cell death by day 10 in cells infected 
with RPL27A-sh2 and RPS14-shRNA, compared with control, empty vector and non-infected cells. 








































































































































































Figure 5.4: RPL27A knockdown in normal CD34+ from PBMCs blocks HSC 
proliferation and differentiation. 
Cells were harvested on day 10–11 after infection, for flow cytometry analysis. A-B) Cells were 
labelled with a mixture of conjugated antibodies including live/dead staining (780), immature 
erythroid (CD71) and mature erythroid (GlyA). Cells expressing RPL27A-shRNA and RPS14 
shRNA showed a significant reduction in erythroid cells. C) Staining with Annexin V and CD71 
showed a significant increase in apoptosis in erythroid positive cells, and in cells with depleted 
RPL27A and RPS14. Data represents 4 independent experiments, bars represent the mean ±SEM. 
  





























































































































































































































5.4.3 Methylcellulose colony assay  
At day 6, after retroviral infection, and day 5 from puromycin selection, cultured cells were 
plated in methylcellulose medium containing Epo, and supplemented with penicillin 
/streptomycin in a 6-well plate. The plated cell suspension, which was at the end of pre-
EPO culture, was made from 2000 cells (mock and control cells) suspended in 3 ml of 
methylcellulose medium per well, and 5000 cells (RPL27A and RPS14 shRNA infected 
cells) suspended in 3 ml of methylcellulose medium per well. One well was filled with 
water, in order to preserve humidity and avoid the medium drying out. Also, the plate was 
placed in a glass container, filled with water, and incubated in a humidified incubator with 
5% CO2 at 37°C. Colony formation was determined after 14–16 days of culture. Evaluation 
of the colony was performed under the supervision of Dr. Nigel Westwood. Expression of 
RPL27A shRNA and RPS14 shRNA severely decreased the formation of all haematopoietic 
colonies (Figure 5.5). The decrease in erythroid colonies (BFU-E) was more dramatic, with 
statistically significant p value less than 0.005 for RPL27A and RPS14 deficient cells, 
compared to the control and non-infected cells (n=4). The suppression of the other 
haematopoietic colonies (CFU-GM) was also significant, with statistically significant p 
value less than 0.005 in RPL27A and RPS14 shRNA expressing cells. The reduction of 
erythroid colony formation in RPL27A shRNA expressing cells was more than the decrease 
in the other colonies, with statistically significant p of less than 0.05. A similar observation 
was made with similar significance for RPS14 shRNA expressing cells. The p values were 






Figure 5.5: Colony forming ability of cells with depleted RPL27A and RPS14. 
A-D) Frequencies of progenitor cells in methylcellulose assay from cells infected with 
control, RPL27A-shRNA and RPS14 shRNA showed significant reduction of erythroid and 
granulocyte/macrophage colonies in RPL27A and RPS14 deficient cells. CFU-E: colony 
forming unit -erythroid, BFU-E: burst forming unit CFU-GM: Colony forming unit-
granulocyte/macrophage colonies. Data represents 4 independent experiments, bars 





















































































































































Decreases in various types of ribosomal proteins have been implicated in the reduction of 
mature ribosomes, which inhibits the translation of proteins essential to cellular processes 
like erythropoiesis. This effect could be a result of the extra ribosomal function of certain 
ribosomal proteins, which activate the p53 pathway and lead to the development of anaemia 
(reviewed in (Narla et al. 2010). As demonstrated in the previous chapter, RPL27A 
knockdown in human cell lines is associated with p53 activation, and induces the 
downstream effect of p53 activation. Thus, chapter I investigated whether RPL27A 
knockdown in normal CD34+ cells has a similar effect on p53, and if that effect 
consequently blocks erythroid proliferation and differentiation, in a similar way to other 
ribosomal protein genes.  
The knockdown of RPL27A in normal CD34+ resulted in a marked reduction of RPL27A 
expression, at both the transcriptional and post-transcriptional levels, in both BM and PB 
mononuclear CD34+ cells. The knockdown experiment, which was performed on the BM 
CD34+, was a preliminary experiment, which showed an induction of p53 and p53 targets, 
but was only on one sample. The challenges involved in obtaining more BM CD34+ 
samples led to the repetition of the same set of experiments on circulating CD34+ from 
peripheral blood. The knockdown experiment was repeated and validated on normal 
CD34+, isolated from four different leukocyte cones. 
The reduction of RPL27A using retrovirally-expressed shRNA in cultured CD34+ cells 
recapitulated the findings observed in human cell lines.  
The knockdown of RPL27A was approximately more than 70%, according to the qRT-PCR 
and western blot analysis. Due to the high expansion rate in CD34+ from blood, it was 
possible to perform RPS14 knockdown and use it as a positive control. The knockdown of 
RPS14 was also more than 70%, according to the qRT-PCR. RPL27A and RPS14 depletion 
increased p53 expression at the post-transcriptional level only. The lack of p53 induction at 
mRNA level could be the consequence of global inhibition of translation, due to impaired 
ribosome biogenesis. According to the results from the previous chapter, reduction of 
RPL27A by more than 50% leads to a decrease in the 60S subunit, which causes the 
disruption of ribosome biogenesis and affects protein translation. Even though the 
knockdown experiment on CD34+ from BM was only conducted on one sample, it showed 
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upregulation of p53. Of note is the fact that a lack of p53 induction, at the mRNA level, has 
been observed in another study (Dutt et al. 2011). 
The knockdown effect on the p53 pathway was confirmed by significant increases in p21 
and Bax expression. Furthermore, the reduction of RPL27A had a dramatic effect on cell 
viability and proliferation, which can also be attributed to either ribosomal stress, or to p53 
activation induced by perturbed ribosome biogenesis. These observations were also seen 
with RPS14 knockdown, and were in agreement with other studies, which link ribosomal 
haploinsufficiency to p53 activation (Ebert et al. 2008, Pellagatti et al. 2010). However, a 
p53 independent effect was reported in recent studies on mouse embryonic stem cells and 
zebra fish embryos, with depleted ribosomal proteins, which have developed anaemia 
regardless of p53 status. This supports the p53 independent mechanism associated with 
anaemia in DBA and 5q- syndrome (Teng et al. 2013, Narla et al. 2014, Singh et al. 2014). 
Due to the high knockdown level, the number of RPL27A and RPS14 deficient cells was 
markedly decreased, making further screening difficult. Therefore, cell cycle marker 
Retinoblastoma protein RB was examined by western blot to show the knockdown effect 
on the cell cycle, based on the phosphorylation status of RB. The knockdown showed a 
significant reduction in the phosphorylated RB (hypophosphorylation), which indicates that 
arrest in the cell cycle is due to RPL27A reduction. This is consistent with the 
haematopoietic phenotype of DBA and 5q-MDS. 
Furthermore, RPL27A depletion is associated with a significant reduction in RPL5, which 
belongs to the same ribosomal subunit. This emphasises the correlation between ribosomal 
insufficiency and reduced cellularity. The role of inhibition of cellular proliferation, due to 
RPL5 reduction, is discussed in chapter 4. The effect on proliferation could be a direct 
impact of RPL27A depletion, or indirectly, via RPL5 reduction. Of note, RPL27A showed 
possible interaction with RPL5 via co-immunoprecipitation (Section 4.4.1), which could 
explain the effects of RPL27A depletion on RPL5 expression. This observation is in 
agreement with the effects of RPS14 reduction on RPL5, as observed in this project and in 
other studies, which have shown that RPS14 knockdown reduces the expression of other 
ribosomal proteins, in addition to its direct effect on genes involved in translation 
(Pellagatti et al. 2008). 
 203 
After 10 days under erythroid differentiation conditions, the knockdown of RPL27A 
impaired the proliferation of HSCs. The effect on erythroid lineage was more dramatic, 
compared to myeloid/megakaryocytic lineages. Both RPL27A and RPS14 shRNA 
decreased erythroid differentiation, relative to myeloid and megakaryocytic differentiation. 
The reduction of erythroid differentiation was primarily caused by the reduction of 
erythroid proliferation, which was assessed by counting the cells during the culture. This is 
similar to defects caused by the knockdown of other ribosomal protein genes, in normal 
haematopoietic progenitor cells and in zebra fish models.  
The reduction of RPL27A and RPS14 did not show any increase in the ratio of immature to 
mature erythroid cells, which contradicts the results observed in RPS14, in Ebert’s study. 
This can be explained by the dramatic increase in cell death, which mainly affects erythroid 
cells. Only a small percentage of the FACS analysed cells were erythroid positive cells. 
Interestingly, in a study conducted by da Cunha et al, on the gene expression analysis of 
genes involved in erythroid differentiation, researchers reported upregulation of RPL27A 
during erythroid differentiation (da Cunha et al. 2010). They performed large-scale gene 
expression, using SAGE, on blood from normal donors, which was cultured in medium 
supplemented with EPO. The analysed samples collected at three time points, 0 hrs, 192 hrs 
and 336 hrs, showed an upregulation of RPL27A which reached a maximum at 192 h, then 
the expression reduced at 336 hrs. Thus, RPL27A is important for early erythroid 
differentiation, and a deficiency blocks erythroid differentiation. In accordance with this 
finding is another study by Ebert, which shows that the expression levels of RPS19 during 
erythroid differentiation in vitro, and their expression data, demonstrates a similar effect on 
RPL27A expression (Ebert et al. 2005). RPS19 and RPL27A expression were high in 
primitive cells, and decreased gradually with cell maturation to erythrocyte. Thus, the 
proliferative defect caused by RPL27A insufficiency may occur in the primitive 
hematopoietic progenitors, similar to RPS19 when deficiency decreases the proliferation 
rate in progenitor cells.  
Also, the colony assay confirmed that RPL27A deficiency blocks erythroid and other 
haematopoietic colony formations, and is in agreement with the observation of RPL27A 
knockdown in sooty foot ataxia mouse. In vivo, homozygous mutations were embryonically 
lethal, and as explained in the previous chapter, heterozygous mutation in sooty foot ataxia 
mouse led to a reduction in the level of RPL27A (on average, between 20–30%), and 
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affected the HSC proliferation, but in a less aggressive way than the effects observed in this 
study. 
The severity of RPL27A deficiency on cell survival is mainly due to the knockdown level. 
The shRNA used in this study decreased RPL27A expression to a very low level, and this 
primarily affected ribosomal maturation and led to disruption of ribosome biogenesis. This 
finding is in agreement with another (Flygare et al. 2005). It showed that the effect of 
RPS19 knockdown in cultured human CD34+ on erythropoiesis and myelopoiesis is 
selectively related to the knockdown level. Additionally, in the current study, different 
RPL27A shRNA (RPL27A sh4) was used to reduce expression levels to 20-30%. 
Unfortunately, all of the performed experiments failed to induce significant changes in the 
expression level of RPL27A. Also, differences in the knockdown effect between studies 
could be attributed to multiple variables other than the level of ribosomal protein 
insufficiency; for example, species effect and in vivo haematopoietic requirements, and 
culture conditions within in vitro experiments. 
RPL27A loss is similar to other ribosomal proteins in its effect on p53. As such, it can be 
postulated that a similar effect would be observed in other BM diseases. In this respect, the 
reduction of RPL27A may contribute to identifying new target genes involved in defects in 
erythropoiesis. 
Taken together with the previous studies, our work suggests the importance of alterations in 
ribosomal protein gene levels on the haematopoietic system. As RPS14 is implicated in the 
5q- phenotype, miRNAs are also critical mediators of certain clinical features of 5q- 
disease, such as the involvement of miR-145 and miR-146a in 5q- syndrome. Thus, to get 
an insight into the relative contribution of miR-595 and RPL27A in MDS, with 
chromosome 7 abnormalities or other MDS subtypes, the expression levels of miR-595 and 
its target RPL27A were examined in MDS with monosomy 7, and compared with other 












Whilst the molecular pathogenesis of MDS is slowly being unravelled, its disease 
heterogeneity makes it challenging to identify all of the key molecular lesions. However, 
the clinical and biological features, including cytogenetic and molecular abnormalities, 
have guided researchers in defining disease stages, prognosis, and risk to AML progression 
(Greenberg 2006). The miRNA and gene expression profiles in AML/MDS have helped to 
segregate patients into risk categories, which provide important diagnostic and prognostic 
information for disease classifications. 
It is plausible that miRNAs play a critical role in the pathogenesis of a heterogeneous 
disease like MDS. As described in Chapter 1, there are several studies, which offer insights 
into the importance of miRNAs in the pathogenesis of MDS, such as miR-145 and miR-
146a and its association with the development of 5q- phenotype (Starczynowski et al. 
2010a). Monosomy 7 or 7q deletion is the second most frequent chromosomal abnormality 
in MDS, and identifies a subgroup of patients with a poor prognosis (Yunis et al. 1986). 
The commonly deleted regions in MDS on chromosome 7 are 7q36 and 7q22. No recurrent 
mutations or haploinsufficiency of genes localised to the deleted regions of chromosome 7 
have been consistently linked with the disease phenotype. Thus, it is important to examine 
the expression of miR-595, localised to 7q36.3 in MDS patients with monosomy 7, and 
compare it with MDS patients with a normal karyotype. 
A lack of recurrent somatic mutations in 40 genes localised to the deleted region of 5q led 
investigators to pursue the role of alternate mechanisms for disease phenotype, and 
eventually led to the concept of haploinsufficiency; i.e. the effect of gene dosage (Ebert et 
al. 2008). The strong link between ribosomal haploinsufficiency and 5q- syndrome, 
coupled with our data linking miR-595 (localised to 7q36) and its target RPL27A (11p.15), 





• Investigate the expression level of miR-595 in MDS patients with -7/7q- and 
compare with normal control and other MDS subtypes including MDS with normal 
karyotype and MDS with 5q-. 
• Examine the expression level of RPL27A and other ribosomal protein genes (RPS14 
and RPL5) in MDS patients with -7/7q- and compare with normal control and other 
MDS subtypes including MDS with normal karyotype and MDS with 5q-. 
6.3 Experimental design 
6.3.1 Patients  
The study comprised 31 BM (CD34+) samples from patients with MDS. Bone marrow 
CD34+ trizol stock was obtained from the King’s College London Haemato-Oncology 
Tissue Bank, which is a Human Tissue Authority licenced research biobank (licence 
number 12223). The samples were collected, stored and used in accordance with donor 
consent given under the auspices of ethics approval, provided by the UK National Research 
Ethics Service (NRES) (approval reference 08/H0906/94). 
The clinical and cytogenetic details are summarised in Table 6.1. Four normal CD34+ cells 
from viably frozen BM cells, were obtained from Lonza. 
6.3.2 Quantitative RT-PCR 
Total RNA was extracted using an RNeasy Mini kit, according to manufacturer protocols. 
To quantify miRNA expression, TaqMan MicroRNA Expression Assay was performed, as 
described in Section 2.3.10, and data was normalised to the endogenous control RNU6B, 
and relative expression was calculated according to the ΔΔCT method. RPL27A was 
amplified form patients cDNA, and the expression was determined according to the qRT-
PCR protocol described in Section 2.3.10, and data normalised to GAPDH, and relative 
expression was calculated according to the ΔΔCT method. Statistical analysis was 





Table 6.1: Patients characteristics 
  
UPN  Karyotype FAB WHO IPSS 
1 45,XX,-7 [30] RAEBt AML  HR 
2 45,XY,-7 [3]46,XY [5] RAEB RAEB-2  HR 
3 45,-7 RAEB RAEB-1 I-2 
4 45,XX,-7[5],46 XX[15] RAEB RAEB-2  HR 
5 45,XY,-7[9]/ 46,XY [1] RA RCMD VH 
6 45,XY,inv(3)(q21q26),-7 [9]/46,XY [1] RAEB RAEB-2  HR 
7 46,XY,-7,+mar [4]/45,XY-7 [3]/46,XY [8] RAEB RAEB-1  HR 
8 45,XY,-7 [17]/46,XY [3] RA RCMD  HR 
9 46,XY,+Y,-7 [6]/46.XY [3] RAEBt AML  HR 
10 45,XY,-7 [3]/46,XY [7] RAEB RAEB-2 VH 
11 45,XY,-7[7]/46,XY[3] sAML sAML H 
12 LOH 7Q34-Q36.3 RAEB RAEB-1 VH 
13 COMPLEX CMML CMML H 
14 COMPLEX RAEB RAEB H 
15 COMPLEX RA RA L 
16 COMPLEX AML tAML VH 
17 COMPLEX RAEB RAEB-1 VH 
18 COMPLEX RAEBt AML VH 
19 COMPLEX (7q22) RA RCMD VH 
20 46,XX,del(5)(q13q31) [9]/46,XX [11] RA 5q L 
21 46,XX,del(5)(q22q35) [13]/46,XX[2] RA  5q L 
22 46,XX,del(5)(q31q31) [15] RA 5q L 
23 46,XX,del(5)(q11q31) [9] RA  5q VL 
24 46,XY,del(5)(q13q33) [11]/46,XY [19] RA 5q L 
25 46,XY,del(5)(q13q31) [30] RAEB RAEB-2 VH 
26 46,XX,del(5)(q13q31) [20] RA 5q L 
27 Nk RAEB RAEB-1 L 
28 Nk RA RA L 
29 Nk RAEB RAEB-1 I 
30 Nk RARS RCMD L 
31 Nk RA 5q L 
*NK: normal karyotype 
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6.4 Result  
6.4.1 miR-595 expression in patients with MDS 
miR-595 expression was measured in CD34+ cells isolated from BM cells from 31 MDS 
patients and 4 normal controls. Reverse transcriptase reaction was carried out as explained 
in Section 2.3.10.1 using specific reverse transcriptase primers for miR-595 and two 
endogenous controls (RNU48 and RNU6B). Subsequently, qRT-PCR was performed in 
triplicate and carried out according to the protocol described in Section 2.3.10.2. Data was 
normalised with RNUB6 and relative expression was calculated, relative to the normal 
control using ΔΔCT methods. Out of the 31 patients and 4 controls, miR-595 was detected 
in 27 patients and 3 controls, and 4 patients and 1 control were excluded. From the 27 
patients, 11 were with mono 7/7q-, 5 with del 5q, 6 with complex karyotype, and 5 with 
normal karyotype. 
miR-595 was significantly downregulated in MDS with mono7/7q- MDS, compared with 
MDS with normal karyotype (P=0.0179). Furthermore, miR-595 was also significantly 
downregulated in MDS with complex karyotype, compared with normal karyotype MDS 
(P=0.0205). Due to the small number of control samples, it was not possible to identify any 
distinct expression between MDS and a normal control. Also, there were no significant 
changes between 5q- and any other groups, as demonstrated in Figure 6.1-A. Data was 
analysed using nonparametric Kruskal-Wallis one-way analysis methods.  
Furthermore, in order to identify a potential association between miR-595, and the clinical 
and biological characteristics of the disease, miR-595 expression level was compared 
between high-risk (HR) MDS and low-risk (LR) MDS, according to IPSS scoring. The 
expression pattern of miR-595 was determined in 18 patients with HR-MDS compared to 9 
patients with LR MDS. miR-595 was overexpressed in 7 out of 9 patients with LR 
compared with 18 HR MDS. The differences in the expression were statistically significant 
(P=0.0009), as shown in Figure 6.1-B. Data was analysed using nonparametric Mann-



























Figure 6.1:miR-595 expressions in MDS patients. 
miR-595 expression was analysed in BM CD34+ samples from 27 MDS patients. A) MDS patients 
were categorised according to their chromosomal abnormalities. From the 27 patients, 11 were with 
mono 7/7q-, 5 with del 5q, 6 with complex karyotype, and 5 with normal karyotype; significant 
differences in miR-595 expression were determined between MDS with mono7/7q- and MDS with 
normal karyotype. Significant differences were also determined between MDS with complex 
karyotype and MDS with normal karyotype. B) The same samples were re-analysed according to 
their IPSS scoring (HR=18, LR=9), and miR-595 was significantly upregulated in LR MDS, 
compared with HR MDS. RNU6B was used to normalise all samples, and relative expression was 












































































6.4.2 RPL27A expression in patients with MDS 
The relative expression of RPL27A, and other ribosomal proteins genes RPS14 and RPL5, 
were determined in CD34+ BM samples, from 31 MDS patients and 4 controls. From the 
31 patients, 11 were with mono 7/7q-, 7 with del 5q, 8 with complex karyotype, and 5 with 
normal karyotype. The transcription level of RPL27A and the other genes were determined 
by qRT-PCR, as explained in Section 2.3.10.4. Data was normalised with GAPDH, and the 
relative expression calculated using ΔΔCT methods. RPL27A was significantly upregulated 
in patients with mon7/7q-, compared with 5q- patients (P=0.0042). There were no 
significant changes with the other MDS groups, as well as no significant difference 
predicted between MDS patients and a normal control, as shown in Figure 6.2 A. Similarly, 
RPS14 and RPL5 were significantly upregulated in mono7/7q-, compared with 5q- MDS 
(P= 0.0012 and P= 0.0027, respectively). Also, significant downregulation of RPS14 was 
detected in 5q- patient, compared with 3 normal controls. One was failed (P= 0.0108), and 
RPL5 was significantly downregulated in MDS with 5q-, compared with MDS with a 
normal control (P= 0.0405), as shown in Figure 6.2.B and C. Data was analysed using 
nonparametric Kruskal-Wallis one-way analysis. RPL5 analysis in 4 normal controls failed 
in two instances, and therefore normal controls were excluded from the analysis.  
Interestingly, attempts to determine the expression of RPL27A in MDS, according to IPSS 
scoring, have shown a relatively high expression of RPL27A in (19) HR MDS versus (12) 
LR-MDS (P= 0.027), as demonstrated in Figure 6.2 D. This data also demonstrates an 
increased RPS14 expression in HR- MDS patients, compared with LR-MDS (P= 0.027). 
No significant change was detected in RPL5 expression between HR and LR- MDS, as 





Figure 6.2: RPL27A, RPS14 and RPL5 expression in MDS patients. 
RPL27A, RPS14 and RPL5 expressions were determined in BM CD34+ samples from 31 MDS 
patients. A, B, C) MDS patients were categorised according to their chromosomal abnormalities. 
From the 31 patients, 11 were with mono 7/7q-, 7 with del 5q, 8 with complex karyotype, and 5 
with normal karyotype, in addition to four normal control. Significant differences in the expression 
of RPL27A, RPS14 and RPL5 were determined between MDS with mono7/7q- and MDS with 5q-. 
Significant difference was also determined in RPS14 expression between MDS with 5q- and normal 
control. D, E, F) Samples were re-analysed, according to their IPSS scores (HR=19, LR=12), and 
RPL27A and RPS14 were significantly upregulated in HR MDS, compared with LR MDS. GAPDH 
was used to normalise all samples, and relative expression was calculated using ΔΔCT method. 




























































































































































































































There are various studies on gene expression and miRNA expression in the profiles of in 
MDS patients, which have increased our knowledge of MDS (Hofmann et al. 2002, Chen et 
al. 2004, Pellagatti et al. 2006, Sridhar et al. 2009, Vasikova et al. 2010, Dostalova 
Merkerova et al. 2011). In this PhD project, we focused on analysing the expression 
patterns of miR-595 and RPL27A, because we anticipated that this analysis might provide 
new information relating to disease pathogenesis and development.  
miR-595 expression level was examined in CD34+ cells obtained from 27 patients with 
MDS and 3 controls. Patients were classified according to their chromosomal 
abnormalities. As expected, miR-595 was significantly downregulated in MDS with -7/7q-, 
compared with patients with normal karyotype. Interestingly, miR-595 was also 
significantly downregulated in MDS with complex karyotype versus MDS with normal 
karyotype. This observation was further confirmed by the detection of significant 
downregulation of miR-595 in HR-MDS, compared with LR-MDS. This significant 
contribution of miR-595 in distinguishing between MDS patients is reported for the first 
time in this study. Comparison relative to normal control was not significant and is mainly 
due to the small number of control samples. Of not is the downregulation of miR-595 in 
patients with complex karyotype without abnormalities in chromosome 7, particularly at 
q36.3 position. This could be attributed to the existence of other factors which control the 
expression of this miRNA, at this stage of the disease. For instance, miR-595 
downregulation can be attributed to epigenetic silencing of the gene which encodes this 
miRNA. Menigatti et al.’s study on early stage colorectal tumoriginesis, identified 56 
miRNAs, including miR-595, that were re-expressed in normal colorectal mucosa and 
HT29 colorectal cancer cells after treatment with the DNA demethylating agent, 5-aza-2-
deoxcytidine, and trichostain the histone deacytylase inhibitor (Menigatti et al. 2013). 
Thus, epigenetic regulation of this miRNA is possible primarily in association with 
mutations in epigenetic modifiers that are commonly seen in MDS such as EZH2, TET2, 
IDH1,2, DNMT3A, MLL and ASXL1; reviewed in (Shih et al. 2012). Interestingly, Mendler 
et al. identified an upregulation of miR-595 in AML patients with normal cytogenetic 
karyotype and with mutation in RUNX1, and it might explain the exceptional upregulation 
of miR-595 in some cases with monosomy 7 or complex karyotype, which might have 
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mutations that control the expression of this miRNA (Mendler et al. 2012). Thus, miR-595 
may hold valuable implications for leukomogenesis, which is still shrouded by uncertainty.  
On the other hand, the expression levels of RPL27A, RPS14 and RPL5 were measured in 31 
MDS patients, classified according to their cytogenetic abnormalities. RPL27A was 
upregulated in MDS with -7/7q-, compared with 5q- MDS. Similarly RPS14 and RPL5 
were significantly upregulated in MDS with chromosome 7 abnormalities, compared with 
5q- MDS. Overexpression in RPL27A and RPS14 was also determined in HR-MDS, 
compared with LR-MDS, but no significant difference was observed in RPL5 expression 
between the two groups. The non-significant difference in RPL27A expression between 
MDS and the normal control could be attributed to the small number of control samples. 
However, RPS14 was significantly low in 5q- MDS, compared with the normal control, and 
this is consistent with previous studies (Ebert et al. 2008, Pellagatti et al. 2008). Pellagatti 
et al. demonstrated that the expression profile of ribosomal and translation related gene in 
CD34+ of MDS patients identified 90% of the differentially expressed ribosomal proteins 
to be lower expressed in 5q- syndrome (Pellagatti et al. 2008).  
In my study, ‘low risk’ MDS patients showed decreased expression of all investigated 
ribosomal proteins. This group of patients includes patients with del (5q) and with normal 
karyotype, and this observation is consistent with other studies, which show 
downregulation of ribosomal protein genes, including RPL27A in patients with 5q- and 
detection of upregulation in tMDS (Sridhar et al. 2009).  
As shown in chapters 4 and 5, the downregulation of RPL27A is associated with p53 
induction and negatively regulated haematopoiesis, particularly erythroid proliferation and 
differentiation. Thus, the putative role of RPL27A is supported by the downregulation of 
RPL27A in LR MDS patients, including patients with 5q-, and this suggests the 
involvement of RPL27A downregulation in LR MDS. 
The upregulation of RPL27A in patients with -7/7q- and HR-MDS is in agreement with 
other studies, which correlate the overexpression of ribosomal protein with disease 
aggressiveness and progression. Mendiburu et al. study was the first study to determine 
gene expression using serials of gene expression (SAGE) in MDS, particularly in patients 
with RAEB. They showed that 40% of the most expressed genes in RAEB belong to 
ribosomal genes, including RPL27A. The RPL27A was from the highest expressed gene in 
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RAEB, in addition to other ribosomal protein genes, including RPS19 (Mendiburu et al. 
2008). This implies possible functional similarities between RPL27A and RPS19, which are 
discussed in chapter 5, in terms of their expression in erythroid cells. This observation 
highlights the importance of RPL27A in RAEB, and its frequent association with -7/7q- 
abnormalities. Furthermore, Dorsam et al. showed that HOXA9 regulates RPL27A 
expression, transient overexpression of HOXA9 in haematopoietic stem cell resulted in 
upregulation of several genes including RPL27A (Dorsam et al. 2004). HOXA9 
overexpression recognised as a poor prognostic marker in MDS and AML patients and was 
detected in MDS patients with -7/7q- (Chen et al. 2004). This observation suggests that 
RPL27A overexpression could be similarly considered as a poor prognostic marker in 
MDS. 
Thus, monosomy 7 or deletion 7q results in the downregulation of miR-595, and the 
upregulation of its target RPL27A. Despite the small sample size, and the relative 
heterogeneity of different disease stages, this data provides insights into a new miRNA, and 
its implication for disease mechanism via its regulation of the target protein, which was 
identified by a novel functional assay. These findings, if verified on larger cohort, could 











The importance of miRNAs and their implication in hematological disorders including 
MDS has been addressed by previous studies as described in the introduction. 
The microRNAs recognised in 5q- syndrome, such as miR-145 and miR-146a have been 
associated with the development of the disease. However, in monosomy 7 there were no 
reported studies that have examined the role of miRNA expression in this MDS subtype. 
There are a small number of studies that focused on the deregulation of a few miRNAs 
located on chromosome 7 in relation to other subtypes of MDS, which was discussed in the 
Introduction Chapter. Therefore, the aim of my PhD was to examine one of the miRNAs on 
the q terminus of chromosome 7, which is miR-595, and apply an in-house developed 
functional assay to identify targets for this miRNA. The other aim of this project was to 
identify the biological function of the identified targets and their implication in the disease 
pathogenesis.  
The available miRNA target prediction methods predict hundreds of target genes for a 
given miRNA of which a large percentage are false-positives. MicroRNAs can either 
degrade their mRNA target or cause inhibition of translation therefore target prediction 
based on expression profiling which will miss targets that are regulated by translational 
inhibition. Furthermore, these expression studies cannot discriminate cause from 
consequence. Therefore, a novel ‘in-house’ functional assay for microRNA target 
identification was used. This assay has the potential for rapid and specific detection of 
several targets in a single assay and will identify targets that are either regulated by mRNA 
degradation or translational inhibition.  
The functional assay is based on introducing a cDNA library representing approximately 
17,000 genes downstream of a TKzeo selectable marker providing both resistance to zeocin 
and sensitivity to GCV. The plasmid library was transduced into the MCF7 cell line, which 
does not express the mir-595 and was selected with zeocin resulting in cells that contain at 
least one member of the library. The cells resistant to zeocin were expanded and 
subsequently transfected with plasmid expressing miR-595, which also conferred 
puromycin resistance. For target identification, the transfected cells were selected with 
GCV which selects for cells in which mir-595 has downregulated a target gene from the 
library which also results in downregulation of Tkzeo.  Resistant colonies were isolated and 
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DNA was extracted and the library genes were amplified by PCR. The amplified DNAs 
were analysed on agarose gel and bands of different sizes were isolated and sequenced. The 
sequencing result of 12 different bands identified 2 transcripts, RPL27A, HSPA14, GRM5 
and SEC36. I focused on ascertaining the function of RPL27A due to the association 
between previously identified ribosomal protein gene (RPS14) involved in the pathogenesis 
of 5q-, a subtype of MDS. Target validation confirmed that RPL27A is a target for miR-
595; subsequently I tested the biological function of RPL27A using retroviral shRNA to 
knockdown RPL27A. 
A previous report that studied RPL27A knockdown showed p53 accumulation in Sooty foot 
ataxia mice and these findings where confirmed in this PhD in a number of human cell 
lines. I measured the effect of RPL27A knockdown on day 6 post-infection and the 
knockdown resulted in downregulation of RPL27A at both transcriptional and translational 
levels by more than 70% for shRNA2 and a 40–50% reduction was achieved with shRNA-
4. The knockdown of RPL27A increased the expression of p53 in different human cell lines 
and led to the induction of the p53 targets p21 and Bax. As a control, RPS14 knockdown 
was performed and a similar result was obtained. Another control was also examined which 
was RPL5, the knockdown of which did not cause any significant changes in the p53 
expression.  
In addition to p53 activation, induction of apoptosis and inhibition of cell proliferation was 
observed in all cell lines infected with RPL27A and RPS14 shRNA. 
The knockdown reduces cell proliferation and induces apoptosis which leads to >75% cell 
death within 6 days in a p53-dependent manner. However, the knockdown effect in p53 
(null) cell lines also led to apoptosis but this was less marked in comparison to p53+/+ cell 
lines. These results suggest that the observed induction of apoptosis in p53 null cells is due 
to mechanisms independent of p53 or is the result of a general defect in ribosome 
biogenesis due to RPL27A knockdown. To further investigate this possibility ribosome 
profiling was performed on cells infected with RPL27A and RPS14 shRNA lentiviral 
vectors and compared to cells infected with control lentiviral vectors. Ribosome profiling 
experiments were performed in the MRC laboratory, University of Cambridge. 
Interestingly, the reduction of RPL27A reduced the large (60S) ribosomal subunit in HCT-
116 cell lines (WT cells and null p53 cells). As expected, RPS14 depletion was associated 
with reduction of the 40S subunit. To further validate the effect of RPL27A depletion on 
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ribosome biogenesis, nucleolar staining was performed using anti-fibrillarin antibody. The 
results showed a disruption in nucleolar staining and diffused fibrillarin in RPL27A shRNA 
expressing cells. These results showed the importance of RPL27A in the regulation of 
ribosome biogenesis and the subsequent effect on cellular proliferation and survival. 
Similar results were obtained in RPS14 and RPL5 depleted cells. 
All the above described experiments were performed on day 6 post-infection and to verify 
the p53 dependent induction of apoptosis, some experiments were repeated at 48-hrs post-
infection. The apoptosis and cell viability assays confirmed the p53-dependent effect 
because significant changes were only observed in cell lines that express p53 (HCT-116 
and HEL). At the same time point (48-hr), ribosome profiling was performed and showed a 
reduction in the 60S subunit in cells with reduced RPL27A but the reduction in the 60S 
subunit was considerably less than what was observed on day 6. 
To investigate whether RPL27A reduction activated p53 via its interaction with MDM2, a 
Co-IP- assay was performed which confirmed the interaction between RPL27A-MDM2 by 
the detection of MDM2 after pull-down with RPL27A antibody. However, detection of 
RPL27A in MDM2 pull down experiments was not conclusive due to the overlap with the 
light chain, which has a similar molecular weight as RPL27A. Furthermore, RPL27A pull 
down experiments showed that it also interacts with RPL5. 
 Further functional studies were performed on the cell lines to identify the effect of RPL27A 
overexpression on cellular processes. The ectopic expression of RPL27A did not show any 
effect on the cell cycle or the p53 pathway. This is in accordance with previous studies that 
showed the association of RPL27A overexpression with tumor aggressiveness, however, the 
levels of overexpression achieved in my experiments was only 2 fold and therefore it is not 
possible to draw firm conclusions as yet. 
Haploinsufficiency of ribosomal protein genes has been linked to the development of a 
haematological phenotype mainly through their effect on erythropoiesis. Therefore I carried 
out experiments to examine whether there is any association between RPL27A deficiency 
and erythropoiesis.  
RPL27A knockdown on normal hematopoietic progenitor cells (CD34+) showed a marked 
reduction in the erythroid lineage and moderate reduction in other lineages. This was 
associated with p53 activation as measured by p21 and Bax up-regulation and a reduction in 
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cell proliferation. These results were similar to the effects seen with RPS14 knockdown 
which was investigated similarly at the same time and emphasizes the important role of 
RPL27A in the haematopoiesis 
To identify the association of miR-595 and RPL27A with MDS pathogenesis, their 
expression levels were measured in BM CD34+ from MDS patients with-7/7q- and other 
MDS subtypes. The results showed that miR-595 was downregulated in -7/7q- MDS and 
MDS with complex karyotype as compared to MDS with normal karyotype. On the other 
hand, the expression level of RPL27A was downregulated in MDS with normal karyotype. 
In marked contrast as expected the RPL27A expression was upregulated in MDS with -
7/7q-. The data was reanalysed according to the IPSS score and the results confirmed the 
downregulation of miR-595 in HR-MDS versus LR-MDS and up-regulation of RPL27A in 
HR-MDS versus LR-MDS. These findings may be of importance when considering 
ribosomal protein deficiency as a possible prognostic tool in low risk MDS. 
Despite the heterogeneity of the disease, the biological and clinical insights into ribosomal 
insufficiency and microRNA deregulation will manifest certain prognostic and diagnostic 
biomarkers that will help better understand the molecular pathogenesis of MDS and will 
guide the improvements in the therapy of these disease.  
7.2 Possible Future Experiments 
The results of this study raise interesting questions, which can be addressed in future 
studies. 
• To investigate the contribution of other miRNAs located on chromosome 7 
especially 7q.  
• To identify the mechanistic involvement of RPL27A on the MDM2-p53 loop. 
Determine whether RPL27A interacts directly with MDM2 or via other auxiliary 
proteins.  
• To assess whether RPS14 overexpression rescues the 5q- phenotype and can the 
overexpression of RPL27A in LR MDS achieve the same? . 
• The results presented in Chapter 6 showed an interesting association of miR-595 
and RPL27A expression with MDS with different chromosomal subtypes of MDS. 
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However, the data was based on a small sample size and needs confirmation in a 
larger cohort of patient samples.  
• The regulation of miR-595 seems to depend on the epigenetic status as seen in other 
diseases. Therefore, it is necessary to examine the methylation status in del7q with 
intact q36.3, where miR-595 is localised. This could identify important epigenetic 
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A1.2 Sequencing result of miRNA-595 amplified from MCF7cells 
A1.2.1 Mir-595 with forward primer 
>lcl|18163  
Length=605 
 Score =  911 bits (493),  Expect = 0.0 
 Identities = 510/518 (99%), Gaps = 2/518 (0%) 
 Strand=Plus/Minus 
Query  968   GCACGCTCAATGTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTGGAGGA  1027 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  605   GCACGCTCAATGTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTGGAGGA  546 
Query  1028  AGCGCCTGTTGCTGgtttttgttgttttgttatgtattttttgCCATGTTCCATGCTGTT  1087 
             ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  545   AGCACCTGTTGCTGGTTTTTGTTGTTTTGTTATGTATTTTTTGCCATGTTCCATGCTGTT  486 
Query  1088  CCTCTAATCACATCATGTCCCGGgtttttgaagtttagtgac--gtttttggtcttttct  1145 
             |||||||||||||||||||| |||||||||||||||||||||   ||||||||||||||| 
Sbjct  485   CCTCTAATCACATCATGTCCTGGGTTTTTGAAGTTTAGTGACTTTTTTTTGGTCTTTTCT  426 
Query  1146  tactttttacccatgttttttcctctttGTAGGATCAAAGTCACATACAATAGCAACTTT  1205 
             ||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  425   TACTTTTTACCCATGTTCTTTCCTCTTTGTAGGATCAAAGTCACATACAATAGCAACTTT  366 
Query  1206  ATTATAACGCACGGTCCACCACGCTCCAACTTCCAGTGTGGAGGCATCGGTGGGGGTTTG  1265 
             ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  365   ATTATAACGCACGGTCCACCACGCTCCAACTTCCAGTGTGGGGGCATCGGTGGGGGTTTG  306 
Query  1266  CTGAAAGTCTGAGCAAATCTCATGGCTGTCTCTGCTGTCTCCGTGATGACTCTGTGGGGC  1325 
             ||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  305   CTGAAAGCCTGAGCAAATCTCATGGCTGTCTCTGCTGTCTCCGTGATGACTCTGTGGGGC  246 
Query  1326  ACGTGACTGGAATGCTCTGATGCCTGTTTGACATCTGGGGCTTCTCAGAAGCCACAGGAG  1385 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  245   ACGTGACTGGAATGCTCTGATGCCTGTTTGACATCTGGGGCTTCTCAGAAGCCACAGGAG  186 
Query  1386  CCACGCTGGGGGCTGACAGTTTCCTCTCCCAATGTCGCTTTTGGGCATCTAAGAGCCTGG  1445 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  185   CCACGCTGGGGGCTGACAGTTTCCTCTCCCAATGTCGCTTTTGGGCATCTAAGAGCCTGG  126 
 249 
Query  1446  TCATAGAGACGTGACGTGGCTTGAGAATGGACAGAGGC  1483 
             |||||||||||||||||||||||||||||||||||||| 
Sbjct  125   TCATAGAGACGTGACGTGGCTTGAGAATGGACAGAGGC  88 
A1.2.2 Mir-595 with the reverse primer 
>lcl|21203  
Length=627 
 Score =  915 bits (495),  Expect = 0.0 
 Identities = 510/517 (99%), Gaps = 2/517 (0%) 
 Strand=Plus/Minus 
Query  969   CACGCTCAATGTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTGGAGGAA  1028 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  627   CACGCTCAATGTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTGGAGGAA  568 
Query  1029  GCGCCTGTTGCTGgtttttgttgttttgttatgtattttttgCCATGTTCCATGCTGTTC  1088 
             || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  567   GCACCTGTTGCTGGTTTTTGTTGTTTTGTTATGTATTTTTTGCCATGTTCCATGCTGTTC  508 
Query  1089  CTCTAATCACATCATGTCCCGGgtttttgaagtttagtgac--gtttttggtcttttctt  1146 
             ||||||||||||||||||| |||||||||||||||||||||   |||||||||||||||| 
Sbjct  507   CTCTAATCACATCATGTCCTGGGTTTTTGAAGTTTAGTGACTTTTTTTTGGTCTTTTCTT  448 
Query  1147  actttttacccatgttttttcctctttGTAGGATCAAAGTCACATACAATAGCAACTTTA  1206 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  447   ACTTTTTACCCATGTTTTTTCCTCTTTGTAGGATCAAAGTCACATACAATAGCAACTTTA  388 
Query  1207  TTATAACGCACGGTCCACCACGCTCCAACTTCCAGTGTGGAGGCATCGGTGGGGGTTTGC  1266 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  387   TTATAACGCACGGTCCACCACGCTCCAACTTCCAGTGTGGAGGCATCGGTGGGGGTTTGC  328 
Query  1267  TGAAAGTCTGAGCAAATCTCATGGCTGTCTCTGCTGTCTCCGTGATGACTCTGTGGGGCA  1326 
             ||| || ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  327   TGAGAGCCTGAGCAAATCTCATGGCTGTCTCTGCTGTCTCCGTGATGACTCTGTGGGGCA  268 
Query  1327  CGTGACTGGAATGCTCTGATGCCTGTTTGACATCTGGGGCTTCTCAGAAGCCACAGGAGC  1386 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  267   CGTGACTGGAATGCTCTGATGCCTGTTTGACATCTGGGGCTTCTCAGAAGCCACAGGAGC  208 
Query  1387  CACGCTGGGGGCTGACAGTTTCCTCTCCCAATGTCGCTTTTGGGCATCTAAGAGCCTGGT  1446 
 250 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  207   CACGCTGGGGGCTGACAGTTTCCTCTCCCAATGTCGCTTTTGGGCATCTAAGAGCCTGGT  148 
Query  1447  CATAGAGACGTGACGTGGCTTGAGAATGGACAGAGGC  1483 
             ||||||||||||||||||||||||||||||||||||| 




Error in the Pre-miRNA sequence 
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A1.3 Sequencing result of miRNA-595 amplified from HeLa cells 
A1.3.1 Mir-595 with the forward primer 
>lcl|33681  
Length=655 
 Score =  950 bits (514),  Expect = 0.0 
 Identities = 520/523 (99%), Gaps = 0/523 (0%) 
 Strand=Plus/Plus 
Query  345  GGGCCACATTCTCTCTGCCATGTGCAGAGGGCTCCTGCACGGAAGCCTGCACGCATTTAA  
404 
            ||| || ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  6    GGGTCAAATTCTCTCTGCCATGTGCAGAGGGCTCCTGCACGGAAGCCTGCACGCATTTAA  
65 
Query  405  CACCAGCACGCTCAATGTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTG  
464 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  66   CACCAGCACGCTCAATGTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTG  
125 
Query  465  GAGGAAGCGCCTGTTGCTGgtttttgttgttttgttatgtattttttgCCATGTTCCATG  
524 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  126  GAGGAAGCGCCTGTTGCTGGTTTTTGTTGTTTTGTTATGTATTTTTTGCCATGTTCCATG  
185 
Query  525  CTGTTCCTCTAATCACATCATGTCCCGGgtttttgaagtttagtgacgtttttggtcttt  
584 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  186  CTGTTCCTCTAATCACATCATGTCCCGGGTTTTTGAAGTTTAGTGACGTTTTTGGTCTTT  
245 
Query  585  tcttactttttacccatgttttttcctctttGTAGGATCAAAGTCACATACAATAGCAAC  
644 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  246  TCTTACTTTTTACCCATGTTTTTTCCTCTTTGTAGGATCAAAGTCACATACAATAGCAAC  
305 
Query  645  TTTATTATAACGCACGGTCCACCACGCTCCAACTTCCAGTGTGGAGGCATCGGTGGGGGT  
704 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  306  TTTATTATAACGCACGGTCCACCACGCTCCAACTTCCAGTGTGGAGGCATCGGTGGGGGT  
365 
Query  705  TTGCTGAAAGTCTGAGCAAATCTCATGGCTGTCTCTGCTGTCTCCGTGATGACTCTGTGG  
764 
            |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  366  TTGCTGAAAGCCTGAGCAAATCTCATGGCTGTCTCTGCTGTCTCCGTGATGACTCTGTGG  
425 
Query  765  GGCACGTGACTGGAATGCTCTGATGCCTGTTTGACATCTGGGGCTTCTCAGAAGCCACAG  
 252 
824 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  426  GGCACGTGACTGGAATGCTCTGATGCCTGTTTGACATCTGGGGCTTCTCAGAAGCCACAG  
485 
Query  825  GAGCCACGCTGGGGGCTGACAGTTTCCTCTCCCAATGTCGCTT  867 
            ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  486  GAGCCACGCTGGGGGCTGACAGTTTCCTCTCCCAATGTCGCTT  528 
A1.3.2 Mir-595 with the reverse primer 
>lcl|55633  
Length=697 
 Score =  924 bits (500),  Expect = 0.0 
 Identities = 507/510 (99%), Gaps = 2/510 (0%) 
 Strand=Plus/Minus 
Query  1    CCCAGTATCTCCAGGGATTTGAGAATCAGTTCATTCTGCAAGTAACAAAACTAGGGAAGG  
60 
            ||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||| 
Sbjct  517  CCCAGTATCTCCAGGGATTTGAGAATCAGTTCATTCTACAAGTAACAAAACTAGGGAAGG  
458 
Query  61   AAGTGGTTTTCAAGCTCCCGTGGTTGTTGGAGGTGAGCTAATTCTTTGCGAGTTATTAAT  
120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  457  AAGTGGTTTTCAAGCTCCCGTGGTTGTTGGAGGTGAGCTAATTCTTTGCGAGTTATTAAT  
398 
Query  121  TGCTGGTCTCTTGGAATGGCTTGGGAGCACAAAGTGACAGGAACCCAAGTCATTTCTGTT  
180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  397  TGCTGGTCTCTTGGAATGGCTTGGGAGCACAAAGTGACAGGAACCCAAGTCATTTCTGTT  
338 
Query  181  CTGTTTGCTTGTGTTTGTTTTGCTTTAAGTTAATCCTTTGGTGGTTCTGGGGATGAGGCC  
240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  337  CTGTTTGCTTGTGTTTGTTTTGCTTTAAGTTAATCCTTTGGTGGTTCTGGGGATGAGGCC  
278 
Query  241  TTGTCCCTGGCTTGGTAGAGAGAGGCCAGTCAGGAGGGAGCAGGTGTGGTGGAGCCTGGC  
300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  277  TTGTCCCTGGCTTGGTAGAGAGAGGCCAGTCAGGAGGGAGCAGGTGTGGTGGAGCCTGGC  
218 
Query  301  CGTCCCTGAGCCATCAAGATGGTCTGCGCGTCAGAGTGCAGCACGGGCCACATTCTCTCT  
360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  217  CGTCCCTGAGCCATCAAGATGGTCTGCGCGTCAGAGTGCAGCACGGGCCACATTCTCTCT  
 253 
158 
Query  361  GCCATGTGCAGAGGGCTCCTGCACGGAAGCCTGCACGCATTTAACACCAGCACGCTCAAT  
420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  157  GCCATGTGCAGAGGGCTCCTGCACGGAAGCCTGCACGCATTTAACACCAGCACGCTCAAT  
98 
Query  421  GTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTGGAGGAAGCGCCTGTTG  
480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  97   GTAGTCTTGTAAGGAACAGGTTGAAGTGTGCCGTGGTGTGTCTGGAGGAAGCGCCTGTTG  
38 
Query  481  CTGgtttttgttgttttgttatgtattttt  510 
            ||||||||||| |||| ||||||||||||| 




A1.4 p3’UTRTkzeo sequence with primers alignment 
GGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTATCGCATGGCTTCGTACCCCGGCCATCAACACGCGTCTGCGTTCGACCAGGCTGCGCGTTCTCGCGGCCATA
GCAACCGACGTACGGCGTTGCGCCCTCGCCGGCAGCAAGAAGCCACGGAAGTCCGCCCGGAGCAGAAAATGCCCACGCTACTGCGGGTTTATATAGACGGTCCCCA
CGGGATGGGGAAAACCACCACCACGCAACTGCTGGTGGCCCTGGGTTCGCGCGACGATATCGTCTACGTACCCGAGCCGATGACTTACTGGCGGGTGCTGGGGGCTT
CCGAGACAATCGCGAACATCTACACCACACAACACCGCCTCGACCAGGGTGAGATATCGGCCGGGGACGCGGCGGTGGTAATGACAAGCGCCCAGATAACAATGGG
CATGCCTTATGCCGTGACCGACGCCGTTCTGGCTCCTCATATCGGGGGGGAGGCTGGGAGCTCACATGCCCCGCCCCCGGCCCTCACCCTCATCTTCGACCGCCATCC
CATCGCCGCCCTCCTGTGCTACCCGGCCGCGCGGTACCTTATGGGCAGCATGACCCCCCAGGCCGTGCTGGCGTTCGTGGCCCTCATCCCGCCGACCTTGCCCGGCAC
CAACATCGTGCTTGGGGCCCTTCCGGAGGACAGACACATCGACCGCCTGGCCAAACGCCAGCGCCCCGGCGAGCGGCTGGACCTGGCTATGCTGGCTGCGATTCGCC
GCGTTTACGGGCTACTTGCCAATACGGTGCGGTATCTGCAGTGCGGCGGGTCGTGGCGGGAGGACTGGGGACAGCTTTCGGGGACGGCCGTGCCGCCCCAGGGTGCC
GAGCCCCAGAGCAACGCGGGCCCACGACCCCATATCGGGGACACGTTATTTACCCTGTTTCGGGCCCCCGAGTTGCTGGCCCCCAACGGCGACCTGTATAACGTGTTT
GCCTGGGCCTTGGACGTCTTGGCCAAACGCCTCCGTTCCATGCACGTCTTTATCCTGGATTACGACCAATCGCCCGCCGGCTGCCGGGACGCCCTGCTGCAACTTACC
TCCGGGATGGTCCAGACCCACGTCACCACCCCCGGCTCCATACCGACGATATGCGACCTGGCGCGCACGTTTGCCCGAGAGATGATCAGCGGAGCTAATGGCGTCAT
GGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACCGCGCGCGACGTCGCCGGAGCGGTCGAGTTCTGGACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACG
ACTTCGCCGGTGTGGTCCGGGACGACGTGACCCTGTTCATCAGCGCGGTCCAGGACCAGGTGGTGCCGGACAACACCCTGGCCTGGGTGTGGGTGCGCGGCCTGGAC
GAGCTGTACGCCGAGTGGTCGGAGGTCGTGTCCACGAACTTCCGGGACGCCTCCGGGCCGGCCATGACCGAGATCGGCGAGCAGCCGTGGGGGCGGGAGTTCGCCC
TGCGCGACCCGGCCGGCAACTGCGTGCACTTCGTGGCCGAGGAGCAGGACTGACCGACGCCGACCAACACCGCCGGTCCGACGCGGCCCGACGGGTCCGAGGGGGG
TCGACCTCGAATCCTTAGGCCATTAAGGCCGGCCGCCTCGGCCCACTTCGTGGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAAC
CCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGGCCGAGG
AGCAGGACTGACACGTGCTACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCG
GGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTG
TGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTG
CGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAA
GAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGA
CGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGA
TACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG
AACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGA
TTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCA
GTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGG
ATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTA
GATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGAT
CTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCC
ACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTG
CCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAG
CTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGT
GTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAG
TGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCG
AAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCA
AAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTA
TTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGATCGGGAG
ATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCG
AGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATAC
GCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCC
GCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTT
ACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACAT
GACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGAC
TCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACG
CAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTA
TAGGGAGACCCAAGCTGGCTAGT 
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